Payload Information

General Information of This Payload
Payload ID
PAY0WUZLC
Name
Camptothecin
Synonyms
Camptothecin; 7689-03-4; Camptothecine; (S)-(+)-Camptothecin; Campathecin; (+)-Camptothecine; d-Camptothecin; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; Camptothecine (S,+); CHEMBL65; (S)-4-ethyl-4-hydroxy-1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NSC-94600; MLS000766223; XT3Z54Z28A; CHEBI:27656; MFCD00081076; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione; (S)-Camptothecin; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 20(S)-Camptothecin; 4-ETHYL-4-HYDROXY-1,12-DIHYDRO-4H-2-OXA-6,12A-DIAZA-DIBENZO[B,H]FLUORENE-3,13-DIONE; SR-01000075798; SR-01000597379; d-camptothecine; (s)-camptothecine; Camptothecin,(S); (4S)-4-ETHYL-4-HYDROXY-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE; (S)-4-ethyl-4-hydroxy-1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; Prestwick_102; (+)-Camptothecin;; Camptothecine (8CI); Spectrum_000299; Tocris-1100; SpecPlus_000712; Prestwick0_000200; Prestwick1_000200; Prestwick2_000200; Prestwick3_000200; Spectrum2_000903; Spectrum3_001203; Spectrum4_000738; Spectrum5_001126; CAMPTOTHECIN [MI]; Lopac-C-9911; D09YDM; SCHEMBL6038; UNII-XT3Z54Z28A; Lopac0_000341; BSPBio_000159; BSPBio_002586; KBioGR_001036; KBioSS_000779; KBioSS_002283; cid_24360; CAMPTOTHECIN [WHO-DD]; DivK1c_000826; DivK1c_006808; SPECTRUM1502232; SPBio_000746; SPBio_002080; BPBio1_000175; DTXSID0030956; HMS502J08; KBio1_000826; KBio1_001752; KBio2_000779; KBio2_003347; KBio2_005915; KBio3_002086; 4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NINDS_000826; Bio1_000400; Bio1_000889; Bio1_001378; HMS1568H21; HMS1921N08; HMS2089F08; HMS2095H21; HMS3261E03; HMS3414J17; HMS3654D13; HMS3678J15; HMS3712H21; BCP02857; Tox21_500341; AC-202; BBL033963; BDBM50008923; CCG-40255; GR-301; s1288; STK801886; AKOS004119861; CS-1049; DB04690; KS-5235; LP00341; SDCCGMLS-0066688.P001; SDCCGSBI-0050329.P003; CAS-2114454; IDI1_000826; NCGC00015290-01; NCGC00016994-01; NCGC00016994-02; NCGC00016994-03; NCGC00016994-04; NCGC00016994-05; NCGC00016994-06; NCGC00016994-07; NCGC00016994-08; NCGC00016994-09; NCGC00016994-10; NCGC00016994-11; NCGC00016994-12; NCGC00016994-16; NCGC00016994-29; NCGC00024997-01; NCGC00024997-02; NCGC00024997-03; NCGC00024997-04; NCGC00024997-05; NCGC00024997-06; NCGC00178592-01; NCGC00178592-02; NCGC00261026-01; HY-16560; NCI60_042105; SMR000445686; SY010324; EU-0100341; SW196414-3; C 9911; C01897; M01564; AB00052452-08; AB00052452-09; AB00052452_10; EN300-1725804; (S)-(+)-Camptothecin, >=90% (HPLC), powder; A838882; Q419964; Q-200785; SR-01000075798-1; SR-01000075798-4; SR-01000597379-1; SR-01000597379-3; BRD-K37890730-001-09-4; BRD-K37890730-001-10-2; Z1741982070; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]florene-3,13-dione; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 4-Ethyl-4-hydroxy-1H-pyrano-[3[,4[:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;(S)-(+)-Camptothecin; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 4(S)-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14 (4H,12H)-dione; 4-ethyl-4-hydroxy-(4S)-3,4,12,14-tetrahydro-1H-pyrano[3'',4'':6,7]indolizino[1,2-b]quinoline-3,14-dione; 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (camptothecin or CPT); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (Camptothecin); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (CPT, Camptothecin)
   Click to Show/Hide
Target(s) DNA topoisomerase 1 (TOP1)
 Target Info 
Structure
Formula
C20H16N2O4
Isosmiles
CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
PubChem CID
24360
InChI
InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1
InChIKey
VSJKWCGYPAHWDS-FQEVSTJZSA-N
IUPAC Name
(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
Pharmaceutical Properties
Molecule Weight
348.4
Polar area
79.7
Complexity
742
xlogp Value
1
Heavy Count
26
Rot Bonds
1
Hbond acc
5
Hbond Donor
1
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Half Maximal Inhibitory Concentration (IC50) 0.001 ug/mL
Lu-99 cells
Lung giant cell carcinoma
CVCL_3015 
Half Maximal Inhibitory Concentration (IC50) 0.00463 ug/mL
QG-56 cells
Lung squamous cell carcinoma
CVCL_6943 
[1]
Half Maximal Inhibitory Concentration (IC50) 0.00463 ug/mL
QG-56 cells
Lung squamous cell carcinoma
CVCL_6943 
[2]
Half Maximal Inhibitory Concentration (IC50) 0.00474 ug/mL
P388 cells
Lymphoma
CVCL_7222 
[1]
Half Maximal Inhibitory Concentration (IC50) 0.00474 ug/mL
P388 cells
Lymphoma
CVCL_7222 
[2]
Half Maximal Inhibitory Concentration (IC50) 0.005 ug/mL
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
Half Maximal Inhibitory Concentration (IC50) <0.005 ug/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[3]
Half Maximal Inhibitory Concentration (IC50) <0.005 ug/mL
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[3]
Half Maximal Inhibitory Concentration (IC50) 0.005 ug/mL
P388 cells
Lymphoma
CVCL_7222 
Half Maximal Inhibitory Concentration (IC50) 0.01 ug/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
Half Maximal Inhibitory Concentration (IC50) 0.01 ug/mL
SW480 cells
Colon adenocarcinoma
CVCL_0546 
Half Maximal Inhibitory Concentration (IC50) 0.01 ug/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[4]
Half Maximal Inhibitory Concentration (IC50) 0.0147 ug/mL
HOC-21 cells
Ovarian adenocarcinoma
CVCL_8692 
[1]
Half Maximal Inhibitory Concentration (IC50) 0.0147 ug/mL
HOC-21 cells
Ovarian adenocarcinoma
CVCL_8692 
[2]
Half Maximal Inhibitory Concentration (IC50) 0.02 ug/mL
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
Half Maximal Inhibitory Concentration (IC50) 0.02 ug/mL
Vero cells
Normal
CVCL_0059 
[5]
Half Maximal Inhibitory Concentration (IC50) 0.02 ug/mL
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[6]
Half Maximal Inhibitory Concentration (IC50) <0.024 ug/mL
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[7]
Half Maximal Inhibitory Concentration (IC50) 0.03 ug/mL
KB VCR R cells
Normal
Undisclosed
Half Maximal Inhibitory Concentration (IC50) 0.03 ug/mL
WI-38 cells
Normal
CVCL_0579 
[8]
Half Maximal Inhibitory Concentration (IC50) 0.04 ug/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
Half Maximal Inhibitory Concentration (IC50) 0.054 ug/mL
Vero cells
Normal
CVCL_0059 
[9]
Half Maximal Inhibitory Concentration (IC50) 0.054 ug/mL
Vero cells
Normal
CVCL_0059 
[10]
Half Maximal Inhibitory Concentration (IC50) 0.07 ug/mL
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[11]
Half Maximal Inhibitory Concentration (IC50) 0.07 ug/mL
WiDr cells
Colon adenocarcinoma
CVCL_2760 
[6]
Half Maximal Inhibitory Concentration (IC50) 0.072 ug/mL
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[12]
Half Maximal Inhibitory Concentration (IC50) 0.09 ug/mL
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
Half Maximal Inhibitory Concentration (IC50) 0.096 ug/mL
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[12]
Half Maximal Inhibitory Concentration (IC50) 0.19 ug/mL
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[6]
Half Maximal Inhibitory Concentration (IC50) 0.28 ug/mL
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[13]
Half Maximal Inhibitory Concentration (IC50) 0.4 ug/mL
WI-38 cells
Normal
CVCL_0579 
[14]
Half Maximal Inhibitory Concentration (IC50) 0.6 ug/mL
Vero cells
Normal
CVCL_0059 
[15]
Half Maximal Inhibitory Concentration (IC50) 1.54 ug/mL
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[12]
Half Maximal Inhibitory Concentration (IC50) 11.71 ug/mL
L-M(TK-) cells
Normal
CVCL_4536 
[16]
Half Maximal Inhibitory Concentration (IC50) <2 ug/mL
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[17]
Half Maximal Inhibitory Concentration (IC50) 2 ug/mL
CCD 19Lu cells
Normal
CVCL_2382 
Half Maximal Inhibitory Concentration (IC50) 2.05 ug/mL
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
[16]
Half Maximal Inhibitory Concentration (IC50) 2.72 ug/mL
Bel-7402 cells
Hepatoma
CVCL_5492 
[3]
Half Maximal Inhibitory Concentration (IC50) 5.87 ug/mL
Embryonic fibroblast MEF cells
Normal
Undisclosed [16]
Half Maximal Inhibitory Concentration (IC50) 58 ug/mL
Vero cells
Normal
CVCL_0059 
[13]
Half Maximal Inhibitory Concentration (IC50) 6.88 ug/mL
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[12]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 0.023 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[18]
Half Maximal Inhibitory Concentration (IC50) 0.02543 nM
ES7 cells
Ewing sarcoma
CVCL_1203 
Half Maximal Inhibitory Concentration (IC50) 0.04 nM
MOLT-4 cells
Adult T acute lymphoblastic leukemia
CVCL_0013 
[19]
Half Maximal Inhibitory Concentration (IC50) 0.04843 nM
NCI-H209 cells
Lung small cell carcinoma
CVCL_1525 
Half Maximal Inhibitory Concentration (IC50) 0.09574 nM
ES1 cells
Ewing sarcoma
CVCL_1198 
Half Maximal Inhibitory Concentration (IC50) 0.1016 nM
P12-Ichikawa cells
T-cell leukemia
CVCL_1630 
Half Maximal Inhibitory Concentration (IC50) 0.1214 nM
EW-16 cells
Ewing sarcoma
CVCL_1212 
Half Maximal Inhibitory Concentration (IC50) 0.1293 nM
MHH-ES-1 cells
Ewing sarcoma
CVCL_1411 
Half Maximal Inhibitory Concentration (IC50) 0.1315 nM
D-566MG cells
Glioblastoma
CVCL_1166 
Half Maximal Inhibitory Concentration (IC50) 0.1398 nM
BFTC-905 cells
Bladder carcinoma
CVCL_1083 
Half Maximal Inhibitory Concentration (IC50) 0.15 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[20]
Half Maximal Inhibitory Concentration (IC50) 0.1714 nM
639-V cells
Ureter urothelial carcinoma
CVCL_1048 
Half Maximal Inhibitory Concentration (IC50) 0.1816 nM
HSC-4 cells
Cervical lymph node
CVCL_1289 
Half Maximal Inhibitory Concentration (IC50) 0.1936 nM
NBsusSR cells
Neuroblastoma
CVCL_1450 
Half Maximal Inhibitory Concentration (IC50) 0.2119 nM
HT-3 cells
Cervical carcinoma
CVCL_1293 
Half Maximal Inhibitory Concentration (IC50) 0.2738 nM
NTERA-2-cl-D1 cells
Teratocarcinoma
CVCL_3407 
Half Maximal Inhibitory Concentration (IC50) 0.3192 nM
EW-3 cells
Ewing sarcoma
CVCL_1216 
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
LN-229 cells
Glioblastoma
CVCL_0393 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
MHCC97H cells
Hepatocellular carcinoma
CVCL_4972 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.3582 nM
H9 cells
Sezary syndrome
CVCL_1240 
Half Maximal Inhibitory Concentration (IC50) 0.4281 nM
COLO-800 cells
Cutaneous melanoma
CVCL_1135 
Half Maximal Inhibitory Concentration (IC50) 0.4292 nM
CTB-1 cells
Diffuse large B-cell lymphoma
CVCL_1149 
Half Maximal Inhibitory Concentration (IC50) 0.441 nM
NKM-1 cells
Acute myeloid leukemia
CVCL_1607 
Half Maximal Inhibitory Concentration (IC50) 0.4809 nM
Daoy cells
Medulloblastoma
CVCL_1167 
Half Maximal Inhibitory Concentration (IC50) 0.5 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[22]
Half Maximal Inhibitory Concentration (IC50) 0.513 nM
MC-IXC cells
Askin tumor
CVCL_1398 
Half Maximal Inhibitory Concentration (IC50) 0.5292 nM
NCI-H1048 cells
Lung small cell carcinoma
CVCL_1453 
Half Maximal Inhibitory Concentration (IC50) 0.5392 nM
FaDu cells
Hypopharyngeal squamous cell carcinoma
CVCL_1218 
Half Maximal Inhibitory Concentration (IC50) 0.5566 nM
EW-22 cells
Ewing sarcoma
CVCL_1214 
Half Maximal Inhibitory Concentration (IC50) 0.56 nM
HEK293 cells
Normal
CVCL_0045 
[23]
Half Maximal Inhibitory Concentration (IC50) 0.5694 nM
NB69 cells
Neuroblastoma
CVCL_1448 
Half Maximal Inhibitory Concentration (IC50) 0.5865 nM
LU-134-A cells
Lung small cell carcinoma
CVCL_1387 
Half Maximal Inhibitory Concentration (IC50) 0.6 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[20]
Half Maximal Inhibitory Concentration (IC50) 0.6022 nM
DoHH2 CDX model cells
Diffuse large B-cell lymphoma germinal center B-cell type
CVCL_1179 
Half Maximal Inhibitory Concentration (IC50) 0.6143 nM
NB10 cells
Neuroblastoma
CVCL_1441 
Half Maximal Inhibitory Concentration (IC50) 0.6154 nM
H4 cells
Neuroglioma
CVCL_1239 
Half Maximal Inhibitory Concentration (IC50) 0.7 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[24]
Half Maximal Inhibitory Concentration (IC50) 0.701 nM
GR-ST cells
B acute lymphoblastic leukemia
CVCL_1236 
Half Maximal Inhibitory Concentration (IC50) 0.7058 nM
MV4-11 cells
Childhood acute monocytic leukemia
CVCL_0064 
Half Maximal Inhibitory Concentration (IC50) 0.7058 nM
GOTO cells
Adrenal gland neuroblastoma
CVCL_1234 
Half Maximal Inhibitory Concentration (IC50) 0.7318 nM
MOLT-16 cells
T acute lymphoblastic leukemia
CVCL_1424 
Half Maximal Inhibitory Concentration (IC50) 0.7479 nM
NCI-H1623 cells
Lung adenocarcinoma
CVCL_1481 
Half Maximal Inhibitory Concentration (IC50) 0.7735 nM
ES5 cells
Ewing sarcoma
CVCL_1201 
Half Maximal Inhibitory Concentration (IC50) 0.7753 nM
QIMR-WIL cells
Acute myeloid leukemia
CVCL_1645 
Half Maximal Inhibitory Concentration (IC50) 0.7956 nM
ES8 cells
Ewing sarcoma
CVCL_1204 
Half Maximal Inhibitory Concentration (IC50) 0.8149 nM
A673 cells
Rhabdomyosarcoma
CVCL_0080 
Half Maximal Inhibitory Concentration (IC50) 0.8157 nM
DEL/BVR cells
Anaplastic large cell lymphoma
CVCL_1170 
Half Maximal Inhibitory Concentration (IC50) 0.8385 nM
HO-1-N-1 cells
Buccal mucosa squamous cell carcinoma
CVCL_1284 
Half Maximal Inhibitory Concentration (IC50) 0.84 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[25]
Half Maximal Inhibitory Concentration (IC50) 0.8418 nM
MHH-NB-11 cells
Neuroblastoma
CVCL_1412 
Half Maximal Inhibitory Concentration (IC50) 0.8814 nM
HuP-T4 cells
Pancreatic adenocarcinoma
CVCL_1300 
Half Maximal Inhibitory Concentration (IC50) 0.8868 nM
OCI-AML-2 cells
Adult acute myeloid leukemia
CVCL_1619 
Half Maximal Inhibitory Concentration (IC50) 0.8964 nM
647-V cells
Bladder carcinoma
CVCL_1049 
Half Maximal Inhibitory Concentration (IC50) 0.9022 nM
RS4
11 cells
Adult B acute lymphoblastic leukemia
CVCL_0093 
Half Maximal Inhibitory Concentration (IC50) 0.9054 nM
CTV-1 cells
T acute lymphoblastic leukemia
CVCL_1150 
Half Maximal Inhibitory Concentration (IC50) 0.9071 nM
NB14 cells
Neuroblastoma
CVCL_1444 
Half Maximal Inhibitory Concentration (IC50) 0.9311 nM
ES3 cells
Ewing sarcoma
CVCL_1199 
Half Maximal Inhibitory Concentration (IC50) 0.981 nM
PA-1 cells
Ovarian mixed germ cell tumor
CVCL_0479 
Half Maximal Inhibitory Concentration (IC50) 0.9836 nM
CAL-62 cells
Thyroid gland anaplastic carcinoma
CVCL_1112 
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[26]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[27]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[23]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[28]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[29]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[30]
Half Maximal Inhibitory Concentration (IC50) 1 nM
NCI-H69 cells
Small cell lung carcinoma
CVCL_1579 
[31]
Half Maximal Inhibitory Concentration (IC50) 1.026 nM
CHP-212 cells
Neuroblastoma
CVCL_1125 
Half Maximal Inhibitory Concentration (IC50) 1.028 nM
NCI-H526 cells
Lung small cell carcinoma
CVCL_1569 
Half Maximal Inhibitory Concentration (IC50) 1.11 nM
KG-1 cells
Adult acute myeloid leukemia
CVCL_0374 
Half Maximal Inhibitory Concentration (IC50) 1.16 nM
SK-PN-DW cells
Primitive neuroectodermal tumor
CVCL_1703 
Half Maximal Inhibitory Concentration (IC50) 1.161 nM
DB cells
Diffuse large B-cell lymphoma
CVCL_1168 
Half Maximal Inhibitory Concentration (IC50) 1.188 nM
NCI-H1155 cells
Lung large cell carcinoma
CVCL_1456 
Half Maximal Inhibitory Concentration (IC50) 1.227 nM
SK-NEP-1 cells
Ewing sarcoma
CVCL_0631 
Half Maximal Inhibitory Concentration (IC50) 1.241 nM
SAS cells
Tongue squamous cell carcinoma
CVCL_1675 
Half Maximal Inhibitory Concentration (IC50) 1.398 nM
HOS cells
Osteosarcoma
CVCL_0312 
Half Maximal Inhibitory Concentration (IC50) 1.399 nM
HN cells
Cervical lymph node
CVCL_1283 
Half Maximal Inhibitory Concentration (IC50) 1.4 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[32]
Half Maximal Inhibitory Concentration (IC50) 1.4 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[33]
Half Maximal Inhibitory Concentration (IC50) 1.474 nM
ES4 cells
Ewing sarcoma
CVCL_1200 
Half Maximal Inhibitory Concentration (IC50) 1.502 nM
8-MG-BA cells
Glioblastoma
CVCL_1052 
Half Maximal Inhibitory Concentration (IC50) 1.527 nM
GAMG cells
Glioblastoma
CVCL_1226 
Half Maximal Inhibitory Concentration (IC50) 1.534 nM
ALL-PO cells
B acute lymphoblastic leukemia
CVCL_1069 
Half Maximal Inhibitory Concentration (IC50) 1.535 nM
KE-37 cells
T acute lymphoblastic leukemia
CVCL_1327 
Half Maximal Inhibitory Concentration (IC50) 1.557 nM
NOMO-1 cells
Acute monocytic leukemia
CVCL_1609 
Half Maximal Inhibitory Concentration (IC50) 1.6 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[34]
Half Maximal Inhibitory Concentration (IC50) 1.6 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[35]
Half Maximal Inhibitory Concentration (IC50) 1.614 nM
T24 cells
Bladder carcinoma
CVCL_0554 
Half Maximal Inhibitory Concentration (IC50) 1.616 nM
MOLT-4 cells
Adult T acute lymphoblastic leukemia
CVCL_0013 
Half Maximal Inhibitory Concentration (IC50) 1.634 nM
HD-MY-Z cells
Acute myeloid leukemia
CVCL_1273 
Half Maximal Inhibitory Concentration (IC50) 1.669 nM
A3-KAW cells
Diffuse large B-cell lymphoma
CVCL_1062 
Half Maximal Inhibitory Concentration (IC50) 1.699 nM
NCI-H510A cells
Lung small cell carcinoma
CVCL_1565 
Half Maximal Inhibitory Concentration (IC50) 1.725 nM
RPMI-8866 cells
Chronic myelogenous leukemia
CVCL_1668 
Half Maximal Inhibitory Concentration (IC50) 1.749 nM
A4-Fuk cells
B acute lymphoblastic leukemia
CVCL_1064 
Half Maximal Inhibitory Concentration (IC50) 1.759 nM
GT3TKB cells
Lung squamous cell carcinoma
CVCL_1237 
Half Maximal Inhibitory Concentration (IC50) 1.777 nM
EW-1 cells
Ewing sarcoma
CVCL_1208 
Half Maximal Inhibitory Concentration (IC50) 1.787 nM
MOLT-13 cells
T acute lymphoblastic leukemia
CVCL_1422 
Half Maximal Inhibitory Concentration (IC50) <1.8 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[36]
Half Maximal Inhibitory Concentration (IC50) <1.8 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[36]
Half Maximal Inhibitory Concentration (IC50) <1.8 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[36]
Half Maximal Inhibitory Concentration (IC50) 1.814 nM
HCE-4 cells
Esophageal squamous cell carcinoma
CVCL_1271 
Half Maximal Inhibitory Concentration (IC50) 1.822 nM
BHT-101 cells
Anaplastic thyroid carcinoma
CVCL_1085 
Half Maximal Inhibitory Concentration (IC50) 1.853 nM
BB65-RCC cells
Renal cell carcinoma
CVCL_1078 
Half Maximal Inhibitory Concentration (IC50) 1.869 nM
U-251MG cells
Astrocytoma
CVCL_0021 
Half Maximal Inhibitory Concentration (IC50) 1.869 nM
L-363 cells
Plasma cell myeloma
CVCL_1357 
Half Maximal Inhibitory Concentration (IC50) 1.925 nM
NB5 cells
Neuroblastoma
CVCL_8822 
Half Maximal Inhibitory Concentration (IC50) <10 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[37]
Half Maximal Inhibitory Concentration (IC50) <10 nM
SK-BR-3 cells
Breast adenocarcinoma
CVCL_0033 
[38]
Half Maximal Inhibitory Concentration (IC50) <10 nM
ZR-75-1 cells
Invasive breast carcinoma
CVCL_0588 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MOLT-4 cells
Adult T acute lymphoblastic leukemia
CVCL_0013 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
U-251MG cells
Astrocytoma
CVCL_0021 
[40]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[41]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[51]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[59]
Half Maximal Inhibitory Concentration (IC50) <10 nM
BT-20 cells
Invasive breast carcinoma of no special type
CVCL_0178 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[39]
Half Maximal Inhibitory Concentration (IC50) <10 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
Hep 3B2.1-7 cells
Childhood hepatocellular carcinoma
CVCL_0326 
[60]
Half Maximal Inhibitory Concentration (IC50) <10 nM
MDA-MB-453 cells
Breast adenocarcinoma
CVCL_0418 
[38]
Half Maximal Inhibitory Concentration (IC50) <10 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) <10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[59]
Half Maximal Inhibitory Concentration (IC50) <10 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF268 cells
Astrocytoma
CVCL_1689 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF268 cells
Astrocytoma
CVCL_1689 
[47]
Half Maximal Inhibitory Concentration (IC50) <10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[38]
Half Maximal Inhibitory Concentration (IC50) <10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[37]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[41]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[41]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[60]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[62]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[63]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
Panel NCI-60 cells
Normal
Undisclosed [64]
Half Maximal Inhibitory Concentration (IC50) <10 nM
Hs 683 cells
Glioma
CVCL_0844 
[37]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DMS-273 cells
Small cell lung carcinoma
CVCL_1176 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) <10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[51]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[59]
Half Maximal Cell Growth Inhibitory Concentration (GI50) <10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[65]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[59]
Half Maximal Inhibitory Concentration (IC50) <10 nM
MCF-12A cells
Normal
CVCL_3744 
[38]
Half Maximal Inhibitory Concentration (IC50) 10 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[66]
Half Maximal Inhibitory Concentration (IC50) 10 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[37]
Half Maximal Inhibitory Concentration (IC50) 10 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[67]
Half Maximal Inhibitory Concentration (IC50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[68]
Half Maximal Inhibitory Concentration (IC50) 10 nM
SK-MES-1 cells
Lung squamous cell carcinoma
CVCL_0630 
[68]
Half Maximal Inhibitory Concentration (IC50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[69]
Half Maximal Inhibitory Concentration (IC50) 10 nM
Human umbilical vein endothelial cells(HUVEC)
Normal
Undisclosed [70]
Half Maximal Inhibitory Concentration (IC50) 10 nM
HEK293 cells
Normal
CVCL_0045 
[71]
Half Maximal Inhibitory Concentration (IC50) 10 nM
GLC4 cells
Lung small cell carcinoma
CVCL_0279 
[72]
Half Maximal Inhibitory Concentration (IC50) 10 nM
KB 3-1 cells
Cervical epithelial carcinoma
CVCL_2088 
[73]
Half Maximal Inhibitory Concentration (IC50) 10 nM
P388 cells
Lymphoma
CVCL_7222 
[73]
Half Maximal Inhibitory Concentration (IC50) 10.12 nM
A388 cells
Skin squamous cell carcinoma
CVCL_1063 
Half Maximal Inhibitory Concentration (IC50) 10.51 nM
Ramos-2G6-4C10 cells
Burkitt lymphoma
CVCL_1646 
Half Maximal Inhibitory Concentration (IC50) 10.56 nM
IST-MES1 cells
Pleural epithelioid mesothelioma
CVCL_1311 
Half Maximal Inhibitory Concentration (IC50) 10.59 nM
KGN cells
Ovarian granulosa cell tumor
CVCL_0375 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10.64 nM
UACC-62 cells
Melanoma
CVCL_1780 
[39]
Half Maximal Inhibitory Concentration (IC50) 10.78 nM
SK-MES-1 cells
Lung squamous cell carcinoma
CVCL_0630 
Half Maximal Inhibitory Concentration (IC50) <100 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[74]
Half Maximal Inhibitory Concentration (IC50) <100 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[74]
Half Maximal Inhibitory Concentration (IC50) <100 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[75]
Half Maximal Inhibitory Concentration (IC50) <100 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[74]
Half Maximal Inhibitory Concentration (IC50) <100 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[75]
Half Maximal Inhibitory Concentration (IC50) <100 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[74]
Half Maximal Inhibitory Concentration (IC50) <100 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[75]
Half Maximal Inhibitory Concentration (IC50) <100 nM
Mahlavu cells
Hepatoma
CVCL_0405 
[74]
Half Maximal Inhibitory Concentration (IC50) <100 nM
FOCUS cells
Hepatocellular carcinoma
CVCL_7955 
[74]
Half Maximal Inhibitory Concentration (IC50) 100 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[76]
Half Maximal Inhibitory Concentration (IC50) 100 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[77]
Half Maximal Inhibitory Concentration (IC50) 100 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[78]
Half Maximal Inhibitory Concentration (IC50) 100 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[79]
Half Maximal Inhibitory Concentration (IC50) 100 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[80]
Half Maximal Inhibitory Concentration (IC50) 100 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[80]
Half Maximal Inhibitory Concentration (IC50) 100 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[81]
Half Maximal Inhibitory Concentration (IC50) 100 nM
CNE-2 cells
Normal
CVCL_6889 
[82]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[83]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[75]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[67]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
Hep 3B2.1-7 cells
Childhood hepatocellular carcinoma
CVCL_0326 
[75]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[67]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[67]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
Mahlavu cells
Hepatoma
CVCL_0405 
[75]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
SNU-475 cells
Hepatocellular carcinoma
CVCL_0497 
[75]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
MFE-296 cells
Endometrial adenocarcinoma
CVCL_1406 
[67]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1000 nM
CEM/C2 cells
T acute lymphoblastic leukemia
CVCL_3497 
[84]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
FOCUS cells
Hepatocellular carcinoma
CVCL_7955 
[67]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
FOCUS cells
Hepatocellular carcinoma
CVCL_7955 
[75]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
QSG-7701 cells
Endocervical adenocarcinoma
CVCL_6944 
[83]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[85]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
Raji cells
EBV-related Burkitt lymphoma
CVCL_0511 
[86]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[87]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[88]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[76]
Half Maximal Inhibitory Concentration (IC50) >1000 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >1000 nM
CEM/C2 cells
T acute lymphoblastic leukemia
CVCL_3497 
[41]
Half Maximal Inhibitory Concentration (IC50) 10000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[89]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[90]
Half Maximal Inhibitory Concentration (IC50) 10000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[91]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [90]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[92]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[73]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
P388 cells
Lymphoma
CVCL_7222 
[93]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
P388 cells
Lymphoma
CVCL_7222 
[94]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
P388 cells
Lymphoma
CVCL_7222 
[95]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
P388CPT45 cells
Lymphoma
CVCL_D638 
[96]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
P388CPT45 cells
Lymphoma
CVCL_D638 
[97]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
CPT-K5 cells
T acute lymphoblastic leukemia
CVCL_2878 
[96]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
CPT-K5 cells
T acute lymphoblastic leukemia
CVCL_2878 
[93]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
CPT-K5 cells
T acute lymphoblastic leukemia
CVCL_2878 
[94]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
CPT-K5 cells
T acute lymphoblastic leukemia
CVCL_2878 
[97]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[70]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
SH-SY5Y cells
Bone marrow neuroblastoma
CVCL_0019 
[98]
Half Maximal Inhibitory Concentration (IC50) 10070 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[99]
Half Maximal Inhibitory Concentration (IC50) 1009.34 nM
NCI-H727 cells
Lung carcinoid tumor
CVCL_1584 
Half Maximal Inhibitory Concentration (IC50) 1010 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[100]
Half Maximal Inhibitory Concentration (IC50) 1010 nM
HEK293 cells
Normal
CVCL_0045 
[101]
Half Maximal Inhibitory Concentration (IC50) 10100 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[102]
Half Maximal Inhibitory Concentration (IC50) 102.32 nM
WM-115 cells
Melanoma
CVCL_0040 
Half Maximal Inhibitory Concentration (IC50) 102.97 nM
KP-N-YN cells
Adrenal gland neuroblastoma
CVCL_1341 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1030 nM
BT-483 cells
Ductal carcinoma
CVCL_2319 
[103]
Half Maximal Inhibitory Concentration (IC50) 1040 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[104]
Half Maximal Inhibitory Concentration (IC50) 105.42 nM
NCI-H358 cells
Minimally invasive lung adenocarcinoma
CVCL_1559 
Half Maximal Inhibitory Concentration (IC50) 106.62 nM
SK-N-FI cells
Neuroblastoma
CVCL_1702 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 106.66 nM
NCI-H322M cells
Minimally invasive lung adenocarcinoma
CVCL_1557 
[39]
Half Maximal Inhibitory Concentration (IC50) 1060 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[101]
Half Maximal Inhibitory Concentration (IC50) 1060 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[105]
Half Maximal Inhibitory Concentration (IC50) 1060 nM
HFL1 cells
Normal
CVCL_0298 
[106]
Half Maximal Inhibitory Concentration (IC50) 107.08 nM
BEN cells
Lung non-small cell carcinoma
CVCL_1082 
Half Maximal Inhibitory Concentration (IC50) 1070 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[87]
Half Maximal Inhibitory Concentration (IC50) 1077.74 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
Half Maximal Inhibitory Concentration (IC50) 108.94 nM
BALL-1 cells
B acute lymphoblastic leukemia
CVCL_1075 
Half Maximal Inhibitory Concentration (IC50) 1080 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[88]
Half Maximal Inhibitory Concentration (IC50) 1080 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[107]
Half Maximal Inhibitory Concentration (IC50) 1080 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[108]
Half Maximal Inhibitory Concentration (IC50) 109.27 nM
COLO-741 cells
Melanoma
CVCL_1133 
Half Maximal Inhibitory Concentration (IC50) 109.97 nM
TGBC1TKB cells
Gallbladder undifferentiated carcinoma
CVCL_1769 
Half Maximal Inhibitory Concentration (IC50) 1093.19 nM
HT-1197 cells
Recurrent bladder carcinoma
CVCL_1291 
Half Maximal Inhibitory Concentration (IC50) 11 nM
A-431 cells
Skin squamous cell carcinoma
CVCL_0037 
[109]
Half Maximal Inhibitory Concentration (IC50) 11 nM
ADR5000 cells
Leukemia
CVCL_D544 
[110]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.07 nM
U-251MG cells
Astrocytoma
CVCL_0021 
[39]
Half Maximal Inhibitory Concentration (IC50) 11.26 nM
KMOE-2 cells
Erythroleukemia
CVCL_1332 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.35 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[39]
Half Maximal Inhibitory Concentration (IC50) 11.5 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[111]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.51 nM
SF268 cells
Astrocytoma
CVCL_1689 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.53 nM
SF-295 cells
Glioblastoma
CVCL_1690 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.56 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.64 nM
ACHN cells
Renal adenocarcinoma
CVCL_1067 
[39]
Half Maximal Inhibitory Concentration (IC50) 11.65 nM
YH-13 cells
Glioblastoma
CVCL_1795 
Half Maximal Inhibitory Concentration (IC50) 11.67 nM
COLO-829 cells
Cutaneous melanoma
CVCL_1137 
Half Maximal Inhibitory Concentration (IC50) 11.7 nM
HSC-2 cells
Oral cavity squamous cell carcinoma
CVCL_1287 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.8 nM
Caki-1 cells
Clear cell renal cell carcinoma
CVCL_0234 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.97 nM
NCI-ADR-RES cells
High grade ovarian serous adenocarcinoma
CVCL_1452 
[39]
Half Maximal Inhibitory Concentration (IC50) 110 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[77]
Half Maximal Inhibitory Concentration (IC50) 110 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[112]
Half Maximal Inhibitory Concentration (IC50) 110 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[113]
Half Maximal Inhibitory Concentration (IC50) 110 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[106]
Half Maximal Inhibitory Concentration (IC50) 110 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[114]
Half Maximal Inhibitory Concentration (IC50) 110 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[115]
Half Maximal Inhibitory Concentration (IC50) 110.1 nM
NCI-H1395 cells
Lung adenocarcinoma
CVCL_1467 
Half Maximal Inhibitory Concentration (IC50) 1100 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[116]
Half Maximal Inhibitory Concentration (IC50) 11120 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[117]
Half Maximal Inhibitory Concentration (IC50) 11170 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[118]
Half Maximal Inhibitory Concentration (IC50) 113.08 nM
no-11 cells
Glioblastoma
CVCL_3076 
Half Maximal Inhibitory Concentration (IC50) 113.62 nM
RCC10RGB cells
Renal cell carcinoma
CVCL_1647 
Half Maximal Inhibitory Concentration (IC50) 11360 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[119]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 114.82 nM
BT-549 cells
Breast ductal carcinoma
CVCL_1092 
[39]
Half Maximal Inhibitory Concentration (IC50) 115.84 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
Half Maximal Inhibitory Concentration (IC50) 115.96 nM
UACC-257 cells
Melanoma
CVCL_1779 
Half Maximal Inhibitory Concentration (IC50) 116.78 nM
BxPC-3 CDX model cells
Pancreatic ductal adenocarcinoma
CVCL_0186 
Half Maximal Inhibitory Concentration (IC50) 11620 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[120]
Half Maximal Inhibitory Concentration (IC50) 117.2 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[121]
Half Maximal Inhibitory Concentration (IC50) 1170 nM
KATO III cells
Down syndrome
CVCL_0371 
Half Maximal Inhibitory Concentration (IC50) 1180 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[100]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 12 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[122]
Half Maximal Inhibitory Concentration (IC50) 12 nM
IA-LM cells
Lung large cell carcinoma
CVCL_1302 
Half Maximal Inhibitory Concentration (IC50) 12 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[31]
Half Maximal Inhibitory Concentration (IC50) 12 nM
Human umbilical vein endothelial cells(HUVEC)
Normal
Undisclosed [123]
Half Maximal Inhibitory Concentration (IC50) 12.24 nM
TGBC11TKB cells
Gastric carcinoma
CVCL_1768 
Half Maximal Inhibitory Concentration (IC50) 12.49 nM
GP5d cells
Colon adenocarcinoma
CVCL_1235 
Half Maximal Inhibitory Concentration (IC50) 12.65 nM
HuO-3N1 cells
Osteosarcoma
CVCL_1297 
Half Maximal Inhibitory Concentration (IC50) 12.76 nM
A-172 cells
Glioblastoma
CVCL_0131 
Half Maximal Inhibitory Concentration (IC50) 12.86 nM
HCC38 cells
Breast ductal carcinoma
CVCL_1267 
Half Maximal Inhibitory Concentration (IC50) 12.98 nM
NCI-H2122 cells
Lung adenocarcinoma
CVCL_1531 
Half Maximal Inhibitory Concentration (IC50) 120 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[98]
Half Maximal Inhibitory Concentration (IC50) 120 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[124]
Half Maximal Inhibitory Concentration (IC50) 120 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[125]
Half Maximal Inhibitory Concentration (IC50) 120 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[126]
Half Maximal Inhibitory Concentration (IC50) 120 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[70]
Half Maximal Inhibitory Concentration (IC50) 120 nM
LX-1 cells
Lung carcinoma
CVCL_5791 
[127]
Half Maximal Inhibitory Concentration (IC50) 120.28 nM
BB49-HNC cells
Floor of mouth squamous cell carcinoma
CVCL_1077 
Half Maximal Inhibitory Concentration (IC50) 1200 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[128]
Half Maximal Inhibitory Concentration (IC50) 1200 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[129]
Half Maximal Inhibitory Concentration (IC50) 1200 nM
NCI-H1975 cells
Lung adenocarcinoma
CVCL_1511 
[130]
Half Maximal Inhibitory Concentration (IC50) 12000 nM
NIH3T3 cells
Normal
CVCL_0594 
[131]
Half Maximal Inhibitory Concentration (IC50) 121 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[132]
Half Maximal Inhibitory Concentration (IC50) 121.91 nM
CAS-1 cells
Glioblastoma
CVCL_1117 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 122.18 nM
HOP-18 cells
Non-small cell lung adenocarcinoma
CVCL_H642 
[39]
Half Maximal Inhibitory Concentration (IC50) 1220 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[133]
Half Maximal Inhibitory Concentration (IC50) 1220 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[133]
Half Maximal Inhibitory Concentration (IC50) 1220 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[133]
Half Maximal Inhibitory Concentration (IC50) 1220 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[133]
Half Maximal Inhibitory Concentration (IC50) 124.47 nM
LAN-6 cells
Neuroblastoma
CVCL_1363 
Half Maximal Inhibitory Concentration (IC50) 1240 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
[134]
Half Maximal Inhibitory Concentration (IC50) 1240 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
[135]
Half Maximal Inhibitory Concentration (IC50) 12500 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[136]
Half Maximal Inhibitory Concentration (IC50) 12500 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[137]
Half Maximal Inhibitory Concentration (IC50) 126 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
Half Maximal Inhibitory Concentration (IC50) 126.89 nM
EFM-19 cells
Breast ductal carcinoma
CVCL_0253 
Half Maximal Inhibitory Concentration (IC50) 1270 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[138]
Half Maximal Inhibitory Concentration (IC50) 127000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[139]
Half Maximal Inhibitory Concentration (IC50) 12750 nM
BT474-M1 cells
Invasive breast carcinoma
CVCL_0179 
[38]
Half Maximal Inhibitory Concentration (IC50) 128.79 nM
SNU-423 cells
Hepatocellular carcinoma
CVCL_0366 
Half Maximal Inhibitory Concentration (IC50) 1290 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[118]
Half Maximal Inhibitory Concentration (IC50) <13 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[140]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[59]
Half Maximal Inhibitory Concentration (IC50) <13 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[140]
Half Maximal Inhibitory Concentration (IC50) 13 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[88]
Half Maximal Inhibitory Concentration (IC50) 13 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[19]
Half Maximal Inhibitory Concentration (IC50) 13 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[31]
Half Maximal Inhibitory Concentration (IC50) 13 nM
A375 cells
Amelanotic melanoma
CVCL_0132 
[141]
Half Maximal Inhibitory Concentration (IC50) 13 nM
P388 cells
Lymphoma
CVCL_7222 
[142]
Half Maximal Inhibitory Concentration (IC50) 13 nM
P388 cells
Lymphoma
CVCL_7222 
[143]
Half Maximal Inhibitory Concentration (IC50) 13.12 nM
JEG-3 cells
Gestational choriocarcinoma
CVCL_0363 
Half Maximal Inhibitory Concentration (IC50) 13.18 nM
KYSE-180 cells
Esophageal squamous cell carcinoma
CVCL_1349 
Half Maximal Inhibitory Concentration (IC50) 13.34 nM
Detroit 562 cells
Pharyngeal squamous cell carcinoma
CVCL_1171 
Half Maximal Inhibitory Concentration (IC50) 13.37 nM
C32 cells
Amelanotic melanoma
CVCL_1097 
Half Maximal Inhibitory Concentration (IC50) 13.52 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
Half Maximal Inhibitory Concentration (IC50) 13.52 nM
HH cells
T-cell non-Hodgkin lymphoma
CVCL_1280 
Half Maximal Inhibitory Concentration (IC50) 13.54 nM
U2OS cells
Osteosarcoma
CVCL_0042 
Half Maximal Inhibitory Concentration (IC50) 13.55 nM
NCI-H661 cells
Lung large cell carcinoma
CVCL_1577 
Half Maximal Inhibitory Concentration (IC50) 13.58 nM
PC-14 cells
Lung adenocarcinoma
CVCL_1640 
Half Maximal Inhibitory Concentration (IC50) 13.71 nM
NCI-H2170 cells
Lung squamous cell carcinoma
CVCL_1535 
Half Maximal Inhibitory Concentration (IC50) 13.82 nM
COLO-684 cells
Endometrial adenocarcinoma
CVCL_1132 
Half Maximal Inhibitory Concentration (IC50) 130 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[144]
Half Maximal Inhibitory Concentration (IC50) 130 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[24]
Half Maximal Inhibitory Concentration (IC50) 130 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[33]
Half Maximal Inhibitory Concentration (IC50) 130 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[145]
Half Maximal Inhibitory Concentration (IC50) 130 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[146]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1300 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[147]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1300 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[148]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1300 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[149]
Half Maximal Inhibitory Concentration (IC50) 1300 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[22]
Half Maximal Inhibitory Concentration (IC50) 1300 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[150]
Half Maximal Inhibitory Concentration (IC50) 130000 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[151]
Half Maximal Inhibitory Concentration (IC50) 1310 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[152]
Half Maximal Inhibitory Concentration (IC50) 13200 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[82]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1324.34 nM
TK-10 cells
Renal carcinoma
CVCL_1773 
[39]
Half Maximal Inhibitory Concentration (IC50) 134.42 nM
MDA-MB-415 cells
Breast adenocarcinoma
CVCL_0621 
Half Maximal Inhibitory Concentration (IC50) 134.47 nM
KARPAS-45 cells
T acute lymphoblastic leukemia
CVCL_1326 
Half Maximal Inhibitory Concentration (IC50) 1360 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[108]
Half Maximal Inhibitory Concentration (IC50) 13620 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[153]
Half Maximal Inhibitory Concentration (IC50) 13640 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[102]
Half Maximal Inhibitory Concentration (IC50) 1367.35 nM
HCC1395 cells
Breast ductal carcinoma
CVCL_1249 
Half Maximal Inhibitory Concentration (IC50) 1370 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[154]
Half Maximal Inhibitory Concentration (IC50) 1370 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[155]
Half Maximal Inhibitory Concentration (IC50) 1370 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[156]
Half Maximal Inhibitory Concentration (IC50) 13700 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[106]
Half Maximal Inhibitory Concentration (IC50) 1380 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[101]
Half Maximal Inhibitory Concentration (IC50) 14 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[157]
Half Maximal Inhibitory Concentration (IC50) 14 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[158]
Half Maximal Inhibitory Concentration (IC50) 14 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[159]
Half Maximal Inhibitory Concentration (IC50) 14 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[160]
Half Maximal Inhibitory Concentration (IC50) 14 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[161]
Half Maximal Inhibitory Concentration (IC50) 14 nM
P388 cells
Lymphoma
CVCL_7222 
[162]
Half Maximal Inhibitory Concentration (IC50) 14 nM
P388 cells
Lymphoma
CVCL_7222 
[96]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 14.03 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[39]
Half Maximal Inhibitory Concentration (IC50) 14.09 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
Half Maximal Inhibitory Concentration (IC50) 14.11 nM
MZ2-MEL cells
Melanoma
CVCL_1435 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 14.49 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[39]
Half Maximal Inhibitory Concentration (IC50) 14.54 nM
JAR cells
Gestational choriocarcinoma
CVCL_0360 
Half Maximal Inhibitory Concentration (IC50) 14.55 nM
TI-73 cells
Normal
CVCL_3605 
Half Maximal Inhibitory Concentration (IC50) 14.75 nM
CFPAC-1 cells
Pancreatic ductal adenocarcinoma
CVCL_1119 
Half Maximal Inhibitory Concentration (IC50) 14.88 nM
RT-112 cells
Bladder carcinoma
CVCL_1670 
Half Maximal Inhibitory Concentration (IC50) 14.91 nM
RO82-W-1 cells
Thyroid gland follicular carcinoma
CVCL_0582 
Half Maximal Inhibitory Concentration (IC50) 14.93 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
Half Maximal Inhibitory Concentration (IC50) 14.95 nM
Capan-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0237 
Half Maximal Inhibitory Concentration (IC50) 14.95 nM
NCI-H1651 cells
Lung adenocarcinoma
CVCL_1484 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 14.96 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[39]
Half Maximal Inhibitory Concentration (IC50) 140 nM
A-172 cells
Glioblastoma
CVCL_0131 
Half Maximal Inhibitory Concentration (IC50) 140 nM
BEL-7404 tumor cells
Endocervical adenocarcinoma
CVCL_6568 
[76]
Half Maximal Inhibitory Concentration (IC50) 140 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[163]
Half Maximal Inhibitory Concentration (IC50) 1400 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[164]
Half Maximal Inhibitory Concentration (IC50) 14000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[165]
Half Maximal Inhibitory Concentration (IC50) 14000000 nM
DLD-1 cells
Colon adenocarcinoma
CVCL_0248 
[166]
Half Maximal Inhibitory Concentration (IC50) 1410 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[138]
Half Maximal Inhibitory Concentration (IC50) 1414.4 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[121]
Half Maximal Inhibitory Concentration (IC50) 14200 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[116]
Half Maximal Inhibitory Concentration (IC50) 144.23 nM
MKN7 cells
Gastric tubular adenocarcinoma
CVCL_1417 
Half Maximal Inhibitory Concentration (IC50) 144.69 nM
Hs 578T cells
Invasive breast carcinoma
CVCL_0332 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 145.21 nM
MDA-N cells
Breast carcinoma
CVCL_1910 
[39]
Half Maximal Inhibitory Concentration (IC50) 1460 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[167]
Half Maximal Inhibitory Concentration (IC50) 147.61 nM
TE-10 cells
Esophageal squamous cell carcinoma
CVCL_1760 
Half Maximal Inhibitory Concentration (IC50) 14760 nM
MDA-MB-468 cells
Breast adenocarcinoma
CVCL_0419 
[168]
Half Maximal Inhibitory Concentration (IC50) 148.3 nM
L-428 cells
Hodgkin lymphoma
CVCL_1361 
Half Maximal Inhibitory Concentration (IC50) 149.39 nM
NCI-H1650 cells
Lung adenocarcinoma
CVCL_1483 
Half Maximal Inhibitory Concentration (IC50) 15 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[169]
Half Maximal Inhibitory Concentration (IC50) 15 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[170]
Half Maximal Inhibitory Concentration (IC50) 15 nM
786-O cells
Renal cell carcinoma
CVCL_1051 
[171]
Half Maximal Inhibitory Concentration (IC50) 15 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[172]
Half Maximal Inhibitory Concentration (IC50) 15 nM
KB 3-1 cells
Cervical epithelial carcinoma
CVCL_2088 
[93]
Half Maximal Inhibitory Concentration (IC50) 15 nM
KB 3-1 cells
Cervical epithelial carcinoma
CVCL_2088 
[95]
Half Maximal Inhibitory Concentration (IC50) 15 nM
U-373MG ATCC cells
Astrocytoma
CVCL_2219 
[37]
Half Maximal Inhibitory Concentration (IC50) 15.35 nM
A704 cells
Renal carcinoma
CVCL_1065 
Half Maximal Inhibitory Concentration (IC50) 15.74 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
Half Maximal Inhibitory Concentration (IC50) 15.75 nM
DSH1 cells
Bladder carcinoma
CVCL_1182 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 15.78 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[39]
Half Maximal Inhibitory Concentration (IC50) 15.8 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[132]
Half Maximal Inhibitory Concentration (IC50) 15.86 nM
MC116 cells
B-cell non-Hodgkin lymphoma
CVCL_1399 
Half Maximal Inhibitory Concentration (IC50) 150 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[67]
Half Maximal Inhibitory Concentration (IC50) 150.08 nM
EW-18 cells
Ewing sarcoma
CVCL_1213 
Half Maximal Inhibitory Concentration (IC50) 150.28 nM
HCC 2998 cells
Colon adenocarcinoma
CVCL_1266 
Half Maximal Inhibitory Concentration (IC50) 150.37 nM
NCI-H1563 cells
Lung adenocarcinoma
CVCL_1475 
Half Maximal Inhibitory Concentration (IC50) 150.57 nM
CAL-72 cells
Osteosarcoma
CVCL_1113 
Half Maximal Inhibitory Concentration (IC50) 1500 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[173]
Half Maximal Inhibitory Concentration (IC50) >150000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[174]
Half Maximal Inhibitory Concentration (IC50) >150000 nM
HGC-27 cells
Gastric carcinoma
CVCL_1279 
[174]
Half Maximal Inhibitory Concentration (IC50) >150000 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[174]
Half Maximal Inhibitory Concentration (IC50) >150000 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[174]
Half Maximal Inhibitory Concentration (IC50) >150000 nM
HCCLM9 cells
Adult hepatocellular carcinoma
CVCL_A5CU 
[174]
Half Maximal Inhibitory Concentration (IC50) 151.26 nM
IGR-1 cells
Cutaneous melanoma
CVCL_1303 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 151.71 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[39]
Half Maximal Inhibitory Concentration (IC50) 1520 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[138]
Half Maximal Inhibitory Concentration (IC50) 15200 nM
FHCC-98 cells
Hepatocellular carcinoma
CVCL_L437 
[175]
Half Maximal Inhibitory Concentration (IC50) 1530 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[101]
Half Maximal Inhibitory Concentration (IC50) 1540 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[77]
Half Maximal Inhibitory Concentration (IC50) 1543.63 nM
SHP-77 cells
Small cell lung carcinoma
CVCL_1693 
Half Maximal Inhibitory Concentration (IC50) 1552.36 nM
A-431 cells
Skin squamous cell carcinoma
CVCL_0037 
Half Maximal Inhibitory Concentration (IC50) 1560 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[70]
Half Maximal Inhibitory Concentration (IC50) 157.32 nM
NCI-H1770 cells
Lung non-small cell carcinoma
CVCL_1493 
Half Maximal Inhibitory Concentration (IC50) 1570 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[176]
Half Maximal Inhibitory Concentration (IC50) 1570 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[177]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 158.85 nM
HCC 2998 cells
Colon adenocarcinoma
CVCL_1266 
[39]
Half Maximal Inhibitory Concentration (IC50) 159 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[178]
Half Maximal Inhibitory Concentration (IC50) 159 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[179]
Half Maximal Inhibitory Concentration (IC50) 1590 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[180]
Half Maximal Inhibitory Concentration (IC50) 16 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[181]
Half Maximal Inhibitory Concentration (IC50) 16 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[182]
Half Maximal Inhibitory Concentration (IC50) 16 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[183]
Half Maximal Inhibitory Concentration (IC50) 16.13 nM
AGS cells
Gastric adenocarcinoma
CVCL_0139 
Half Maximal Inhibitory Concentration (IC50) 16.33 nM
TE-11 cells
Esophageal squamous cell carcinoma
CVCL_1761 
Half Maximal Inhibitory Concentration (IC50) 16.44 nM
LU-139 cells
Lung small cell carcinoma
CVCL_1390 
Half Maximal Inhibitory Concentration (IC50) 16.8 nM
NB7 cells
Neuroblastoma
CVCL_8824 
Half Maximal Inhibitory Concentration (IC50) 160 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[115]
Half Maximal Inhibitory Concentration (IC50) 1600 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[165]
Half Maximal Inhibitory Concentration (IC50) 1600 nM
KG-1 cells
Adult acute myeloid leukemia
CVCL_0374 
[184]
Half Maximal Inhibitory Concentration (IC50) 162 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[19]
Half Maximal Inhibitory Concentration (IC50) 162.01 nM
NCI-H520 cells
Lung squamous cell carcinoma
CVCL_1566 
Half Maximal Inhibitory Concentration (IC50) 1620 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[180]
Half Maximal Inhibitory Concentration (IC50) 16240 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[185]
Half Maximal Inhibitory Concentration (IC50) 16440 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[186]
Half Maximal Inhibitory Concentration (IC50) 165 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[159]
Half Maximal Inhibitory Concentration (IC50) 166 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[187]
Half Maximal Inhibitory Concentration (IC50) 166 nM
HGC-27 cells
Gastric carcinoma
CVCL_1279 
[156]
Half Maximal Inhibitory Concentration (IC50) 1660 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[188]
Half Maximal Inhibitory Concentration (IC50) 1670 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[70]
Half Maximal Inhibitory Concentration (IC50) 168.37 nM
AsPC-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0152 
Half Maximal Inhibitory Concentration (IC50) 169.17 nM
COLO-792 cells
Melanoma
CVCL_1134 
Half Maximal Inhibitory Concentration (IC50) 17 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[109]
Half Maximal Inhibitory Concentration (IC50) 17 nM
MKN45 cells
Gastric adenocarcinoma
CVCL_0434 
[157]
Half Maximal Inhibitory Concentration (IC50) 17 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[189]
Half Maximal Inhibitory Concentration (IC50) 17 nM
WiDr cells
Colon adenocarcinoma
CVCL_2760 
[157]
Half Maximal Inhibitory Concentration (IC50) 17.13 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
Half Maximal Inhibitory Concentration (IC50) 17.34 nM
SNB-75 cells
Glioblastoma
CVCL_1706 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 17.38 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[56]
Half Maximal Inhibitory Concentration (IC50) 17.64 nM
BT-549 cells
Breast ductal carcinoma
CVCL_1092 
Half Maximal Inhibitory Concentration (IC50) 17.73 nM
D-392MG cells
Glioblastoma
CVCL_1158 
Half Maximal Inhibitory Concentration (IC50) 17.77 nM
SAOS-2 cells
Osteosarcoma
CVCL_0548 
Half Maximal Inhibitory Concentration (IC50) 17.86 nM
HT-144 cells
Melanoma
CVCL_0318 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 17.95 nM
NCI-H226 cells
Pleural epithelioid mesothelioma
CVCL_1544 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 170 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[190]
Half Maximal Inhibitory Concentration (IC50) 170 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[189]
Half Maximal Inhibitory Concentration (IC50) 170 nM
MDA-MB-361 cells
Breast adenocarcinoma
CVCL_0620 
[38]
Half Maximal Inhibitory Concentration (IC50) 170 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[191]
Half Maximal Inhibitory Concentration (IC50) 170 nM
4T1 cells
Mammary carcinoma
CVCL_0125 
[77]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1700 nM
WiDr cells
Colon adenocarcinoma
CVCL_2760 
[147]
Half Maximal Inhibitory Concentration (IC50) 1700 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[184]
Half Maximal Inhibitory Concentration (IC50) 1700 nM
MRC5 cells
Normal
CVCL_0440 
[85]
Half Maximal Inhibitory Concentration (IC50) 1700 nM
MX1 cells
Breast carcinoma
CVCL_4774 
[192]
Half Maximal Inhibitory Concentration (IC50) 1710 nM
MDA-MB-468 cells
Breast adenocarcinoma
CVCL_0419 
[193]
Half Maximal Inhibitory Concentration (IC50) 1720 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
[152]
Half Maximal Inhibitory Concentration (IC50) 173.4 nM
NCI-H1573 cells
Lung adenocarcinoma
CVCL_1478 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 173.78 nM
Malme-3M cells
Melanoma
CVCL_1438 
[39]
Half Maximal Inhibitory Concentration (IC50) 174.04 nM
no-10 cells
Glioblastoma
CVCL_3075 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 176.6 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[39]
Half Maximal Inhibitory Concentration (IC50) 178.42 nM
NCI-H2126 cells
Lung large cell carcinoma
CVCL_1532 
Half Maximal Inhibitory Concentration (IC50) 178.5 nM
TE-6 cells
Esophageal squamous cell carcinoma
CVCL_1765 
Half Maximal Inhibitory Concentration (IC50) 178.95 nM
Calu-6 cells
Lung adenocarcinoma
CVCL_0236 
Half Maximal Inhibitory Concentration (IC50) 1780.55 nM
HT-1376 cells
Bladder carcinoma
CVCL_1292 
Half Maximal Inhibitory Concentration (IC50) 18 nM
SJSA-1 cells
Osteosarcoma
CVCL_1697 
Half Maximal Inhibitory Concentration (IC50) 18 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[194]
Half Maximal Inhibitory Concentration (IC50) 18 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[195]
Half Maximal Inhibitory Concentration (IC50) 18 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[196]
Half Maximal Inhibitory Concentration (IC50) 18 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[197]
Half Maximal Inhibitory Concentration (IC50) 18 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[198]
Half Maximal Inhibitory Concentration (IC50) 18 nM
NCI-H128 cells
Lung carcinoma
CVCL_1460 
[157]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 18.11 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[39]
Half Maximal Inhibitory Concentration (IC50) 18.13 nM
HEC-1 cells
Endometrial adenocarcinoma
CVCL_1274 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 18.16 nM
SNB-19 cells
Astrocytoma
CVCL_0535 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 18.2 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[56]
Half Maximal Inhibitory Concentration (IC50) 18.37 nM
LB831-BLC cells
Bladder carcinoma
CVCL_1370 
Half Maximal Inhibitory Concentration (IC50) 18.57 nM
SCC-15 cells
Squamous carcinoma
CVCL_1681 
Half Maximal Inhibitory Concentration (IC50) 18.71 nM
NCI-H1666 cells
Lung adenocarcinoma
CVCL_1485 
Half Maximal Inhibitory Concentration (IC50) 18.92 nM
DOK cells
Oral epithelial dysplasia
CVCL_1180 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 180 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[199]
Half Maximal Inhibitory Concentration (IC50) 180 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
Half Maximal Inhibitory Concentration (IC50) 180 nM
PANC-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0480 
[200]
Half Maximal Inhibitory Concentration (IC50) 180 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[201]
Half Maximal Inhibitory Concentration (IC50) 180 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[202]
Half Maximal Inhibitory Concentration (IC50) 180 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[171]
Half Maximal Inhibitory Concentration (IC50) 180 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[203]
Half Maximal Inhibitory Concentration (IC50) 180.87 nM
SK-LMS-1 cells
Vulvar leiomyosarcoma
CVCL_0628 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1800 nM
WiDr cells
Colon adenocarcinoma
CVCL_2760 
[204]
Half Maximal Inhibitory Concentration (IC50) 1800 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[205]
Half Maximal Inhibitory Concentration (IC50) 1800 nM
Ca-Ski cells
Cervical squamous cell carcinoma
CVCL_1100 
[206]
Half Maximal Inhibitory Concentration (IC50) 182.71 nM
NB6 cells
Neuroblastoma
CVCL_8823 
Half Maximal Inhibitory Concentration (IC50) 18240 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[186]
Half Maximal Inhibitory Concentration (IC50) 18300 nM
QSG-7701 cells
Endocervical adenocarcinoma
CVCL_6944 
[175]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 184.08 nM
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
CVCL_1304 
[39]
Half Maximal Inhibitory Concentration (IC50) 184.93 nM
COR-L105 cells
Lung adenocarcinoma
CVCL_1138 
Half Maximal Inhibitory Concentration (IC50) 1840 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[201]
Half Maximal Inhibitory Concentration (IC50) 1840 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[202]
Half Maximal Inhibitory Concentration (IC50) 1840 nM
MS cells
Diffuse large B-cell lymphoma
CVCL_ZC25 
[134]
Half Maximal Inhibitory Concentration (IC50) 185.61 nM
NCI-H2347 cells
Lung adenocarcinoma
CVCL_1550 
Half Maximal Inhibitory Concentration (IC50) <1850 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
RKO cells
Colon carcinoma
CVCL_0504 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
U-87MG ATCC cells
Glioblastoma
CVCL_0022 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
C6 cells
Glioma
CVCL_0194 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
SGC-7901 cells
Gastric carcinoma
CVCL_0520 
[174]
Half Maximal Inhibitory Concentration (IC50) 1850 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[167]
Half Maximal Inhibitory Concentration (IC50) 188.55 nM
OVCAR-4 cells
Ovarian adenocarcinoma
CVCL_1627 
Half Maximal Inhibitory Concentration (IC50) 1880 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[135]
Half Maximal Inhibitory Concentration (IC50) 1880 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[152]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 19 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[207]
Half Maximal Inhibitory Concentration (IC50) 19 nM
U-118-MG cells
Astrocytoma
CVCL_0633 
Half Maximal Inhibitory Concentration (IC50) 19 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[178]
Half Maximal Inhibitory Concentration (IC50) 19 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[179]
Half Maximal Inhibitory Concentration (IC50) 19.16 nM
G-401 cells
Kidney Wilm's tumor
CVCL_0270 
Half Maximal Inhibitory Concentration (IC50) 19.16 nM
CAL-39 cells
Vulvar squamous cell carcinoma
CVCL_1109 
Half Maximal Inhibitory Concentration (IC50) 19.26 nM
SCC-4 cells
Tongue squamous cell carcinoma
CVCL_1684 
Half Maximal Inhibitory Concentration (IC50) 19.37 nM
LS-513 cells
Cecum adenocarcinoma
CVCL_1386 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 19.41 nM
NCI-H23 cells
Lung adenocarcinoma
CVCL_1547 
[39]
Half Maximal Inhibitory Concentration (IC50) 19.42 nM
KNS-81-FD cells
Glioblastoma
CVCL_1336 
Half Maximal Inhibitory Concentration (IC50) 19.46 nM
23132-87 cells
Gastric adenocarcinoma
CVCL_1046 
Half Maximal Inhibitory Concentration (IC50) 19.68 nM
Panc1005 cells
Pancreatic carcinoma
CVCL_1639 
Half Maximal Inhibitory Concentration (IC50) 19.82 nM
NMC-G1 cells
Astrocytoma
CVCL_1608 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 190 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[40]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 190 nM
SF268 cells
Astrocytoma
CVCL_1689 
[208]
Half Maximal Inhibitory Concentration (IC50) 190 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[128]
Half Maximal Inhibitory Concentration (IC50) 190 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[129]
Half Maximal Inhibitory Concentration (IC50) 190 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[209]
Half Maximal Inhibitory Concentration (IC50) 190 nM
SF268 cells
Astrocytoma
CVCL_1689 
[117]
Half Maximal Inhibitory Concentration (IC50) 190 nM
PC-3M cells
Bone metastasis of prostate carcinoma
CVCL_9555 
[210]
Half Maximal Inhibitory Concentration (IC50) 190.35 nM
SW1116 cells
Colon adenocarcinoma
CVCL_0544 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1900 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[147]
Half Maximal Inhibitory Concentration (IC50) 192.44 nM
HT55 cells
Rectal adenocarcinoma
CVCL_1294 
Half Maximal Inhibitory Concentration (IC50) 194.29 nM
SNU-449 cells
Hepatocellular carcinoma
CVCL_0454 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 195 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[40]
Half Maximal Inhibitory Concentration (IC50) 196.84 nM
LB771-HNC cells
Head and neck squamous cell carcinoma
CVCL_1369 
Half Maximal Inhibitory Concentration (IC50) 1980 nM
U-937 cells
Adult acute monocytic leukemia
CVCL_0007 
[211]
Half Maximal Inhibitory Concentration (IC50) 1980 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[212]
Half Maximal Inhibitory Concentration (IC50) 19800 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[213]
Half Maximal Inhibitory Concentration (IC50) 1985.76 nM
BT474-M1 cells
Invasive breast carcinoma
CVCL_0179 
Half Maximal Inhibitory Concentration (IC50) >19952.62 nM
Vero C1008 cells
Normal
CVCL_0574 
[214]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[41]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[84]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[207]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[215]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[216]
Half Maximal Inhibitory Concentration (IC50) 2 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[86]
Half Maximal Inhibitory Concentration (IC50) 2 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[217]
Half Maximal Inhibitory Concentration (IC50) 2 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[182]
Half Maximal Inhibitory Concentration (IC50) 2 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[69]
Half Maximal Inhibitory Concentration (IC50) 2 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[218]
Half Maximal Inhibitory Concentration (IC50) 2.01 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[219]
Half Maximal Inhibitory Concentration (IC50) 2.018 nM
CAL-27 cells
Tongue adenosquamous carcinom
CVCL_1107 
Half Maximal Inhibitory Concentration (IC50) 2.029 nM
697 cells
Childhood B acute lymphoblastic leukemia
CVCL_0079 
Half Maximal Inhibitory Concentration (IC50) 2.043 nM
ATN-1 cells
T acute lymphoblastic leukemia
CVCL_1073 
Half Maximal Inhibitory Concentration (IC50) 2.076 nM
LB2241-RCC cells
Renal cell carcinoma
CVCL_1365 
Half Maximal Inhibitory Concentration (IC50) 2.082 nM
BPH-1 cells
Benign prostatic hyperplasia
CVCL_1091 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2.1 nM
MSTO-211H cells
Pleural biphasic mesothelioma
CVCL_1430 
[215]
Half Maximal Inhibitory Concentration (IC50) 2.165 nM
ML-2 cells
Acute myeloid leukemia
CVCL_1418 
Half Maximal Inhibitory Concentration (IC50) 2.175 nM
NB17 cells
Neuroblastoma
CVCL_1445 
Half Maximal Inhibitory Concentration (IC50) 2.21 nM
VM-CUB-1 cells
Bladder carcinoma
CVCL_1786 
Half Maximal Inhibitory Concentration (IC50) 2.21 nM
IMR-32 cells
Neuroblastoma
CVCL_0346 
[220]
Half Maximal Inhibitory Concentration (IC50) 2.211 nM
Ca9-22 cells
Gingival squamous cell carcinoma
CVCL_1102 
Half Maximal Inhibitory Concentration (IC50) 2.217 nM
RPMI-2650 cells
Head and neck squamous cell carcinoma
CVCL_1664 
Half Maximal Inhibitory Concentration (IC50) 2.24 nM
NCI-H292 cells
Lung mucoepidermoid carcinoma
CVCL_0455 
Half Maximal Inhibitory Concentration (IC50) 2.3 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[182]
Half Maximal Inhibitory Concentration (IC50) 2.348 nM
SW1573 cells
Lung carcinoma
CVCL_1720 
Half Maximal Inhibitory Concentration (IC50) 2.381 nM
BV-173 cells
Chronic myelogenous leukemia
CVCL_0181 
Half Maximal Inhibitory Concentration (IC50) 2.406 nM
ONS-76 cells
Medulloblastoma
CVCL_1624 
Half Maximal Inhibitory Concentration (IC50) 2.438 nM
C2BBe1 cells
Colon adenocarcinoma
CVCL_1096 
Half Maximal Inhibitory Concentration (IC50) 2.504 nM
JVM-3 cells
B-cell prolymphocytic leukemia
CVCL_1320 
Half Maximal Inhibitory Concentration (IC50) 2.506 nM
OC-314 cells
Ovarian serous adenocarcinoma
CVCL_1616 
Half Maximal Inhibitory Concentration (IC50) 2.551 nM
D-423MG cells
Glioblastoma
CVCL_1160 
Half Maximal Inhibitory Concentration (IC50) 2.551 nM
HAL-01 cells
B acute lymphoblastic leukemia
CVCL_1242 
Half Maximal Inhibitory Concentration (IC50) 2.579 nM
J-RT3-T3-5 cells
T acute lymphoblastic leukemi
CVCL_1316 
Half Maximal Inhibitory Concentration (IC50) 2.659 nM
EW-11 cells
Ewing sarcoma
CVCL_1209 
Half Maximal Inhibitory Concentration (IC50) 2.692 nM
ME-180 cells
Cervical squamous cell carcinoma
CVCL_1401 
Half Maximal Inhibitory Concentration (IC50) 2.733 nM
MHH-PREB-1 cells
B-cell non-Hodgkin lymphoma
CVCL_1413 
Half Maximal Inhibitory Concentration (IC50) 2.759 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
Half Maximal Inhibitory Concentration (IC50) 2.774 nM
MS-1 cells
Lung small cell carcinoma
CVCL_1429 
Half Maximal Inhibitory Concentration (IC50) 2.792 nM
P30-OHK cells
B acute lymphoblastic leukemia
CVCL_1631 
Half Maximal Inhibitory Concentration (IC50) 2.806 nM
LC-2-ad cells
Lung adenocarcinoma
CVCL_1373 
Half Maximal Inhibitory Concentration (IC50) 2.835 nM
SF-126 cells
Glioblastoma
CVCL_1688 
Half Maximal Inhibitory Concentration (IC50) 2.881 nM
HuO9 cells
Osteosarcoma
CVCL_1298 
Half Maximal Inhibitory Concentration (IC50) 2.902 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
Half Maximal Inhibitory Concentration (IC50) 2.993 nM
SW13 cells
Adrenal cortex carcinoma
CVCL_0542 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[65]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[51]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[59]
Half Maximal Inhibitory Concentration (IC50) 20 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[221]
Half Maximal Inhibitory Concentration (IC50) 20 nM
SK-BR-3 cells
Breast adenocarcinoma
CVCL_0033 
[157]
Half Maximal Inhibitory Concentration (IC50) 20 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[169]
Half Maximal Inhibitory Concentration (IC50) 20 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[222]
Half Maximal Inhibitory Concentration (IC50) 20 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[201]
Half Maximal Inhibitory Concentration (IC50) 20 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[202]
Half Maximal Inhibitory Concentration (IC50) 20 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[223]
Half Maximal Inhibitory Concentration (IC50) 20 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[145]
Half Maximal Inhibitory Concentration (IC50) 20 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[73]
Half Maximal Inhibitory Concentration (IC50) 20 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[24]
Half Maximal Inhibitory Concentration (IC50) 20 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[157]
Half Maximal Inhibitory Concentration (IC50) 20 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[140]
Half Maximal Inhibitory Concentration (IC50) 20 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[185]
Half Maximal Inhibitory Concentration (IC50) 20 nM
MDA-MB-157 cells
Breast carcinoma
CVCL_0618 
[38]
Half Maximal Inhibitory Concentration (IC50) 20 nM
KB 3-1 cells
Cervical epithelial carcinoma
CVCL_2088 
[73]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20.18 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[39]
Half Maximal Inhibitory Concentration (IC50) 20.32 nM
EFO-21 cells
Ovarian serous cystadenocarcinoma
CVCL_0029 
Half Maximal Inhibitory Concentration (IC50) 20.33 nM
MZ1-PC cells
Pancreatic ductal adenocarcinoma
CVCL_1434 
Half Maximal Inhibitory Concentration (IC50) 20.35 nM
SW 954 cells
Vulva squamous carcinoma
CVCL_1732 
Half Maximal Inhibitory Concentration (IC50) 20.49 nM
LCLC-103H cells
Lung large cell carcinoma
CVCL_1375 
Half Maximal Inhibitory Concentration (IC50) 20.51 nM
SW 962 cells
Vulva lymphoid carcinoma
CVCL_1733 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20.56 nM
DMS 114 cells
Lung small cell carcinoma
CVCL_1174 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20.65 nM
M14 cells
Melanoma
CVCL_1395 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 200 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[148]
Half Maximal Inhibitory Concentration (IC50) 200 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[60]
Half Maximal Inhibitory Concentration (IC50) 200 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[128]
Half Maximal Inhibitory Concentration (IC50) 200 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[129]
Half Maximal Inhibitory Concentration (IC50) 200 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[60]
Half Maximal Inhibitory Concentration (IC50) 200 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[66]
Half Maximal Inhibitory Concentration (IC50) 200 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[224]
Half Maximal Inhibitory Concentration (IC50) 200 nM
SW1990 cells
Pancreatic adenocarcinoma
CVCL_1723 
[225]
Half Maximal Inhibitory Concentration (IC50) 200 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[66]
Half Maximal Inhibitory Concentration (IC50) 200 nM
Human umbilical vein endothelial cells(HUVEC)
Normal
Undisclosed [144]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2000 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[149]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2000 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[204]
Half Maximal Inhibitory Concentration (IC50) 2000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[91]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
Vero C1008 cells
Normal
CVCL_0574 
[214]
Half Maximal Inhibitory Concentration (IC50) >200000 nM
NCI-H446 cells
Lung small cell carcinoma
CVCL_1562 
[76]
Half Maximal Inhibitory Concentration (IC50) >200000 nM
NCI-H446 cells
Lung small cell carcinoma
CVCL_1562 
[223]
Half Maximal Inhibitory Concentration (IC50) 207 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[226]
Half Maximal Inhibitory Concentration (IC50) 208.15 nM
CP66-MEL cells
Melanoma
CVCL_1144 
Half Maximal Inhibitory Concentration (IC50) 208.78 nM
NCI-H1755 cells
Lung adenocarcinoma
CVCL_1492 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 209.41 nM
OVCAR-4 cells
Ovarian adenocarcinoma
CVCL_1627 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 21 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[227]
Half Maximal Inhibitory Concentration (IC50) 21 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[123]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 21.38 nM
786-O cells
Renal cell carcinoma
CVCL_1051 
[39]
Half Maximal Inhibitory Concentration (IC50) 21.55 nM
BB30-HNC cells
Head and neck squamous cell carcinoma
CVCL_1076 
Half Maximal Inhibitory Concentration (IC50) 21.56 nM
MFE-280 cells
Endometrial adenocarcinoma
CVCL_1405 
Half Maximal Inhibitory Concentration (IC50) 21.69 nM
SK-N-DZ cells
Neuroblastoma
CVCL_1701 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 210 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[227]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 210 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[122]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 210 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[228]
Half Maximal Inhibitory Concentration (IC50) 210 nM
DLD-1 cells
Colon adenocarcinoma
CVCL_0248 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 210 nM
SW1573 cells
Lung carcinoma
CVCL_1720 
[147]
Half Maximal Inhibitory Concentration (IC50) 210 nM
SK-BR-3 cells
Breast adenocarcinoma
CVCL_0033 
[105]
Half Maximal Inhibitory Concentration (IC50) 210 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[229]
Half Maximal Inhibitory Concentration (IC50) 210 nM
Capan-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0237 
[200]
Half Maximal Inhibitory Concentration (IC50) 210 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[197]
Half Maximal Inhibitory Concentration (IC50) 210 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[230]
Half Maximal Inhibitory Concentration (IC50) 210 nM
HPDE6c7 cells
Normal
CVCL_0P38 
[203]
Half Maximal Inhibitory Concentration (IC50) 2100 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[231]
Half Maximal Inhibitory Concentration (IC50) 2100 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[232]
Half Maximal Inhibitory Concentration (IC50) 2110 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[171]
Half Maximal Inhibitory Concentration (IC50) 2150 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[233]
Half Maximal Inhibitory Concentration (IC50) 218.07 nM
GAK cells
Vulvar melanoma
CVCL_1225 
Half Maximal Inhibitory Concentration (IC50) 2190 nM
MCF-10A cells
Normal
CVCL_0598 
[77]
Half Maximal Inhibitory Concentration (IC50) 22.03 nM
KU-19-19 cells
Bladder carcinoma
CVCL_1344 
Half Maximal Inhibitory Concentration (IC50) 22.32 nM
COLO-668 cells
Lung small cell carcinoma
CVCL_1128 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 22.34 nM
NCI-H522 cells
Non-small cell lung carcinoma
CVCL_1567 
[39]
Half Maximal Inhibitory Concentration (IC50) 22.49 nM
NCI-H226 cells
Pleural epithelioid mesothelioma
CVCL_1544 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 22.54 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[39]
Half Maximal Inhibitory Concentration (IC50) 22.59 nM
D-502MG cells
Glioblastoma
CVCL_1162 
Half Maximal Inhibitory Concentration (IC50) 22.87 nM
RERF-LC-MS cells
Lung adenocarcinoma
CVCL_1655 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[59]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
[199]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
[103]
Half Maximal Inhibitory Concentration (IC50) 220 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
[171]
Half Maximal Inhibitory Concentration (IC50) 220 nM
RPMI-7951 cells
Malignant melanoma
CVCL_1666 
[234]
Half Maximal Inhibitory Concentration (IC50) 22000 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[235]
Half Maximal Inhibitory Concentration (IC50) 2210 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[186]
Half Maximal Inhibitory Concentration (IC50) 2260 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
[236]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 227.51 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
[39]
Half Maximal Inhibitory Concentration (IC50) 2281.94 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
Half Maximal Inhibitory Concentration (IC50) 2281.97 nM
SK-MEL-30 cells
Cutaneous melanoma
CVCL_0039 
Half Maximal Inhibitory Concentration (IC50) 229.98 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
Half Maximal Inhibitory Concentration (IC50) 23 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[237]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 23.01 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[39]
Half Maximal Inhibitory Concentration (IC50) 23.34 nM
Becker cells
Astrocytoma
CVCL_1093 
Half Maximal Inhibitory Concentration (IC50) 23.65 nM
TE-9 cells
Esophageal squamous cell carcinoma
CVCL_1767 
Half Maximal Inhibitory Concentration (IC50) 23.73 nM
KYSE-450 cells
Esophageal squamous cell carcinoma
CVCL_1353 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 230 nM
HBL-100 cells
Normal
CVCL_4362 
[147]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 230 nM
HBL-100 cells
Normal
CVCL_4362 
[204]
Half Maximal Inhibitory Concentration (IC50) 230 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[229]
Half Maximal Inhibitory Concentration (IC50) 230 nM
WI-38 cells
Normal
CVCL_0579 
[238]
Half Maximal Inhibitory Concentration (IC50) 230 nM
MS cells
Diffuse large B-cell lymphoma
CVCL_ZC25 
[239]
Half Maximal Inhibitory Concentration (IC50) 2300 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[116]
Half Maximal Inhibitory Concentration (IC50) 2310 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[240]
Half Maximal Inhibitory Concentration (IC50) 2320 nM
NCI-N87 cells
Gastric tubular adenocarcinoma
CVCL_1603 
[105]
Half Maximal Inhibitory Concentration (IC50) 2370 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[100]
Half Maximal Inhibitory Concentration (IC50) 23760 nM
AGS cells
Gastric adenocarcinoma
CVCL_0139 
[171]
Half Maximal Inhibitory Concentration (IC50) 23980 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[241]
Half Maximal Inhibitory Concentration (IC50) 24 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[19]
Half Maximal Inhibitory Concentration (IC50) 24 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[242]
Half Maximal Inhibitory Concentration (IC50) 24 nM
A-427 cells
Lung carcinoma
CVCL_1055 
[243]
Half Maximal Inhibitory Concentration (IC50) 24 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[161]
Half Maximal Inhibitory Concentration (IC50) 24.12 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
Half Maximal Inhibitory Concentration (IC50) 24.16 nM
SW872 cells
Liposarcoma
CVCL_1730 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 24.49 nM
SN12K1 cells
Lung metastasis of renal carcinoma
CVCL_D106 
[39]
Half Maximal Inhibitory Concentration (IC50) 24.5 nM
G-402 cells
Kidney neoplasm
CVCL_1221 
Half Maximal Inhibitory Concentration (IC50) 24.57 nM
SW1783 cells
Anaplastic astrocytoma
CVCL_1722 
Half Maximal Inhibitory Concentration (IC50) 240 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[244]
Half Maximal Inhibitory Concentration (IC50) 240 nM
BxPC-3 CDX model cells
Pancreatic ductal adenocarcinoma
CVCL_0186 
[66]
Half Maximal Inhibitory Concentration (IC50) 240 nM
ZR-75-30 cells
Breast carcinoma
CVCL_1661 
[125]
Half Maximal Inhibitory Concentration (IC50) 241 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[189]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 242.66 nM
DLD-1 cells
Colon adenocarcinoma
CVCL_0248 
[39]
Half Maximal Inhibitory Concentration (IC50) 2430 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[245]
Half Maximal Inhibitory Concentration (IC50) 244.5 nM
RMG-I cells
Ovarian clear cell adenocarcinoma
CVCL_1662 
Half Maximal Inhibitory Concentration (IC50) 245.96 nM
KYSE-150 cells
Esophageal squamous cell carcinoma
CVCL_1348 
Half Maximal Inhibitory Concentration (IC50) 24770 nM
MCF10 cells
Normal
Undisclosed [246]
Half Maximal Inhibitory Concentration (IC50) 25 nM
Sf9 cells
Normal
CVCL_0549 
[247]
Half Maximal Inhibitory Concentration (IC50) 25 nM
Sf9 cells
Normal
CVCL_0549 
[248]
Half Maximal Inhibitory Concentration (IC50) 25 nM
KB-V1 cells
Cervical carcinoma
CVCL_2089 
[93]
Half Maximal Inhibitory Concentration (IC50) 25 nM
KB-V1 cells
Cervical carcinoma
CVCL_2089 
[95]
Half Maximal Inhibitory Concentration (IC50) 25.07 nM
EGI-1 cells
Cholangiocarcinoma
CVCL_1193 
Half Maximal Inhibitory Concentration (IC50) 25.34 nM
769-P cells
Renal cell carcinom
CVCL_1050 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 25.35 nM
P388/ADR cells
Lymphoma
CVCL_IZ75 
[39]
Half Maximal Inhibitory Concentration (IC50) 25.55 nM
OE33 cells
Barrett adenocarcinoma
CVCL_0471 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 25.64 nM
RXF 393 cells
Renal carcinoma
CVCL_1673 
[39]
Half Maximal Inhibitory Concentration (IC50) 25.78 nM
SW780 cells
Bladder carcinoma
CVCL_1728 
Half Maximal Inhibitory Concentration (IC50) 25.99 nM
BT-20 cells
Invasive breast carcinoma of no special type
CVCL_0178 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 250 nM
SW1573 cells
Lung carcinoma
CVCL_1720 
[204]
Half Maximal Inhibitory Concentration (IC50) 250 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[249]
Half Maximal Inhibitory Concentration (IC50) 250 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[241]
Half Maximal Inhibitory Concentration (IC50) 2500 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[76]
Half Maximal Inhibitory Concentration (IC50) 2500 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[247]
Half Maximal Inhibitory Concentration (IC50) 2500 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[248]
Half Maximal Inhibitory Concentration (IC50) 2500 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[248]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[250]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
GLC-82 cells
Endocervical adenocarcinoma
CVCL_3371 
[250]
Half Maximal Inhibitory Concentration (IC50) 2511.11 nM
UMC-11 cells
Lung carcinoid tumor
CVCL_1784 
Half Maximal Inhibitory Concentration (IC50) 253.14 nM
NCI-H1838 cells
Lung adenocarcinoma
CVCL_1499 
Half Maximal Inhibitory Concentration (IC50) 2530 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[164]
Half Maximal Inhibitory Concentration (IC50) 2544 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[187]
Half Maximal Inhibitory Concentration (IC50) 2544.45 nM
G-361 cells
Melanoma
CVCL_1220 
Half Maximal Inhibitory Concentration (IC50) 256.33 nM
SNU-387 cells
Hepatocellular carcinoma
CVCL_0250 
Half Maximal Inhibitory Concentration (IC50) 257.84 nM
A101D cells
Melanoma
CVCL_1057 
Half Maximal Inhibitory Concentration (IC50) 2580 nM
MCF-10A cells
Normal
CVCL_0598 
[105]
Half Maximal Inhibitory Concentration (IC50) 26 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[211]
Half Maximal Inhibitory Concentration (IC50) 26 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[19]
Half Maximal Inhibitory Concentration (IC50) 26 nM
KBH5.0 cells
Endocervical adenocarcinoma
CVCL_D644 
[93]
Half Maximal Inhibitory Concentration (IC50) 26 nM
KBH5.0 cells
Endocervical adenocarcinoma
CVCL_D644 
[95]
Half Maximal Inhibitory Concentration (IC50) 26.03 nM
PFSK-1 cells
Primitive neuroectodermal tumor
CVCL_1642 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 26.06 nM
LOX IMVI cells
Melanoma
CVCL_1381 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 26.67 nM
P388 cells
Lymphoma
CVCL_7222 
[39]
Half Maximal Inhibitory Concentration (IC50) 26.69 nM
NCI-H1693 cells
Lung adenocarcinoma
CVCL_1488 
Half Maximal Inhibitory Concentration (IC50) 260 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[251]
Half Maximal Inhibitory Concentration (IC50) 260 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[125]
Half Maximal Inhibitory Concentration (IC50) 260 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[251]
Half Maximal Inhibitory Concentration (IC50) 260 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[100]
Half Maximal Inhibitory Concentration (IC50) 260 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[112]
Half Maximal Inhibitory Concentration (IC50) 260 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[232]
Half Maximal Inhibitory Concentration (IC50) 260 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[31]
Half Maximal Inhibitory Concentration (IC50) 260 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[251]
Half Maximal Inhibitory Concentration (IC50) 260 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[251]
Half Maximal Inhibitory Concentration (IC50) 260.2 nM
SW948 cells
Colon adenocarcinoma
CVCL_0632 
Half Maximal Inhibitory Concentration (IC50) 2600 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[205]
Half Maximal Inhibitory Concentration (IC50) 261 nM
ZR-75-30 cells
Breast carcinoma
CVCL_1661 
Half Maximal Inhibitory Concentration (IC50) 2610 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[114]
Half Maximal Inhibitory Concentration (IC50) 262.05 nM
CAL-12T cells
Lung non-small cell carcinoma
CVCL_1105 
Half Maximal Inhibitory Concentration (IC50) 2620 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[240]
Half Maximal Inhibitory Concentration (IC50) 264 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[77]
Half Maximal Inhibitory Concentration (IC50) 26450 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[120]
Half Maximal Inhibitory Concentration (IC50) 265.25 nM
TE-12 cells
Esophageal squamous cell carcinoma
CVCL_1762 
Half Maximal Inhibitory Concentration (IC50) 266.61 nM
HCC1954 cells
Breast ductal carcinoma
CVCL_1259 
Half Maximal Inhibitory Concentration (IC50) 267.54 nM
HCC1569 cells
Breast ductal carcinoma
CVCL_1255 
Half Maximal Inhibitory Concentration (IC50) 269.5 nM
COLO-824 cells
Breast carcinoma
CVCL_1136 
Half Maximal Inhibitory Concentration (IC50) 27.08 nM
MFH-ino cells
Pleomorphic sarcoma
CVCL_1407 
Half Maximal Inhibitory Concentration (IC50) 27.15 nM
T98G cells
Glioblastoma
CVCL_0556 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 27.16 nM
SK-MEL-5 cells
Cutaneous melanoma
CVCL_0527 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 27.16 nM
SNB-75 cells
Glioblastoma
CVCL_1706 
[39]
Half Maximal Inhibitory Concentration (IC50) 27.23 nM
NCI-H1793 cells
Lung adenocarcinoma
CVCL_1496 
Half Maximal Inhibitory Concentration (IC50) 27.24 nM
MPP-89 cells
Pleural epithelioid mesothelioma
CVCL_1427 
Half Maximal Inhibitory Concentration (IC50) 27.5 nM
MKN45 cells
Gastric adenocarcinoma
CVCL_0434 
Half Maximal Inhibitory Concentration (IC50) 27.77 nM
SW1088 cells
Astrocytoma
CVCL_1715 
Half Maximal Inhibitory Concentration (IC50) 27.79 nM
SBC-1 cells
Lung small cell carcinoma
CVCL_1676 
Half Maximal Inhibitory Concentration (IC50) 270 nM
MCF-10A cells
Normal
CVCL_0598 
[99]
Half Maximal Inhibitory Concentration (IC50) 2700 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[223]
Half Maximal Inhibitory Concentration (IC50) 2700 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[205]
Half Maximal Inhibitory Concentration (IC50) 27000 nM
Vero cells
Normal
CVCL_0059 
[131]
Half Maximal Inhibitory Concentration (IC50) 27200 nM
TERT-RPE1 cells
Normal
CVCL_4388 
[221]
Half Maximal Inhibitory Concentration (IC50) 276.33 nM
Lu-65 cells
Lung giant cell carcinoma
CVCL_1392 
Half Maximal Inhibitory Concentration (IC50) 2770 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[167]
Half Maximal Inhibitory Concentration (IC50) 2780 nM
B16-F10 cells
Mouse melanoma
CVCL_0159 
[252]
Half Maximal Inhibitory Concentration (IC50) 28.16 nM
LU-135 cells
Lung small cell carcinoma
CVCL_1389 
Half Maximal Inhibitory Concentration (IC50) 28.34 nM
NCI-H2052 cells
Pleural mesothelioma
CVCL_1518 
Half Maximal Inhibitory Concentration (IC50) 28.4 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[253]
Half Maximal Inhibitory Concentration (IC50) 28.66 nM
RCM-1 cells
Rectal adenocarcinoma
CVCL_1648 
Half Maximal Inhibitory Concentration (IC50) 28.7 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[132]
Half Maximal Inhibitory Concentration (IC50) 28.7 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[254]
Half Maximal Inhibitory Concentration (IC50) 28.7 nM
Lu1 cells
Lung carcinoma
Undisclosed [254]
Half Maximal Inhibitory Concentration (IC50) 28.7 nM
SW626 cells
Colon adenocarcinoma
CVCL_1725 
[254]
Half Maximal Inhibitory Concentration (IC50) 28.8 nM
NB13 cells
Neuroblastoma
CVCL_1443 
Half Maximal Inhibitory Concentration (IC50) 280 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[136]
Half Maximal Inhibitory Concentration (IC50) 280 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[230]
Half Maximal Inhibitory Concentration (IC50) 280 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[255]
Half Maximal Inhibitory Concentration (IC50) 280 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[99]
Half Maximal Inhibitory Concentration (IC50) 280 nM
HEK293 cells
Normal
CVCL_0045 
[212]
Half Maximal Inhibitory Concentration (IC50) 280 nM
SNU-638 cells
Gastric carcinoma
CVCL_0102 
[256]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2800 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[103]
Half Maximal Inhibitory Concentration (IC50) 2800 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[223]
Half Maximal Inhibitory Concentration (IC50) 282.32 nM
NCI-H630 cells
Colon carcinoma
CVCL_1572 
Half Maximal Inhibitory Concentration (IC50) 2820 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[201]
Half Maximal Inhibitory Concentration (IC50) 2820 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[202]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 285.76 nM
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[39]
Half Maximal Inhibitory Concentration (IC50) 28660 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[102]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >287000 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[190]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >287000 nM
U2OS cells
Osteosarcoma
CVCL_0042 
[190]
Half Maximal Inhibitory Concentration (IC50) 2892.53 nM
Karpas-299 cells/Karpas BVR cells
ALK-positive anaplastic large cell lymphoma
CVCL_1324 
Half Maximal Inhibitory Concentration (IC50) 29 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[161]
Half Maximal Inhibitory Concentration (IC50) 29.49 nM
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
Half Maximal Inhibitory Concentration (IC50) 29.6 nM
YAPC cells
Pancreas carincoma
CVCL_1794 
Half Maximal Inhibitory Concentration (IC50) 29.71 nM
HT cells
Diffuse large B-cell lymphoma
CVCL_1290 
Half Maximal Inhibitory Concentration (IC50) 29.74 nM
CAL-51 cells
Breast carcinoma
CVCL_1110 
Half Maximal Inhibitory Concentration (IC50) 290 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[257]
Half Maximal Inhibitory Concentration (IC50) 2900000 nM
Caov-3 cells
Ovarian serous adenocarcinoma
CVCL_0201 
[166]
Half Maximal Inhibitory Concentration (IC50) 291 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[158]
Half Maximal Inhibitory Concentration (IC50) 291.41 nM
D-542MG cells
Glioblastoma
CVCL_1164 
Half Maximal Inhibitory Concentration (IC50) 296.49 nM
NCI-H747 cells
Cecum adenocarcinoma
CVCL_1587 
Half Maximal Inhibitory Concentration (IC50) 2960 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[258]
Half Maximal Inhibitory Concentration (IC50) 2968.73 nM
NCI-H596 cells
Lung adenosquamous carcinoma
CVCL_1571 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 297.85 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[39]
Half Maximal Inhibitory Concentration (IC50) 298.06 nM
SJRH30 cells
Alveolar rhabdomyosarcoma
CVCL_0041 
Half Maximal Inhibitory Concentration (IC50) 29810 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[98]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[207]
Half Maximal Inhibitory Concentration (IC50) <3 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[76]
Half Maximal Inhibitory Concentration (IC50) <3 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[223]
Half Maximal Inhibitory Concentration (IC50) <3 nM
MV3 cells
Amelanotic melanoma
CVCL_W280 
[76]
Half Maximal Inhibitory Concentration (IC50) 3 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[68]
Half Maximal Inhibitory Concentration (IC50) 3 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[110]
Half Maximal Inhibitory Concentration (IC50) 3 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[141]
Half Maximal Inhibitory Concentration (IC50) 3 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[69]
Half Maximal Inhibitory Concentration (IC50) 3 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[66]
Half Maximal Inhibitory Concentration (IC50) 3 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[259]
Half Maximal Inhibitory Concentration (IC50) 3 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[69]
Half Maximal Inhibitory Concentration (IC50) 3 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[22]
Half Maximal Inhibitory Concentration (IC50) 3 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[260]
Half Maximal Inhibitory Concentration (IC50) 3.015 nM
HSC-3 cells
Oral squamous cell carcinoma
CVCL_1288 
Half Maximal Inhibitory Concentration (IC50) 3.017 nM
SW48 cells
Colon adenocarcinoma
CVCL_1724 
Half Maximal Inhibitory Concentration (IC50) 3.041 nM
BCPAP cells
Thyroid carcinoma
CVCL_0153 
Half Maximal Inhibitory Concentration (IC50) 3.067 nM
SK-UT-1 cells
Uterine corpus leiomyosarcoma
CVCL_0533 
Half Maximal Inhibitory Concentration (IC50) 3.067 nM
DU-4475 cells
Breast adenocarcinoma
CVCL_1183 
Half Maximal Inhibitory Concentration (IC50) 3.069 nM
PSN1 cells
Pancreatic adenocarcinoma
CVCL_1644 
Half Maximal Inhibitory Concentration (IC50) 3.093 nM
UM-UC-3 cells
Bladder carcinoma
CVCL_1783 
Half Maximal Inhibitory Concentration (IC50) 3.1 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[243]
Half Maximal Inhibitory Concentration (IC50) 3.108 nM
NEC8 cells
Testicular embryonal carcinoma
CVCL_1604 
Half Maximal Inhibitory Concentration (IC50) 3.136 nM
NUGC-3 cells
Gastric carcinoma
CVCL_1612 
Half Maximal Inhibitory Concentration (IC50) 3.143 nM
HCC1806 cells
Breast squamous cell carcinoma
CVCL_1258 
Half Maximal Inhibitory Concentration (IC50) 3.162 nM
KP-4 cells
Pancreatic carcinoma
CVCL_1338 
Half Maximal Inhibitory Concentration (IC50) 3.198 nM
D283 Med cells
Medulloblastoma
CVCL_1155 
Half Maximal Inhibitory Concentration (IC50) 3.267 nM
EW-13 cells
Ewing sarcoma
CVCL_1211 
Half Maximal Inhibitory Concentration (IC50) 3.275 nM
CGTH-W-1 cells
Thyroid gland squamous cell carcinoma
CVCL_1120 
Half Maximal Inhibitory Concentration (IC50) 3.3 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[24]
Half Maximal Inhibitory Concentration (IC50) 3.301 nM
8505C cells
Thyroid gland anaplastic carcinoma
CVCL_1054 
Half Maximal Inhibitory Concentration (IC50) 3.344 nM
HC-1 cells
Hairy cell leukemia
CVCL_1243 
Half Maximal Inhibitory Concentration (IC50) 3.365 nM
GI-1 cells
Gliosarcoma
CVCL_1231 
Half Maximal Inhibitory Concentration (IC50) 3.379 nM
SF268 cells
Astrocytoma
CVCL_1689 
Half Maximal Inhibitory Concentration (IC50) 3.382 nM
HuTu 80 cells
Duodenal adenocarcinoma
CVCL_1301 
Half Maximal Inhibitory Concentration (IC50) 3.468 nM
ABC-1 cells
Lung adenocarcinoma
CVCL_1066 
Half Maximal Inhibitory Concentration (IC50) 3.469 nM
VA-ES-BJ cells
Epithelioid sarcoma
CVCL_1785 
Half Maximal Inhibitory Concentration (IC50) 3.599 nM
A2058 cells
Melanoma
CVCL_1059 
Half Maximal Inhibitory Concentration (IC50) 3.68 nM
AU565 cells
Breast adenocarcinoma
CVCL_1074 
Half Maximal Inhibitory Concentration (IC50) 3.688 nM
A375 cells
Amelanotic melanoma
CVCL_0132 
Half Maximal Inhibitory Concentration (IC50) 3.72 nM
LOX IMVI cells
Melanoma
CVCL_1381 
Half Maximal Inhibitory Concentration (IC50) 3.734 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
Half Maximal Inhibitory Concentration (IC50) 3.793 nM
NH-12 cells
Adrenal gland neuroblastoma
CVCL_1605 
Half Maximal Inhibitory Concentration (IC50) 3.81 nM
IST-MEL1 cells
Melanoma
CVCL_1308 
Half Maximal Inhibitory Concentration (IC50) 3.853 nM
ECC10 cells
Gastric small cell carcinoma
CVCL_1188 
Half Maximal Inhibitory Concentration (IC50) 3.854 nM
LU-99A cells
Lung giant cell carcinoma
CVCL_1393 
Half Maximal Inhibitory Concentration (IC50) 3.86 nM
RH-1 cells
Ewing sarcoma
CVCL_1658 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[41]
Half Maximal Inhibitory Concentration (IC50) 30 nM
Caov-3 cells
Ovarian serous adenocarcinoma
CVCL_0201 
Half Maximal Inhibitory Concentration (IC50) 30 nM
Caov-3 cells
Ovarian serous adenocarcinoma
CVCL_0201 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[59]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[208]
Half Maximal Inhibitory Concentration (IC50) 30 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[222]
Half Maximal Inhibitory Concentration (IC50) 30 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[261]
Half Maximal Inhibitory Concentration (IC50) 30 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[222]
Half Maximal Inhibitory Concentration (IC50) 30 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[68]
Half Maximal Inhibitory Concentration (IC50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[261]
Half Maximal Inhibitory Concentration (IC50) 30 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[198]
Half Maximal Inhibitory Concentration (IC50) 30 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[261]
Half Maximal Inhibitory Concentration (IC50) 30 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[104]
Half Maximal Inhibitory Concentration (IC50) 30 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[117]
Half Maximal Inhibitory Concentration (IC50) 30 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[261]
Half Maximal Inhibitory Concentration (IC50) 30 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[262]
Half Maximal Inhibitory Concentration (IC50) 30 nM
WI-38 cells
Normal
CVCL_0579 
[263]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30.27 nM
UO-31 cells
Renal carcinoma
CVCL_1911 
[39]
Half Maximal Inhibitory Concentration (IC50) 300 nM
U-937 cells
Adult acute monocytic leukemia
CVCL_0007 
[60]
Half Maximal Inhibitory Concentration (IC50) 300 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[91]
Half Maximal Inhibitory Concentration (IC50) 300 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[137]
Half Maximal Inhibitory Concentration (IC50) 300 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[264]
Half Maximal Inhibitory Concentration (IC50) 300 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[113]
Half Maximal Inhibitory Concentration (IC50) 300 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[265]
Half Maximal Inhibitory Concentration (IC50) 300 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[78]
Half Maximal Inhibitory Concentration (IC50) >300 nM
H69AR cells
Lung small cell carcinoma
CVCL_3513 
[31]
Half Maximal Inhibitory Concentration (IC50) 300 nM
ADR5000 cells
Leukemia
CVCL_D544 
[90]
Half Maximal Inhibitory Concentration (IC50) 3010 nM
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[152]
Half Maximal Inhibitory Concentration (IC50) 3029.5 nM
JVM-2 cells
Mantle cell lymphoma
CVCL_1319 
Half Maximal Inhibitory Concentration (IC50) 304 nM
Renca cells
Renal carcinoma
CVCL_2174 
[198]
Half Maximal Inhibitory Concentration (IC50) 304.67 nM
ChaGo-K-1 cells
Bronchogenic carcinoma
CVCL_1121 
Half Maximal Inhibitory Concentration (IC50) 3040 nM
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[134]
Half Maximal Inhibitory Concentration (IC50) 3040 nM
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[135]
Half Maximal Inhibitory Concentration (IC50) 307 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[266]
Half Maximal Inhibitory Concentration (IC50) 307 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[267]
Half Maximal Inhibitory Concentration (IC50) 3090 nM
T24 cells
Bladder carcinoma
CVCL_0554 
[233]
Half Maximal Inhibitory Concentration (IC50) 31 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[19]
Half Maximal Inhibitory Concentration (IC50) 31.03 nM
LNCaP-Clone-FGC cells
Prostate carcinoma
CVCL_1379 
Half Maximal Inhibitory Concentration (IC50) 31.03 nM
UACC-62 cells
Melanoma
CVCL_1780 
Half Maximal Inhibitory Concentration (IC50) 31.47 nM
HTC-C3 cells
Thyroid gland anaplastic carcinoma
CVCL_1295 
Half Maximal Inhibitory Concentration (IC50) 31.84 nM
SW900 cells
Lung squamous cell carcinoma
CVCL_1731 
Half Maximal Inhibitory Concentration (IC50) 31.85 nM
DMS-79 cells
Small cell lung carcinoma
CVCL_1178 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 310 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[228]
Half Maximal Inhibitory Concentration (IC50) 310 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[107]
Half Maximal Inhibitory Concentration (IC50) 310 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[106]
Half Maximal Inhibitory Concentration (IC50) 310 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[77]
Half Maximal Inhibitory Concentration (IC50) 310 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[268]
Half Maximal Inhibitory Concentration (IC50) 3100 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[137]
Half Maximal Inhibitory Concentration (IC50) 3100 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[269]
Half Maximal Inhibitory Concentration (IC50) 311.44 nM
NCI-H69 cells
Small cell lung carcinoma
CVCL_1579 
Half Maximal Inhibitory Concentration (IC50) 3120 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[136]
Half Maximal Inhibitory Concentration (IC50) 314.07 nM
HCC1187 cells
Breast ductal carcinoma
CVCL_1247 
Half Maximal Inhibitory Concentration (IC50) 3140 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[171]
Half Maximal Inhibitory Concentration (IC50) 3150 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[136]
Half Maximal Inhibitory Concentration (IC50) 31860 nM
MDA-MB-436 cells
Metastasis of ductal carcinoma
CVCL_0623 
[241]
Half Maximal Inhibitory Concentration (IC50) 32 nM
U-937 cells
Adult acute monocytic leukemia
CVCL_0007 
[270]
Half Maximal Inhibitory Concentration (IC50) 32 nM
P388 cells
Lymphoma
CVCL_7222 
[271]
Half Maximal Inhibitory Concentration (IC50) 32.1 nM
P388 cells
Lymphoma
CVCL_7222 
[272]
Half Maximal Inhibitory Concentration (IC50) 32.15 nM
SBC-5 cells
Lung small cell carcinoma
CVCL_1679 
Half Maximal Inhibitory Concentration (IC50) 32.8 nM
Calu-3 cells
Lung adenocarcinoma
CVCL_0609 
Half Maximal Inhibitory Concentration (IC50) 320 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[70]
Half Maximal Inhibitory Concentration (IC50) 320 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[273]
Half Maximal Inhibitory Concentration (IC50) 3200 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[88]
Half Maximal Inhibitory Concentration (IC50) 3200 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[116]
Half Maximal Inhibitory Concentration (IC50) 3200 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[137]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3210 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[228]
Half Maximal Inhibitory Concentration (IC50) 32110 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[235]
Half Maximal Inhibitory Concentration (IC50) 32300 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[274]
Half Maximal Inhibitory Concentration (IC50) 3270 nM
Raji cells
EBV-related Burkitt lymphoma
CVCL_0511 
[186]
Half Maximal Inhibitory Concentration (IC50) 3273.33 nM
OE19 cells
Esophageal adenocarcinoma
CVCL_1622 
Half Maximal Inhibitory Concentration (IC50) 329.41 nM
SK-MEL3 cells
Melanoma
CVCL_0550 
Half Maximal Inhibitory Concentration (IC50) 3293.6 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 33 nM
U-373MG ATCC cells
Astrocytoma
CVCL_2219 
[148]
Half Maximal Inhibitory Concentration (IC50) 33 nM
Lewis lung carcinoma cells
Lung carcinoma
CVCL_4358 
[275]
Half Maximal Inhibitory Concentration (IC50) 33 nM
Lewis lung carcinoma cells
Lung carcinoma
CVCL_4358 
[142]
Half Maximal Inhibitory Concentration (IC50) 33 nM
Lewis lung carcinoma cells
Lung carcinoma
CVCL_4358 
[143]
Half Maximal Inhibitory Concentration (IC50) 33.14 nM
KNS-42 cells
Glioblastoma
CVCL_0378 
Half Maximal Inhibitory Concentration (IC50) 33.19 nM
SCC-9 cells
Tongue squamous cell carcinoma
CVCL_1685 
Half Maximal Inhibitory Concentration (IC50) 33.5 nM
NCI-H1581 cells
Lung large cell carcinoma
CVCL_1479 
Half Maximal Inhibitory Concentration (IC50) 33.57 nM
SW1710 cells
Bladder carcinoma
CVCL_1721 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 33.65 nM
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 33.73 nM
HOP-92 cells
Non-small cell lung carcinoma
CVCL_1286 
[39]
Half Maximal Inhibitory Concentration (IC50) 33.89 nM
GI-ME-N cells
Neuroblastoma
CVCL_1232 
Half Maximal Inhibitory Concentration (IC50) 33.98 nM
AN3-CA cells
Endometrial adenocarcinoma
CVCL_0028 
Half Maximal Inhibitory Concentration (IC50) 330 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[276]
Half Maximal Inhibitory Concentration (IC50) 330 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[185]
Half Maximal Inhibitory Concentration (IC50) 330 nM
Carcinoma cells
Carcinoma
Undisclosed [277]
Half Maximal Inhibitory Concentration (IC50) 330 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[278]
Half Maximal Inhibitory Concentration (IC50) 330000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[166]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 332.66 nM
SNB-78 cells
Glioblastoma
CVCL_B321 
[39]
Half Maximal Inhibitory Concentration (IC50) 332.9 nM
KINGS-1 cells
Anaplastic astrocytoma
CVCL_1328 
Half Maximal Inhibitory Concentration (IC50) 3320 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[279]
Half Maximal Inhibitory Concentration (IC50) 334.48 nM
NCI-H1975 cells
Lung adenocarcinoma
CVCL_1511 
Half Maximal Inhibitory Concentration (IC50) 34 nM
CT26 cells
Colon carcinoma
CVCL_7254 
[198]
Half Maximal Inhibitory Concentration (IC50) 34.07 nM
UO-31 cells
Renal carcinoma
CVCL_1911 
Half Maximal Inhibitory Concentration (IC50) 34.38 nM
IST-SL1 cells
Lung small cell carcinoma
CVCL_1313 
Half Maximal Inhibitory Concentration (IC50) 34.43 nM
MDA-MB-361 cells
Breast adenocarcinoma
CVCL_0620 
Half Maximal Inhibitory Concentration (IC50) 34.89 nM
ETK-1 cells
Cholangiocarcinoma
CVCL_1206 
Half Maximal Inhibitory Concentration (IC50) 34.93 nM
NCI-H1437 cells
Lung adenocarcinoma
CVCL_1472 
Half Maximal Inhibitory Concentration (IC50) 340 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[221]
Half Maximal Inhibitory Concentration (IC50) 340 nM
CNE cells
Nasopharyngeal carcinoma
CVCL_6888 
[108]
Half Maximal Inhibitory Concentration (IC50) 342 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[280]
Half Maximal Inhibitory Concentration (IC50) 349.21 nM
HCC1937 cells
Breast ductal carcinoma
CVCL_0290 
Half Maximal Inhibitory Concentration (IC50) 35 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[141]
Half Maximal Inhibitory Concentration (IC50) 35 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[104]
Half Maximal Inhibitory Concentration (IC50) 35.11 nM
TF-1 cells
Esophageal squamous cell carcinoma
CVCL_1759 
Half Maximal Inhibitory Concentration (IC50) 35.38 nM
SNU-C2B cells
Cecum adenocarcinoma
CVCL_1710 
Half Maximal Inhibitory Concentration (IC50) 35.45 nM
CW-2 cells
Colon adenocarcinoma
CVCL_1151 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 35.48 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[56]
Half Maximal Inhibitory Concentration (IC50) 35.53 nM
LK-2 cells
Lung squamous cell carcinoma
CVCL_1377 
Half Maximal Inhibitory Concentration (IC50) 35.62 nM
MEL-JUSO cells
Cutaneous melanoma
CVCL_1403 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 350 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[228]
Half Maximal Inhibitory Concentration (IC50) 350 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[209]
Half Maximal Inhibitory Concentration (IC50) 350 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[281]
Half Maximal Inhibitory Concentration (IC50) 350 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[163]
Half Maximal Inhibitory Concentration (IC50) 3500 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[92]
Half Maximal Inhibitory Concentration (IC50) 3570 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[282]
Half Maximal Inhibitory Concentration (IC50) 36.34 nM
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
CVCL_1304 
Half Maximal Inhibitory Concentration (IC50) 36.35 nM
HuP-T3 cells
Pancreatic adenocarcinoma
CVCL_1299 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 36.64 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[39]
Half Maximal Inhibitory Concentration (IC50) 3600 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[224]
Half Maximal Inhibitory Concentration (IC50) 3600 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[26]
Half Maximal Inhibitory Concentration (IC50) 3634.01 nM
KURAMOCHI cells
Ovarian serous adenocarcinoma
CVCL_1345 
Half Maximal Inhibitory Concentration (IC50) 3670 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[193]
Half Maximal Inhibitory Concentration (IC50) 3682.73 nM
COLO-678 cells
Colon carcinoma
CVCL_1129 
Half Maximal Inhibitory Concentration (IC50) 37 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[283]
Half Maximal Inhibitory Concentration (IC50) 37 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[181]
Half Maximal Inhibitory Concentration (IC50) 37 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[226]
Half Maximal Inhibitory Concentration (IC50) 37.88 nM
SW1990 cells
Pancreatic adenocarcinoma
CVCL_1723 
Half Maximal Inhibitory Concentration (IC50) 37.91 nM
MKN-1 cells
Gastric carcinoma
CVCL_1415 
Half Maximal Inhibitory Concentration (IC50) 370 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[163]
Half Maximal Inhibitory Concentration (IC50) 370 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[284]
Half Maximal Inhibitory Concentration (IC50) 37050 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[239]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 372.39 nM
LXFL 529 cells
Non-small cell lung carcinoma
CVCL_D085 
[39]
Half Maximal Inhibitory Concentration (IC50) 375 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[170]
Half Maximal Inhibitory Concentration (IC50) 3750 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[285]
Half Maximal Inhibitory Concentration (IC50) 38 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[69]
Half Maximal Inhibitory Concentration (IC50) 38.07 nM
NCI-H1648 cells
Lung adenocarcinoma
CVCL_1482 
Half Maximal Inhibitory Concentration (IC50) 38.13 nM
OCUB-M cells
Breast carcinoma
CVCL_1621 
Half Maximal Inhibitory Concentration (IC50) 38.4 nM
MMAC-SF cells
Melanoma
CVCL_1420 
Half Maximal Inhibitory Concentration (IC50) 38.51 nM
SK-MEL-24 cells
Melanoma
CVCL_0599 
Half Maximal Inhibitory Concentration (IC50) 38.68 nM
NCI-H28 cells
Pleural mesothelioma
CVCL_1555 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 38.82 nM
OVCAR-8 cells
High grade ovarian serous adenocarcinoma
CVCL_1629 
[39]
Half Maximal Inhibitory Concentration (IC50) 380 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[281]
Half Maximal Inhibitory Concentration (IC50) 3800 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[83]
Half Maximal Inhibitory Concentration (IC50) 3820 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[105]
Half Maximal Inhibitory Concentration (IC50) 383.65 nM
UACC-893 cells
Breast carcinoma
CVCL_1782 
Half Maximal Inhibitory Concentration (IC50) 389.64 nM
RH-18 cells
Alveolar rhabdomyosarcoma
CVCL_1659 
Half Maximal Inhibitory Concentration (IC50) 39 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[286]
Half Maximal Inhibitory Concentration (IC50) 39.04 nM
TCCSUP cells
Bladder carcinoma
CVCL_1738 
Half Maximal Inhibitory Concentration (IC50) 39.51 nM
MEG-01 cells
Chronic myeloid leukemia
CVCL_0425 
Half Maximal Inhibitory Concentration (IC50) 39.54 nM
D-247MG cells
Gliosarcoma
CVCL_1153 
Half Maximal Inhibitory Concentration (IC50) 390 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[265]
Half Maximal Inhibitory Concentration (IC50) 3910 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[100]
Half Maximal Inhibitory Concentration (IC50) 3960 nM
CAKI-2 cells
Renal carcinoma
CVCL_0235 
[164]
Half Maximal Inhibitory Concentration (IC50) 3970 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[107]
Half Maximal Inhibitory Concentration (IC50) 4 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[159]
Half Maximal Inhibitory Concentration (IC50) 4 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[127]
Half Maximal Inhibitory Concentration (IC50) 4 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[20]
Half Maximal Inhibitory Concentration (IC50) 4 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[93]
Half Maximal Inhibitory Concentration (IC50) 4 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[94]
Half Maximal Inhibitory Concentration (IC50) 4 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[97]
Half Maximal Inhibitory Concentration (IC50) 4 nM
MT4 cells
Normal
CVCL_2632 
[68]
Half Maximal Inhibitory Concentration (IC50) 4 nM
MT4 cells
Normal
CVCL_2632 
[169]
Half Maximal Inhibitory Concentration (IC50) 4 nM
P388 cells
Lymphoma
CVCL_7222 
[93]
Half Maximal Inhibitory Concentration (IC50) 4 nM
P388 cells
Lymphoma
CVCL_7222 
[94]
Half Maximal Inhibitory Concentration (IC50) 4 nM
P388 cells
Lymphoma
CVCL_7222 
[97]
Half Maximal Inhibitory Concentration (IC50) 4.032 nM
DoTc2-4510 cells
Cervix uteri
CVCL_1181 
Half Maximal Inhibitory Concentration (IC50) 4.033 nM
EW-24 cells
Ewing sarcoma
CVCL_1215 
Half Maximal Inhibitory Concentration (IC50) 4.062 nM
SW982 cells
Biphasic synovial sarcoma
CVCL_1734 
Half Maximal Inhibitory Concentration (IC50) 4.066 nM
Kasumi-1 cells
Myeloid leukemia with maturation
CVCL_0589 
Half Maximal Inhibitory Concentration (IC50) 4.073 nM
HGC-27 cells
Gastric carcinoma
CVCL_1279 
Half Maximal Inhibitory Concentration (IC50) 4.08 nM
EM-2 cells
Chronic myeloid leukemia
CVCL_1196 
Half Maximal Inhibitory Concentration (IC50) 4.082 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
Half Maximal Inhibitory Concentration (IC50) 4.095 nM
M059J cells
Glioblastoma
CVCL_0400 
Half Maximal Inhibitory Concentration (IC50) 4.17 nM
TE-8 cells
Esophageal squamous cell carcinoma
CVCL_1766 
Half Maximal Inhibitory Concentration (IC50) 4.183 nM
5637 cells
Bladder carcinoma
CVCL_0126 
Half Maximal Inhibitory Concentration (IC50) 4.211 nM
SW756 cells
Cervical squamous cell carcinoma
CVCL_1727 
Half Maximal Inhibitory Concentration (IC50) 4.23 nM
RKO cells
Colon carcinoma
CVCL_0504 
Half Maximal Inhibitory Concentration (IC50) 4.251 nM
A-427 cells
Lung carcinoma
CVCL_1055 
Half Maximal Inhibitory Concentration (IC50) 4.393 nM
KOSC-2 cells
Floor of mouth squamous cell carcinoma
CVCL_1337 
Half Maximal Inhibitory Concentration (IC50) 4.408 nM
AM-38 cells
Glioblastoma
CVCL_1070 
Half Maximal Inhibitory Concentration (IC50) 4.503 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
Half Maximal Inhibitory Concentration (IC50) 4.525 nM
A204 cells
Rhabdomyosarcoma
CVCL_1058 
Half Maximal Inhibitory Concentration (IC50) 4.564 nM
BE-13 cells
T acute lymphoblastic leukemia
CVCL_1081 
Half Maximal Inhibitory Concentration (IC50) 4.567 nM
FTC-133 cells
Thyroid gland follicular carcinoma
CVCL_1219 
Half Maximal Inhibitory Concentration (IC50) 4.582 nM
SKG-IIIa cells
Cervical squamous cell carcinoma
CVCL_1704 
Half Maximal Inhibitory Concentration (IC50) 4.662 nM
RXF 393 cells
Renal carcinoma
CVCL_1673 
Half Maximal Inhibitory Concentration (IC50) 4.677 nM
GB-1 cells
Glioblastoma
CVCL_1227 
Half Maximal Inhibitory Concentration (IC50) 4.713 nM
SK-LU-1 cells
Lung adenocarcinoma
CVCL_0629 
Half Maximal Inhibitory Concentration (IC50) 4.722 nM
J82 cells
Bladder carcinoma
CVCL_0359 
Half Maximal Inhibitory Concentration (IC50) 4.753 nM
RPMI-7951 cells
Malignant melanoma
CVCL_1666 
Half Maximal Inhibitory Concentration (IC50) 4.758 nM
CAL-54 cells
Renal cell carcinoma
CVCL_1111 
Half Maximal Inhibitory Concentration (IC50) 4.94 nM
TYK-nu cells
Ovarian serous adenocarcinoma
CVCL_1776 
Half Maximal Inhibitory Concentration (IC50) 4.97 nM
Ca-Ski cells
Cervical squamous cell carcinoma
CVCL_1100 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[50]
Half Maximal Inhibitory Concentration (IC50) <40 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[287]
Half Maximal Inhibitory Concentration (IC50) 40 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[182]
Half Maximal Inhibitory Concentration (IC50) 40 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[288]
Half Maximal Inhibitory Concentration (IC50) 40 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[289]
Half Maximal Inhibitory Concentration (IC50) 40 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[290]
Half Maximal Inhibitory Concentration (IC50) 40 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[70]
Half Maximal Inhibitory Concentration (IC50) 40 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[291]
Half Maximal Inhibitory Concentration (IC50) 40 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[123]
Half Maximal Inhibitory Concentration (IC50) 40 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[104]
Half Maximal Inhibitory Concentration (IC50) 40 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
[68]
Half Maximal Inhibitory Concentration (IC50) 40 nM
SF268 cells
Astrocytoma
CVCL_1689 
[287]
Half Maximal Inhibitory Concentration (IC50) 40 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[152]
Half Maximal Inhibitory Concentration (IC50) 40 nM
Panel (56 tumour cells)
Tumour
Undisclosed [292]
Half Maximal Inhibitory Concentration (IC50) 40 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[26]
Half Maximal Inhibitory Concentration (IC50) 40.12 nM
NCI-H1792 cells
Lung adenocarcinoma
CVCL_1495 
Half Maximal Inhibitory Concentration (IC50) 40.69 nM
NCI-H23 cells
Lung adenocarcinoma
CVCL_1547 
Half Maximal Inhibitory Concentration (IC50) 40.86 nM
DBTRG-05MG cells
Anaplastic astrocytoma
CVCL_1169 
Half Maximal Inhibitory Concentration (IC50) 40.93 nM
COR-L88 cells
Lung small cell carcinoma
CVCL_1141 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 400 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[40]
Half Maximal Inhibitory Concentration (IC50) 400 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[221]
Half Maximal Inhibitory Concentration (IC50) 400 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[293]
Half Maximal Inhibitory Concentration (IC50) 400 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[225]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[78]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[79]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[176]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[177]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[112]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[106]
Half Maximal Inhibitory Concentration (IC50) 400 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[78]
Half Maximal Inhibitory Concentration (IC50) 400 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[79]
Half Maximal Inhibitory Concentration (IC50) 400 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[268]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[225]
Half Maximal Inhibitory Concentration (IC50) 400 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[294]
Half Maximal Inhibitory Concentration (IC50) 400 nM
L2987 cells
Lung adenocarcinoma
CVCL_H586 
[295]
Half Maximal Inhibitory Concentration (IC50) 400 nM
BEL-7404 tumor cells
Endocervical adenocarcinoma
CVCL_6568 
[223]
Half Maximal Inhibitory Concentration (IC50) 4000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[131]
Half Maximal Inhibitory Concentration (IC50) >40000 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[221]
Half Maximal Inhibitory Concentration (IC50) >40000 nM
BJ cells
Normal
CVCL_3653 
[221]
Half Maximal Inhibitory Concentration (IC50) >40000 nM
TERT-RPE1 cells
Normal
CVCL_4388 
[221]
Half Maximal Inhibitory Concentration (IC50) 4010 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[99]
Half Maximal Inhibitory Concentration (IC50) 41 nM
SK-VLB cells
Ovarian carcinoma
Undisclosed [226]
Half Maximal Inhibitory Concentration (IC50) 41.48 nM
C8166 cells
Leukemia
CVCL_1099 
Half Maximal Inhibitory Concentration (IC50) 410 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[268]
Half Maximal Inhibitory Concentration (IC50) 4100 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[296]
Half Maximal Inhibitory Concentration (IC50) 411.5 nM
KLE cells
Endometrial adenocarcinoma
CVCL_1329 
Half Maximal Inhibitory Concentration (IC50) 4155.69 nM
HCC1419 cells
Breast ductal carcinoma
CVCL_1251 
Half Maximal Inhibitory Concentration (IC50) 4160 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[88]
Half Maximal Inhibitory Concentration (IC50) 42.71 nM
SNU-5 cells
Gastric adenocarcinoma
CVCL_0078 
Half Maximal Inhibitory Concentration (IC50) 420 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[186]
Half Maximal Inhibitory Concentration (IC50) 420 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[265]
Half Maximal Inhibitory Concentration (IC50) 420 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[77]
Half Maximal Inhibitory Concentration (IC50) 420 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[108]
Half Maximal Inhibitory Concentration (IC50) 4200 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[116]
Half Maximal Inhibitory Concentration (IC50) 4270 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[233]
Half Maximal Inhibitory Concentration (IC50) 43.18 nM
NCI-H1092 cells
Lung small cell carcinoma
CVCL_1454 
Half Maximal Inhibitory Concentration (IC50) 43.33 nM
OVCAR-5 cells
Ovarian serous adenocarcinoma
CVCL_1628 
Half Maximal Inhibitory Concentration (IC50) 43.6 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[114]
Half Maximal Inhibitory Concentration (IC50) 430 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[221]
Half Maximal Inhibitory Concentration (IC50) 430 nM
IMR-90 cells
Normal
CVCL_0347 
[218]
Half Maximal Inhibitory Concentration (IC50) 430 nM
CT26.WT cells
Colon adenocarcinoma
CVCL_7256 
[156]
Half Maximal Inhibitory Concentration (IC50) 4356.62 nM
NY cells
Osteosarcoma
CVCL_1613 
Half Maximal Inhibitory Concentration (IC50) 436.37 nM
EKVX cells
Non-small cell lung carcinoma
CVCL_1195 
Half Maximal Inhibitory Concentration (IC50) 436.47 nM
DJM-1 cells
Skin squamous cell carcinoma
CVCL_1172 
Half Maximal Inhibitory Concentration (IC50) 4370 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[221]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 44 nM
Tumor cells
Tumour
Undisclosed [170]
Half Maximal Inhibitory Concentration (IC50) 44 nM
HCC70 cells
Breast ductal carcinoma
CVCL_1270 
[241]
Half Maximal Inhibitory Concentration (IC50) 44.02 nM
NB12 cells
Neuroblastoma
CVCL_1442 
Half Maximal Inhibitory Concentration (IC50) 44.69 nM
NCI-H720 cells
Lung carcinoid tumor
CVCL_1583 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 44.87 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[39]
Half Maximal Inhibitory Concentration (IC50) 44.89 nM
PANC-08-13 cells
Pancreatic ductal adenocarcinoma
CVCL_1638 
Half Maximal Inhibitory Concentration (IC50) 4430 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[258]
Half Maximal Inhibitory Concentration (IC50) 4470 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
[239]
Half Maximal Inhibitory Concentration (IC50) 4490 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
[153]
Half Maximal Inhibitory Concentration (IC50) 45 nM
Col2 cells
Colon carcinoma
CVCL_D645 
[194]
Half Maximal Inhibitory Concentration (IC50) 45 nM
Col2 cells
Colon carcinoma
CVCL_D645 
[196]
Half Maximal Inhibitory Concentration (IC50) 45.46 nM
HCC70 cells
Breast ductal carcinoma
CVCL_1270 
Half Maximal Inhibitory Concentration (IC50) 450 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[257]
Half Maximal Inhibitory Concentration (IC50) 452.29 nM
Capan-2 cells
Pancreatic ductal adenocarcinoma
CVCL_0026 
Half Maximal Inhibitory Concentration (IC50) 4540 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[281]
Half Maximal Inhibitory Concentration (IC50) 455 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[69]
Half Maximal Inhibitory Concentration (IC50) 459.3 nM
Fibroblast cells
Normal
Undisclosed [34]
Half Maximal Inhibitory Concentration (IC50) 46 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[226]
Half Maximal Inhibitory Concentration (IC50) 46.97 nM
MeWo cells
Melanoma
CVCL_0445 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 460 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[147]
Half Maximal Inhibitory Concentration (IC50) 460 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[138]
Half Maximal Inhibitory Concentration (IC50) 460 nM
SK-MEL-24 cells
Melanoma
CVCL_0599 
[234]
Half Maximal Inhibitory Concentration (IC50) 46000000 nM
KATO III cells
Down syndrome
CVCL_0371 
[166]
Half Maximal Inhibitory Concentration (IC50) 4602.33 nM
T84 cells
Colon adenocarcinoma
CVCL_0555 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 47 nM
SK-MEL cells
Melanoma
Undisclosed [148]
Half Maximal Inhibitory Concentration (IC50) 47.35 nM
VMRC-RCZ cells
Renal cell carcinoma
CVCL_1791 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 47.97 nM
M19-MEL cells
Melanoma
CVCL_B415 
[39]
Half Maximal Inhibitory Concentration (IC50) 470 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[236]
Half Maximal Inhibitory Concentration (IC50) 474 nM
ID8 cells
Normal
CVCL_IU14 
[192]
Half Maximal Inhibitory Concentration (IC50) 4750 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[285]
Half Maximal Inhibitory Concentration (IC50) 4790 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[258]
Half Maximal Inhibitory Concentration (IC50) 4791.52 nM
COLO-679 cells
Cutaneous melanoma
CVCL_1130 
Half Maximal Inhibitory Concentration (IC50) 48 nM
LOX IMVI cells
Melanoma
CVCL_1381 
[226]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 48.31 nM
XF498 cells
Glioma
CVCL_8928 
[39]
Half Maximal Inhibitory Concentration (IC50) 48.53 nM
NCI-H2030 cells
Lung adenocarcinoma
CVCL_1517 
Half Maximal Inhibitory Concentration (IC50) 48.92 nM
SW837 cells
Rectal adenocarcinoma
CVCL_1729 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 480 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[148]
Half Maximal Inhibitory Concentration (IC50) 480 nM
PC-3M cells
Bone metastasis of prostate carcinoma
CVCL_9555 
[210]
Half Maximal Inhibitory Concentration (IC50) 486.07 nM
HDLM-2 cells
Hodgkin lymphoma
CVCL_0009 
Half Maximal Inhibitory Concentration (IC50) 49 nM
NCI-H2228 cells
Lung adenocarcinoma
CVCL_1543 
Half Maximal Inhibitory Concentration (IC50) 49 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[241]
Half Maximal Inhibitory Concentration (IC50) 490 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[145]
Half Maximal Inhibitory Concentration (IC50) 490 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[163]
Half Maximal Inhibitory Concentration (IC50) 491.21 nM
NCI-H2029 cells
Lung small cell carcinoma
CVCL_1516 
Half Maximal Inhibitory Concentration (IC50) 4920 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[83]
Half Maximal Inhibitory Concentration (IC50) 4950 nM
VACO 241 cells
Colon carcinoma
CVCL_5396 
[285]
Half Maximal Inhibitory Concentration (IC50) 4960 nM
184B5 cells
Normal
CVCL_4688 
[168]
Half Maximal Inhibitory Concentration (IC50) 5 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
Half Maximal Inhibitory Concentration (IC50) 5 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[297]
Half Maximal Inhibitory Concentration (IC50) 5 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[72]
Half Maximal Inhibitory Concentration (IC50) 5 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[298]
Half Maximal Inhibitory Concentration (IC50) 5 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[95]
Half Maximal Inhibitory Concentration (IC50) 5.021 nM
786-O cells
Renal cell carcinoma
CVCL_1051 
Half Maximal Inhibitory Concentration (IC50) 5.023 nM
GCT cells
Pleomorphic sarcoma
CVCL_1229 
Half Maximal Inhibitory Concentration (IC50) 5.051 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
Half Maximal Inhibitory Concentration (IC50) 5.074 nM
NCI-H2087 cells
Lung adenocarcinoma
CVCL_1524 
Half Maximal Inhibitory Concentration (IC50) 5.083 nM
MN-60 cells
Burkitt lymphoma
CVCL_1421 
Half Maximal Inhibitory Concentration (IC50) 5.205 nM
D-336MG cells
Glioblastoma
CVCL_1156 
Half Maximal Inhibitory Concentration (IC50) 5.223 nM
KYSE-270 cells
Esophageal squamous cell carcinoma
CVCL_1350 
Half Maximal Inhibitory Concentration (IC50) 5.31 nM
BHY cells
Head and neck squamous cell carcinoma
CVCL_1086 
Half Maximal Inhibitory Concentration (IC50) 5.354 nM
Caki-1 cells
Clear cell renal cell carcinoma
CVCL_0234 
Half Maximal Inhibitory Concentration (IC50) 5.377 nM
SK-N-AS cells
Neuroblastoma
CVCL_1700 
Half Maximal Inhibitory Concentration (IC50) 5.379 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[299]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5.4 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[215]
Half Maximal Inhibitory Concentration (IC50) 5.4 nM
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[300]
Half Maximal Inhibitory Concentration (IC50) 5.453 nM
YKG-1 cells
Glioblastoma
CVCL_1796 
Half Maximal Inhibitory Concentration (IC50) 5.469 nM
HCE-T cells
Nornal
CVCL_1272 
Half Maximal Inhibitory Concentration (IC50) 5.5 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[27]
Half Maximal Inhibitory Concentration (IC50) 5.5 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[23]
Half Maximal Inhibitory Concentration (IC50) 5.5 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[28]
Half Maximal Inhibitory Concentration (IC50) 5.5 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[29]
Half Maximal Inhibitory Concentration (IC50) 5.5 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[30]
Half Maximal Inhibitory Concentration (IC50) 5.547 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
Half Maximal Inhibitory Concentration (IC50) 5.6 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[142]
Half Maximal Inhibitory Concentration (IC50) 5.6 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[143]
Half Maximal Inhibitory Concentration (IC50) 5.6 nM
HEK293 cells
Normal
CVCL_0045 
[30]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5.7 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[40]
Half Maximal Inhibitory Concentration (IC50) 5.753 nM
HLE cells
Hepatocellular carcinoma
CVCL_1281 
Half Maximal Inhibitory Concentration (IC50) 5.997 nM
CAL-33 cells
Tongue squamous cell carcinoma
CVCL_1108 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 50 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[216]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 50 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[40]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 50 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[228]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 50 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[62]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 50 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[63]
Half Maximal Inhibitory Concentration (IC50) 50 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[290]
Half Maximal Inhibitory Concentration (IC50) 50 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[241]
Half Maximal Inhibitory Concentration (IC50) 50 nM
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[128]
Half Maximal Inhibitory Concentration (IC50) 50 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[70]
Half Maximal Inhibitory Concentration (IC50) 50 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[154]
Half Maximal Inhibitory Concentration (IC50) 50 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[155]
Half Maximal Inhibitory Concentration (IC50) 50 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[266]
Half Maximal Inhibitory Concentration (IC50) 50 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[267]
Half Maximal Inhibitory Concentration (IC50) 50.3 nM
NCI-H810 cells
Lung large cell carcinoma
CVCL_1590 
Half Maximal Inhibitory Concentration (IC50) 500 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[150]
Half Maximal Inhibitory Concentration (IC50) 500 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[301]
Half Maximal Inhibitory Concentration (IC50) 500 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[293]
Half Maximal Inhibitory Concentration (IC50) 500 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[241]
Half Maximal Inhibitory Concentration (IC50) 500 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[78]
Half Maximal Inhibitory Concentration (IC50) 500 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[79]
Half Maximal Inhibitory Concentration (IC50) 500 nM
U-87MG ATCC cells
Glioblastoma
CVCL_0022 
[173]
Half Maximal Inhibitory Concentration (IC50) 500 nM
CRL-7065 cells
Normal
CVCL_1041 
[68]
Half Maximal Inhibitory Concentration (IC50) >50000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[186]
Half Maximal Inhibitory Concentration (IC50) 50880 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[235]
Half Maximal Inhibitory Concentration (IC50) 51 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[302]
Half Maximal Inhibitory Concentration (IC50) 51.21 nM
MKN-28 cells
Gastric epithelial carcinoma
CVCL_1416 
Half Maximal Inhibitory Concentration (IC50) 51.29 nM
SK-MEL-1 cells
Metastatic melanoma
CVCL_0068 
Half Maximal Inhibitory Concentration (IC50) 51.69 nM
SW1463 cells
Rectal adenocarcinoma
CVCL_1718 
Half Maximal Inhibitory Concentration (IC50) 510 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[192]
Half Maximal Inhibitory Concentration (IC50) 51500 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[235]
Half Maximal Inhibitory Concentration (IC50) 517.64 nM
LN-405 cells
Glioblastoma
CVCL_1378 
Half Maximal Inhibitory Concentration (IC50) 52 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[198]
Half Maximal Inhibitory Concentration (IC50) 52 nM
MES-SA/Dx5 cells
Uterine sarcoma
CVCL_2598 
[31]
Half Maximal Inhibitory Concentration (IC50) 52.7 nM
SW1417 cells
Colon adenocarcinoma
CVCL_1717 
Half Maximal Inhibitory Concentration (IC50) 520 nM
CA46 cells
Burkitt lymphoma
CVCL_1101 
[165]
Half Maximal Inhibitory Concentration (IC50) 520 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[268]
Half Maximal Inhibitory Concentration (IC50) 5270.72 nM
MFM-223 cells
Breast carcinoma
CVCL_1408 
Half Maximal Inhibitory Concentration (IC50) 53 nM
SK-VLB cells
Ovarian carcinoma
Undisclosed [302]
Half Maximal Inhibitory Concentration (IC50) 53.71 nM
TGBC24TKB cells
Gallbladder carcinoma
CVCL_1770 
Half Maximal Inhibitory Concentration (IC50) 5300 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[303]
Half Maximal Inhibitory Concentration (IC50) 5370 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[120]
Half Maximal Inhibitory Concentration (IC50) 5370 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[233]
Half Maximal Inhibitory Concentration (IC50) 5380 nM
NHDF cells
Normal
Undisclosed [188]
Half Maximal Inhibitory Concentration (IC50) 5385 nM
CEM/C2 cells
T acute lymphoblastic leukemia
CVCL_3497 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 54.33 nM
UACC-257 cells
Melanoma
CVCL_1779 
[39]
Half Maximal Inhibitory Concentration (IC50) 54.75 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
Half Maximal Inhibitory Concentration (IC50) 54.96 nM
NCI-H650 cells
Lung adenocarcinoma
CVCL_1575 
Half Maximal Inhibitory Concentration (IC50) 540 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[115]
Half Maximal Inhibitory Concentration (IC50) 540 nM
H22 cells
Hepatoma
CVCL_H613 
[77]
Half Maximal Inhibitory Concentration (IC50) 54690 nM
HEK293 cells
Normal
CVCL_0045 
[153]
Half Maximal Inhibitory Concentration (IC50) 55.12 nM
HPAF-II cells
Pancreatic ductal adenocarcinoma
CVCL_0313 
Half Maximal Inhibitory Concentration (IC50) 55.5 nM
HCC2218 cells
Breast ductal carcinoma
CVCL_1263 
Half Maximal Inhibitory Concentration (IC50) 55.67 nM
KM-H2 cells
Hodgkin lymphoma
CVCL_1330 
Half Maximal Inhibitory Concentration (IC50) 55.79 nM
TK-10 cells
Renal carcinoma
CVCL_1773 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 550 nM
SiHa cells
Cervical squamous cell carcinoma
CVCL_0032 
[40]
Half Maximal Inhibitory Concentration (IC50) 5500 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[82]
Half Maximal Inhibitory Concentration (IC50) 5500 nM
M059J cells
Glioblastoma
CVCL_0400 
[213]
Half Maximal Inhibitory Concentration (IC50) 5500 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[85]
Half Maximal Inhibitory Concentration (IC50) 56 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[304]
Half Maximal Inhibitory Concentration (IC50) 56.63 nM
NCI-H446 cells
Lung small cell carcinoma
CVCL_1562 
Half Maximal Inhibitory Concentration (IC50) 56.73 nM
SCC-25 cells
Squamous carcinoma
CVCL_1682 
Half Maximal Inhibitory Concentration (IC50) 56.87 nM
C3A cells
Hepatoblastoma
CVCL_1098 
Half Maximal Inhibitory Concentration (IC50) 560 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[77]
Half Maximal Inhibitory Concentration (IC50) 5650 nM
HEK-293T cells
Normal
CVCL_0063 
[70]
Half Maximal Inhibitory Concentration (IC50) 5690 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[233]
Half Maximal Inhibitory Concentration (IC50) 57 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[269]
Half Maximal Inhibitory Concentration (IC50) 57 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[243]
Half Maximal Inhibitory Concentration (IC50) 57 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[243]
Half Maximal Inhibitory Concentration (IC50) 57 nM
MES-SA cells
Uterine sarcoma
CVCL_1404 
[31]
Half Maximal Inhibitory Concentration (IC50) 57 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[161]
Half Maximal Inhibitory Concentration (IC50) 57.87 nM
KS-1 cells
Glioblastoma
CVCL_1343 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 570 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[208]
Half Maximal Inhibitory Concentration (IC50) 5770 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[168]
Half Maximal Inhibitory Concentration (IC50) 58 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[305]
Half Maximal Inhibitory Concentration (IC50) 58.08 nM
LS-411N cells
Cecum adenocarcinoma
CVCL_1385 
Half Maximal Inhibitory Concentration (IC50) 58.48 nM
NCI-H2405 cells
Pleural mesothelioma
CVCL_1551 
Half Maximal Inhibitory Concentration (IC50) 580 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[87]
Half Maximal Inhibitory Concentration (IC50) 5800 nM
SGC-7901 cells
Gastric carcinoma
CVCL_0520 
[156]
Half Maximal Inhibitory Concentration (IC50) 588.29 nM
NCI-H82 cells
Lung small cell carcinoma
CVCL_1591 
Half Maximal Inhibitory Concentration (IC50) 59.28 nM
NCI-H1304 cells
Lung small cell carcinoma
CVCL_1462 
Half Maximal Inhibitory Concentration (IC50) 59.8 nM
SH-4 cells
Melanoma
CVCL_1692 
Half Maximal Inhibitory Concentration (IC50) 590 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[306]
Half Maximal Inhibitory Concentration (IC50) 590 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[245]
Half Maximal Inhibitory Concentration (IC50) 590 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[118]
Half Maximal Inhibitory Concentration (IC50) 590 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[281]
Half Maximal Inhibitory Concentration (IC50) 59130 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[98]
Half Maximal Inhibitory Concentration (IC50) 5930 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[134]
Half Maximal Inhibitory Concentration (IC50) 5930 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[135]
Half Maximal Inhibitory Concentration (IC50) 594.73 nM
CAL-120 cells
Breast carcinoma
CVCL_1104 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 6 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[207]
Half Maximal Inhibitory Concentration (IC50) 6 nM
DC3F cells
Normal
CVCL_4704 
Half Maximal Inhibitory Concentration (IC50) 6 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[161]
Half Maximal Inhibitory Concentration (IC50) 6 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[69]
Half Maximal Inhibitory Concentration (IC50) 6 nM
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
[162]
Half Maximal Inhibitory Concentration (IC50) 6 nM
T24 cells
Bladder carcinoma
CVCL_0554 
[158]
Half Maximal Inhibitory Concentration (IC50) 6 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[73]
Half Maximal Inhibitory Concentration (IC50) 6 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[96]
Half Maximal Inhibitory Concentration (IC50) 6.072 nM
DMS-273 cells
Small cell lung carcinoma
CVCL_1176 
Half Maximal Inhibitory Concentration (IC50) 6.091 nM
CHL-1 cells
Melanoma
CVCL_1122 
Half Maximal Inhibitory Concentration (IC50) 6.3 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[300]
Half Maximal Inhibitory Concentration (IC50) 6.311 nM
HEL cells
Erythroleukemia
CVCL_0001 
Half Maximal Inhibitory Concentration (IC50) 6.427 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
Half Maximal Inhibitory Concentration (IC50) 6.427 nM
CaR-1 cells
Rectal adenocarcinoma
CVCL_1116 
Half Maximal Inhibitory Concentration (IC50) 6.477 nM
C-33-A cells
Cervical squamous cell carcinoma
CVCL_1094 
Half Maximal Inhibitory Concentration (IC50) 6.515 nM
NCI-H1703 cells
Lung squamous cell carcinoma
CVCL_1490 
Half Maximal Inhibitory Concentration (IC50) 6.632 nM
U-87MG ATCC cells
Glioblastoma
CVCL_0022 
Half Maximal Inhibitory Concentration (IC50) 6.663 nM
ACHN cells
Renal adenocarcinoma
CVCL_1067 
Half Maximal Inhibitory Concentration (IC50) 6.7 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[307]
Half Maximal Inhibitory Concentration (IC50) 6.754 nM
KYSE-510 cells
Esophageal squamous cell carcinoma
CVCL_1354 
Half Maximal Inhibitory Concentration (IC50) 6.849 nM
COR-L23 cells
Lung carcinoma
CVCL_1139 
Half Maximal Inhibitory Concentration (IC50) 6.925 nM
BFTC-909 cells
Renal pelvis urothelial carcinoma
CVCL_1084 
Half Maximal Inhibitory Concentration (IC50) 6.965 nM
MDA-MB-453 cells
Breast adenocarcinoma
CVCL_0418 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 60 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[40]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 60 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[62]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 60 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[208]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 60 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[62]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 60 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[40]
Half Maximal Inhibitory Concentration (IC50) 60 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[128]
Half Maximal Inhibitory Concentration (IC50) 60 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[232]
Half Maximal Inhibitory Concentration (IC50) 60 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[290]
Half Maximal Inhibitory Concentration (IC50) 60 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[38]
Half Maximal Inhibitory Concentration (IC50) 60 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[308]
Half Maximal Inhibitory Concentration (IC50) 60 nM
HEC-1B cells
Endometrial adenocarcinoma
CVCL_0294 
[166]
Half Maximal Inhibitory Concentration (IC50) 60 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[273]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 600 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[309]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 600 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[204]
Half Maximal Inhibitory Concentration (IC50) 600 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[211]
Half Maximal Inhibitory Concentration (IC50) 600 nM
NCI-N87 cells
Gastric tubular adenocarcinoma
CVCL_1603 
[33]
Half Maximal Inhibitory Concentration (IC50) 600 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[293]
Half Maximal Inhibitory Concentration (IC50) 600 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[163]
Half Maximal Inhibitory Concentration (IC50) 600 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[231]
Half Maximal Inhibitory Concentration (IC50) 600 nM
HEK293 cells
Normal
CVCL_0045 
[225]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 6000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[148]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 6000 nM
SAS cells
Tongue squamous cell carcinoma
CVCL_1675 
[103]
Half Maximal Inhibitory Concentration (IC50) 6000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[213]
Half Maximal Inhibitory Concentration (IC50) 6000 nM
SAS cells
Tongue squamous cell carcinoma
CVCL_1675 
[171]
Half Maximal Inhibitory Concentration (IC50) 60010 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[244]
Half Maximal Inhibitory Concentration (IC50) 6080 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[108]
Half Maximal Inhibitory Concentration (IC50) 6080 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[180]
Half Maximal Inhibitory Concentration (IC50) 61.7 nM
RKO cells
Colon carcinoma
CVCL_0504 
[156]
Half Maximal Inhibitory Concentration (IC50) 610 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[245]
Half Maximal Inhibitory Concentration (IC50) 610 nM
SH-SY5Y cells
Bone marrow neuroblastoma
CVCL_0019 
[163]
Half Maximal Inhibitory Concentration (IC50) 61000 nM
CPT-K5 cells
T acute lymphoblastic leukemia
CVCL_2878 
[95]
Half Maximal Inhibitory Concentration (IC50) 6130 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[168]
Half Maximal Inhibitory Concentration (IC50) 618.33 nM
NCI-H2342 cells
Lung adenocarcinoma
CVCL_1549 
Half Maximal Inhibitory Concentration (IC50) 62.09 nM
COLO 320HSR cells
Colon adenocarcinoma
CVCL_0220 
Half Maximal Inhibitory Concentration (IC50) 620 nM
Macrophage cells
Normal
Undisclosed [310]
Half Maximal Inhibitory Concentration (IC50) 628.09 nM
SCH cells
Gastric choriocarcinoma
CVCL_1687 
Half Maximal Inhibitory Concentration (IC50) 630 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[308]
Half Maximal Inhibitory Concentration (IC50) 6300 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[26]
Half Maximal Inhibitory Concentration (IC50) <64 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[257]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 64.42 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[39]
Half Maximal Inhibitory Concentration (IC50) 640 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[311]
Half Maximal Inhibitory Concentration (IC50) 6400 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[175]
Half Maximal Inhibitory Concentration (IC50) >6400 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[77]
Half Maximal Inhibitory Concentration (IC50) 65 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[282]
Half Maximal Inhibitory Concentration (IC50) 65 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[107]
Half Maximal Inhibitory Concentration (IC50) 65.1 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[192]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 65.77 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[39]
Half Maximal Inhibitory Concentration (IC50) 650 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[312]
Half Maximal Inhibitory Concentration (IC50) 650 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[173]
Half Maximal Inhibitory Concentration (IC50) 6510 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[258]
Half Maximal Inhibitory Concentration (IC50) 66 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[164]
Half Maximal Inhibitory Concentration (IC50) 66.1 nM
NCI-H1355 cells
Lung adenocarcinoma
CVCL_1464 
Half Maximal Inhibitory Concentration (IC50) 66.15 nM
GCIY cells
Gastric adenocarcinoma
CVCL_1228 
Half Maximal Inhibitory Concentration (IC50) 660 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[313]
Half Maximal Inhibitory Concentration (IC50) 660 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[108]
Half Maximal Inhibitory Concentration (IC50) 660 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[308]
Half Maximal Inhibitory Concentration (IC50) 660 nM
A375 cells
Amelanotic melanoma
CVCL_0132 
[163]
Half Maximal Inhibitory Concentration (IC50) 67 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[87]
Half Maximal Inhibitory Concentration (IC50) 67 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[222]
Half Maximal Inhibitory Concentration (IC50) 6700 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[134]
Half Maximal Inhibitory Concentration (IC50) 68.13 nM
NCI-H2009 cells
Lung adenocarcinoma
CVCL_1514 
Half Maximal Inhibitory Concentration (IC50) 680 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[314]
Half Maximal Inhibitory Concentration (IC50) 680 nM
U-937 cells
Adult acute monocytic leukemia
CVCL_0007 
[270]
Half Maximal Inhibitory Concentration (IC50) 680 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[87]
Half Maximal Inhibitory Concentration (IC50) 680 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[313]
Half Maximal Inhibitory Concentration (IC50) 680 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[257]
Half Maximal Inhibitory Concentration (IC50) 6800 nM
T24 cells
Bladder carcinoma
CVCL_0554 
[258]
Half Maximal Inhibitory Concentration (IC50) 69 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[194]
Half Maximal Inhibitory Concentration (IC50) 69 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[196]
Half Maximal Inhibitory Concentration (IC50) 69.51 nM
U266B1 cells
Plasma cell myeloma
CVCL_0566 
Half Maximal Inhibitory Concentration (IC50) 69.74 nM
KYSE-140 cells
Esophageal squamous cell carcinoma
CVCL_1347 
Half Maximal Inhibitory Concentration (IC50) 69.89 nM
KALS-1 cells
Glioblastoma
CVCL_1323 
Half Maximal Inhibitory Concentration (IC50) 690 nM
HEK-293T cells
Normal
CVCL_0063 
[163]
Half Maximal Inhibitory Concentration (IC50) 6960 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[315]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[216]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[227]
Half Maximal Inhibitory Concentration (IC50) 7 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[72]
Half Maximal Inhibitory Concentration (IC50) 7 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[316]
Half Maximal Inhibitory Concentration (IC50) 7 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[316]
Half Maximal Inhibitory Concentration (IC50) 7 nM
P388 cells
Lymphoma
CVCL_7222 
[317]
Half Maximal Inhibitory Concentration (IC50) 7.02 nM
LAMA-84 cells
Chronic myeloid leukemia
CVCL_0388 
Half Maximal Inhibitory Concentration (IC50) 7.054 nM
LXF-289 cells
Lung adenocarcinoma
CVCL_1394 
Half Maximal Inhibitory Concentration (IC50) 7.077 nM
A498 cells
Renal carcinoma
CVCL_1056 
Half Maximal Inhibitory Concentration (IC50) 7.079 nM
ESS-1 cells
Endometrioid stromal sarcoma
CVCL_1205 
Half Maximal Inhibitory Concentration (IC50) 7.103 nM
Panc 03.27 cells
Pancreatic adenocarcinoma
CVCL_1635 
Half Maximal Inhibitory Concentration (IC50) 7.253 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
Half Maximal Inhibitory Concentration (IC50) 7.263 nM
OAW-28 cells
Ovarian serous cystadenocarcinoma
CVCL_1614 
Half Maximal Inhibitory Concentration (IC50) 7.272 nM
OVCAR-8 cells
High grade ovarian serous adenocarcinoma
CVCL_1629 
Half Maximal Inhibitory Concentration (IC50) 7.311 nM
GMS-10 cells
Glioblastoma
CVCL_1233 
Half Maximal Inhibitory Concentration (IC50) 7.38 nM
TE-5 cells
Esophageal squamous cell carcinoma
CVCL_1764 
Half Maximal Inhibitory Concentration (IC50) 7.569 nM
MDA-MB-157 cells
Breast carcinoma
CVCL_0618 
Half Maximal Inhibitory Concentration (IC50) 7.628 nM
MEL-HO cells
Melanoma
CVCL_1402 
Half Maximal Inhibitory Concentration (IC50) 7.654 nM
MG-63 cells
Osteosarcoma
CVCL_0426 
Half Maximal Inhibitory Concentration (IC50) 7.701 nM
KNS-62 cells
Lung squamous cell carcinoma
CVCL_1335 
Half Maximal Inhibitory Concentration (IC50) 7.8 nM
NCI-H928 cells
Normal
Undisclosed [300]
Half Maximal Inhibitory Concentration (IC50) 7.897 nM
LB1047-RCC cells
Renal cell carcinoma
CVCL_1364 
Half Maximal Inhibitory Concentration (IC50) 7.904 nM
EC-GI-10 cells
Esophageal squamous cell carcinoma
CVCL_1187 
Half Maximal Inhibitory Concentration (IC50) 7.909 nM
SF-295 cells
Glioblastoma
CVCL_1690 
Half Maximal Inhibitory Concentration (IC50) 70 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[120]
Half Maximal Inhibitory Concentration (IC50) 70 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[221]
Half Maximal Inhibitory Concentration (IC50) 70 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[284]
Half Maximal Inhibitory Concentration (IC50) 70 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[318]
Half Maximal Inhibitory Concentration (IC50) 70 nM
BT-20 cells
Invasive breast carcinoma of no special type
CVCL_0178 
[67]
Half Maximal Inhibitory Concentration (IC50) 70 nM
BT-20 cells
Invasive breast carcinoma of no special type
CVCL_0178 
[27]
Half Maximal Inhibitory Concentration (IC50) 70 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[312]
Half Maximal Inhibitory Concentration (IC50) 70 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[104]
Half Maximal Inhibitory Concentration (IC50) 70 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[256]
Half Maximal Inhibitory Concentration (IC50) 70 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[154]
Half Maximal Inhibitory Concentration (IC50) 70 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[155]
Half Maximal Inhibitory Concentration (IC50) 70 nM
CAMA-1 cells
Breast adenocarcinoma
CVCL_1115 
[67]
Half Maximal Inhibitory Concentration (IC50) 70 nM
CAMA-1 cells
Breast adenocarcinoma
CVCL_1115 
[38]
Half Maximal Inhibitory Concentration (IC50) 70 nM
NCI-H23 cells
Lung adenocarcinoma
CVCL_1547 
[209]
Half Maximal Inhibitory Concentration (IC50) 70 nM
SF268 cells
Astrocytoma
CVCL_1689 
[218]
Half Maximal Inhibitory Concentration (IC50) 70 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[287]
Half Maximal Inhibitory Concentration (IC50) 700 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[130]
Half Maximal Inhibitory Concentration (IC50) 700 nM
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[222]
Half Maximal Inhibitory Concentration (IC50) 7000 nM
BT474-M1 cells
Invasive breast carcinoma
CVCL_0179 
[296]
Half Maximal Inhibitory Concentration (IC50) 71 nM
THP-1 cells
Childhood acute monocytic leukemia
CVCL_0006 
[211]
Half Maximal Inhibitory Concentration (IC50) 71.47 nM
RVH-421 cells
Melanoma
CVCL_1672 
Half Maximal Inhibitory Concentration (IC50) 710 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[269]
Half Maximal Inhibitory Concentration (IC50) 710 nM
SW579 cells
Thyroid carcinoma
CVCL_3603 
[76]
Half Maximal Inhibitory Concentration (IC50) 7100 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[296]
Half Maximal Inhibitory Concentration (IC50) 711 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[221]
Half Maximal Inhibitory Concentration (IC50) 711.49 nM
SW684 cells
Fibrosarcoma
CVCL_1726 
Half Maximal Inhibitory Concentration (IC50) 71300 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[244]
Half Maximal Inhibitory Concentration (IC50) 72 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[305]
Half Maximal Inhibitory Concentration (IC50) 72.08 nM
CP50-MEL-B cells
Melanoma
CVCL_1143 
Half Maximal Inhibitory Concentration (IC50) 72.45 nM
COLO-680N cells
Esophageal squamous cell carcinoma
CVCL_1131 
Half Maximal Inhibitory Concentration (IC50) 72.8 nM
EPLC-272H cells
Lung mucoepidermoid carcinoma
CVCL_1197 
Half Maximal Inhibitory Concentration (IC50) 7210.91 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
Half Maximal Inhibitory Concentration (IC50) 7325.59 nM
LS-123 cells
Colon adenocarcinoma
CVCL_1383 
Half Maximal Inhibitory Concentration (IC50) 736.29 nM
KP-N-YS cells
Adrenal gland neuroblastoma
CVCL_1342 
Half Maximal Inhibitory Concentration (IC50) 74 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[123]
Half Maximal Inhibitory Concentration (IC50) 74.99 nM
KM12 cells
Colon adenocarcinoma
CVCL_1331 
Half Maximal Inhibitory Concentration (IC50) 7420 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[167]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 75 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[207]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 75 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[227]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 75 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[122]
Half Maximal Inhibitory Concentration (IC50) 750 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[212]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 76.38 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[39]
Half Maximal Inhibitory Concentration (IC50) 76.9 nM
SW626 cells
Colon adenocarcinoma
CVCL_1725 
Half Maximal Inhibitory Concentration (IC50) 760 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[308]
Half Maximal Inhibitory Concentration (IC50) 760 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[240]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 77.62 nM
KM-20L2 cells
Colon carcinoma
CVCL_D889 
[39]
Half Maximal Inhibitory Concentration (IC50) 776.97 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
Half Maximal Inhibitory Concentration (IC50) 78 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[19]
Half Maximal Inhibitory Concentration (IC50) 78.11 nM
KYSE-410 cells
Esophageal squamous cell carcinoma
CVCL_1352 
Half Maximal Inhibitory Concentration (IC50) 78.21 nM
OMC-1 cells
Cervical squamous cell carcinoma
CVCL_1623 
Half Maximal Inhibitory Concentration (IC50) 780 nM
HEK293 cells
Normal
CVCL_0045 
[265]
Half Maximal Inhibitory Concentration (IC50) 786 nM
WI-38 cells
Normal
CVCL_0579 
[192]
Half Maximal Inhibitory Concentration (IC50) 7860 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[187]
Half Maximal Inhibitory Concentration (IC50) 7923.68 nM
CAL-85-1 cells
Breast carcinoma
CVCL_1114 
Half Maximal Inhibitory Concentration (IC50) 7940 nM
HEK293 cells
Normal
CVCL_0045 
[319]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[148]
Half Maximal Inhibitory Concentration (IC50) 8 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[316]
Half Maximal Inhibitory Concentration (IC50) 8 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[211]
Half Maximal Inhibitory Concentration (IC50) 8 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[302]
Half Maximal Inhibitory Concentration (IC50) 8.123 nM
KY821 cells
Acute myelomonocytic leukemia
CVCL_1346 
Half Maximal Inhibitory Concentration (IC50) 8.136 nM
LCLC-97TM1 cells
Lung large cell carcinoma
CVCL_1376 
Half Maximal Inhibitory Concentration (IC50) 8.238 nM
MSTO-211H cells
Pleural biphasic mesothelioma
CVCL_1430 
Half Maximal Inhibitory Concentration (IC50) 8.365 nM
KU812 cells
Chronic myeloid leukemia
CVCL_0379 
Half Maximal Inhibitory Concentration (IC50) 8.5 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[253]
Half Maximal Inhibitory Concentration (IC50) 8.612 nM
MZ7-mel cells
Melanoma
CVCL_1436 
Half Maximal Inhibitory Concentration (IC50) 8.63 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[266]
Half Maximal Inhibitory Concentration (IC50) 8.63 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[267]
Half Maximal Inhibitory Concentration (IC50) 8.743 nM
NCI-N87 cells
Gastric tubular adenocarcinoma
CVCL_1603 
Half Maximal Inhibitory Concentration (IC50) 8.787 nM
HOP-92 cells
Non-small cell lung carcinoma
CVCL_1286 
Half Maximal Inhibitory Concentration (IC50) 8.8 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[320]
Half Maximal Inhibitory Concentration (IC50) 8.887 nM
HMV-2 cells
Vaginal melanoma
CVCL_1282 
Half Maximal Inhibitory Concentration (IC50) 8.99 nM
OAW-42 cells
Ovarian serous cystadenocarcinoma
CVCL_1615 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 80 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[103]
Half Maximal Inhibitory Concentration (IC50) 80 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[311]
Half Maximal Inhibitory Concentration (IC50) 80 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[308]
Half Maximal Inhibitory Concentration (IC50) 80 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[263]
Half Maximal Inhibitory Concentration (IC50) 80 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[90]
Half Maximal Inhibitory Concentration (IC50) 80 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[229]
Half Maximal Inhibitory Concentration (IC50) 80 nM
HT-1080 cells (FAP expression)
Fibrosarcoma
CVCL_0317 
[194]
Half Maximal Inhibitory Concentration (IC50) 80 nM
HT-1080 cells (FAP expression)
Fibrosarcoma
CVCL_0317 
[195]
Half Maximal Inhibitory Concentration (IC50) 80 nM
HT-1080 cells (FAP expression)
Fibrosarcoma
CVCL_0317 
[196]
Half Maximal Inhibitory Concentration (IC50) 80 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[113]
Half Maximal Inhibitory Concentration (IC50) 80 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[33]
Half Maximal Inhibitory Concentration (IC50) 80 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[218]
Half Maximal Inhibitory Concentration (IC50) 80 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[112]
Half Maximal Inhibitory Concentration (IC50) 80 nM
IMR-32 cells
Neuroblastoma
CVCL_0346 
[222]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 80.91 nM
OVCAR-5 cells
Ovarian serous adenocarcinoma
CVCL_1628 
[39]
Half Maximal Inhibitory Concentration (IC50) 80.99 nM
EFO-27 cells
Ovarian mucinous adenocarcinoma
CVCL_1192 
Half Maximal Inhibitory Concentration (IC50) 800 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[321]
Half Maximal Inhibitory Concentration (IC50) 800 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[293]
Half Maximal Inhibitory Concentration (IC50) 800 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[245]
Half Maximal Inhibitory Concentration (IC50) 800 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[130]
Half Maximal Inhibitory Concentration (IC50) 800 nM
MRC5 cells
Normal
CVCL_0440 
[30]
Half Maximal Inhibitory Concentration (IC50) 81.1 nM
DMS 114 cells
Lung small cell carcinoma
CVCL_1174 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 816.58 nM
Hs 578T cells
Invasive breast carcinoma
CVCL_0332 
[39]
Half Maximal Inhibitory Concentration (IC50) 82.56 nM
KYSE-520 cells
Esophageal squamous cell carcinoma
CVCL_1355 
Half Maximal Inhibitory Concentration (IC50) 8280 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[92]
Half Maximal Inhibitory Concentration (IC50) 83 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[159]
Half Maximal Inhibitory Concentration (IC50) 83.02 nM
MDA-MB-175-VII cells
Breast carcinoma
CVCL_1400 
Half Maximal Inhibitory Concentration (IC50) 830 nM
HEK293 cells
Normal
CVCL_0045 
[106]
Half Maximal Inhibitory Concentration (IC50) 8370 nM
WI-38 cells
Normal
CVCL_0579 
[258]
Half Maximal Inhibitory Concentration (IC50) 84 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[286]
Half Maximal Inhibitory Concentration (IC50) 84.75 nM
DK-MG cells
Glioblastoma
CVCL_1173 
Half Maximal Inhibitory Concentration (IC50) 85 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[322]
Half Maximal Inhibitory Concentration (IC50) 85.52 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
Half Maximal Inhibitory Concentration (IC50) 85.66 nM
ACN cells
Melanoma
CVCL_1068 
Half Maximal Inhibitory Concentration (IC50) 850 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[282]
Half Maximal Inhibitory Concentration (IC50) 86.1 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[254]
Half Maximal Inhibitory Concentration (IC50) 86.88 nM
SiHa cells
Cervical squamous cell carcinoma
CVCL_0032 
Half Maximal Inhibitory Concentration (IC50) 860 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[282]
Half Maximal Inhibitory Concentration (IC50) 8640 nM
HEC-1B cells
Endometrial adenocarcinoma
CVCL_0294 
[164]
Half Maximal Inhibitory Concentration (IC50) 87.25 nM
LB2518-MEL cells
Melanoma
CVCL_1366 
Half Maximal Inhibitory Concentration (IC50) 87.43 nM
CAMA-1 cells
Breast adenocarcinoma
CVCL_1115 
Half Maximal Inhibitory Concentration (IC50) 87.5 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[266]
Half Maximal Inhibitory Concentration (IC50) 87.8 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[302]
Half Maximal Inhibitory Concentration (IC50) 8750 nM
HEK293 cells
Normal
CVCL_0045 
[248]
Half Maximal Inhibitory Concentration (IC50) 88 nM
T24 cells
Bladder carcinoma
CVCL_0554 
[323]
Half Maximal Inhibitory Concentration (IC50) 88.05 nM
ES6 cells
Ewing sarcoma
CVCL_1202 
Half Maximal Inhibitory Concentration (IC50) 8830 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[193]
Half Maximal Inhibitory Concentration (IC50) 8870 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[153]
Half Maximal Inhibitory Concentration (IC50) 89 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[305]
Half Maximal Inhibitory Concentration (IC50) 890 nM
HEK293 cells
Normal
CVCL_0045 
[134]
Half Maximal Inhibitory Concentration (IC50) 890 nM
MRC5 cells
Normal
CVCL_0440 
[117]
Half Maximal Inhibitory Concentration (IC50) 8900 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[92]
Half Maximal Inhibitory Concentration (IC50) 8930 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[324]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[207]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[227]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[122]
Half Maximal Inhibitory Concentration (IC50) 9 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[141]
Half Maximal Inhibitory Concentration (IC50) 9 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[127]
Half Maximal Inhibitory Concentration (IC50) 9 nM
P388 cells
Lymphoma
CVCL_7222 
[95]
Half Maximal Inhibitory Concentration (IC50) 9.009 nM
SF539 cells
Gliosarcoma
CVCL_1691 
Half Maximal Inhibitory Concentration (IC50) 9.114 nM
D-263MG cells
Glioblastoma
CVCL_1154 
Half Maximal Inhibitory Concentration (IC50) 9.314 nM
22RV1 cells
Prostate carcinoma
CVCL_1045 
Half Maximal Inhibitory Concentration (IC50) 9.425 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
Half Maximal Inhibitory Concentration (IC50) 9.753 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
Half Maximal Inhibitory Concentration (IC50) 9.948 nM
M14 cells
Melanoma
CVCL_1395 
Half Maximal Inhibitory Concentration (IC50) 9.968 nM
OS-RC-2 cells
Clear cell renal cell carcinoma
CVCL_1626 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 90 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[148]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 90 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[199]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 90 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[103]
Half Maximal Inhibitory Concentration (IC50) 90 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[257]
Half Maximal Inhibitory Concentration (IC50) 90 nM
PANC-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0480 
[200]
Half Maximal Inhibitory Concentration (IC50) 90 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[221]
Half Maximal Inhibitory Concentration (IC50) 90 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[231]
Half Maximal Inhibitory Concentration (IC50) 90 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[76]
Half Maximal Inhibitory Concentration (IC50) 90 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[77]
Half Maximal Inhibitory Concentration (IC50) 90 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[229]
Half Maximal Inhibitory Concentration (IC50) 90.89 nM
NCI-H2452 cells
Pleural mesothelioma
CVCL_1553 
Half Maximal Inhibitory Concentration (IC50) 900 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[26]
Half Maximal Inhibitory Concentration (IC50) 900 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
[223]
Half Maximal Inhibitory Concentration (IC50) 91 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[187]
Half Maximal Inhibitory Concentration (IC50) 91.19 nM
LB373-MEL-D cells
Melanoma
CVCL_1367 
Half Maximal Inhibitory Concentration (IC50) 91.86 nM
NOS-1 cells
Osteosarcoma
CVCL_1610 
Half Maximal Inhibitory Concentration (IC50) 9170 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[319]
Half Maximal Inhibitory Concentration (IC50) 92.14 nM
KYSE-70 cells
Esophageal squamous cell carcinoma
CVCL_1356 
Half Maximal Inhibitory Concentration (IC50) 920 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[315]
Half Maximal Inhibitory Concentration (IC50) 920 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[282]
Half Maximal Inhibitory Concentration (IC50) 9290 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[319]
Half Maximal Inhibitory Concentration (IC50) 93.98 nM
8305C cells
Thyroid gland anaplastic carcinoma
CVCL_1053 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 937.56 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[39]
Half Maximal Inhibitory Concentration (IC50) 940 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[306]
Half Maximal Inhibitory Concentration (IC50) 940 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[206]
Half Maximal Inhibitory Concentration (IC50) 940 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[311]
Half Maximal Inhibitory Concentration (IC50) 9450 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[102]
Half Maximal Inhibitory Concentration (IC50) 9492.4 nM
LS1034 cells
Cecum adenocarcinoma
CVCL_1382 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 95.06 nM
EKVX cells
Non-small cell lung carcinoma
CVCL_1195 
[39]
Half Maximal Inhibitory Concentration (IC50) 95.58 nM
H-EMC-SS cells
Extraskeletal myxoid chondrosarcoma
CVCL_1238 
Half Maximal Inhibitory Concentration (IC50) 950 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[212]
Half Maximal Inhibitory Concentration (IC50) 9520 nM
Eca-109 cells
Esophageal squamous cell carcinoma
CVCL_6898 
[119]
Half Maximal Inhibitory Concentration (IC50) 9550 nM
Caco-2 cells
Colon adenocarcinoma
CVCL_0025 
[89]
Half Maximal Inhibitory Concentration (IC50) 956.65 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
Half Maximal Inhibitory Concentration (IC50) 960 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
[76]
Half Maximal Inhibitory Concentration (IC50) 9621.56 nM
NCI-H1993 cells
Lung adenocarcinoma
CVCL_1512 
Half Maximal Inhibitory Concentration (IC50) 9670 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[136]
Half Maximal Inhibitory Concentration (IC50) 970 nM
Farage cells
Normal
CVCL_0214 
[325]
Half Maximal Inhibitory Concentration (IC50) 970 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[107]
Half Maximal Inhibitory Concentration (IC50) 970 nM
MCF-10A cells
Normal
CVCL_0598 
[113]
Half Maximal Inhibitory Concentration (IC50) 9700 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[137]
Half Maximal Inhibitory Concentration (IC50) 975.25 nM
NCI-H2291 cells
Lung adenocarcinoma
CVCL_1546 
Half Maximal Inhibitory Concentration (IC50) 98 nM
SNU-638 cells
Gastric carcinoma
CVCL_0102 
[194]
Half Maximal Inhibitory Concentration (IC50) 98 nM
SNU-638 cells
Gastric carcinoma
CVCL_0102 
[195]
Half Maximal Inhibitory Concentration (IC50) 98 nM
SNU-638 cells
Gastric carcinoma
CVCL_0102 
[196]
Half Maximal Inhibitory Concentration (IC50) 980 nM
CNE-2 cells
Normal
CVCL_6889 
[108]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 99 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[122]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 99 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[227]
Half Maximal Inhibitory Concentration (IC50) 99 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[19]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 990 nM
Detroit 551 cells
Normal
CVCL_2434 
[208]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 990 nM
Detroit 551 cells
Normal
CVCL_2434 
[103]
Half Maximal Inhibitory Concentration (IC50) 990 nM
Detroit 551 cells
Normal
CVCL_2434 
[171]
Half Maximal Inhibitory Concentration (IC50) 9920 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[319]
Each Antibody-drug Conjugate Related to This Payload
References
Ref 1 Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues. J Med Chem. 1994 Sep 16;37(19):3033-9. doi: 10.1021/jm00045a007.
Ref 2 Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues. J Med Chem. 1998 Jun 18;41(13):2308-18. doi: 10.1021/jm970765q.
Ref 3 Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin. Bioorg Med Chem Lett. 2004 Aug 2;14(15):4023-6. doi: 10.1016/j.bmcl.2004.05.032.
Ref 4 DNA topoisomerase I inhibitors: cytotoxic flavones from Lethedon tannaensis. J Nat Prod. 1996 Jul;59(7):701-3. doi: 10.1021/np960336f.
Ref 5 Biological activity of some coumarins from Sri Lankan Rutaceae. J Nat Prod. 1994 Apr;57(4):518-20. doi: 10.1021/np50106a013.
Ref 6 Frajunolides E-K, briarane diterpenes from Junceella fragilis. J Nat Prod. 2008 Sep;71(9):1551-6. doi: 10.1021/np800126f. Epub 2008 Sep 6.
Ref 7 Three types of cytotoxic natural caged-scaffolds: pure enantiomers or partial racemates. J Nat Prod. 2014 Jul 25;77(7):1562-71. doi: 10.1021/np400996k. Epub 2014 Jun 18.
Ref 8 Strychnobaillonine, an unsymmetrical bisindole alkaloid with an unprecedented skeleton from Strychnos icaja roots. J Nat Prod. 2014 Apr 25;77(4):1078-82. doi: 10.1021/np400908u. Epub 2014 Mar 4.
Ref 9 Bioactive furanonaphthoquinones from Crescentia cujete. J Nat Prod. 1993 Sep;56(9):1500-5. doi: 10.1021/np50099a008.
Ref 10 Limonoids showing selective toxicity to DNA repair-deficient yeast and other constituents of Trichilia emetica. J Nat Prod. 1998 Feb;61(2):179-84. doi: 10.1021/np9701687.
Ref 11 Cytotoxic and other compounds from Didymochlaena truncatula from the Madagascar rain forest. J Nat Prod. 2006 Feb;69(2):284-6. doi: 10.1021/np050351x.
Ref 12 Design and synthesis of 4-amino-2-phenylquinazolines as novel topoisomerase I inhibitors with molecular modeling. Bioorg Med Chem. 2011 Jul 15;19(14):4399-404. doi: 10.1016/j.bmc.2011.05.012. Epub 2011 May 20.
Ref 13 SnO 2 nanoparticles mediated nontraditional synthesis of biologically active 9-chloro-6, 13-dihydro-7-phenyl-5 H-indolo [3, 2-c]-acridine derivatives[J]. Medicinal Chemistry Research, 2011, 20: 732-737.
Ref 14 Antiparasitic hybrids of Cinchona alkaloids and bile acids. Eur J Med Chem. 2013 Aug;66:355-63. doi: 10.1016/j.ejmech.2013.06.004. Epub 2013 Jun 12.
Ref 15 Structure and in vitro antiparasitic activity of constituents of Citropsis articulata root bark. J Nat Prod. 2011 Oct 28;74(10):2286-9. doi: 10.1021/np2004825. Epub 2011 Oct 10.
Ref 16 Synthesis and structure-activity relationship of novel 1,4-diazabicyclo[2.2.2]octane derivatives as potent antimicrobial agents. Eur J Med Chem. 2015 May 5;95:563-73. doi: 10.1016/j.ejmech.2015.03.033. Epub 2015 Mar 17.
Ref 17 Lantadenes and their esters as potential antitumor agents. J Nat Prod. 2008 Jul;71(7):1222-7. doi: 10.1021/np800167x. Epub 2008 Jun 14.
Ref 18 Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues. J Med Chem. 2009 Oct 8;52(19):5937-49. doi: 10.1021/jm9005059.
Ref 19 Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives. ACS Med Chem Lett. 2013 May 28;4(7):651-5. doi: 10.1021/ml400125z. eCollection 2013 Jul 11.
Ref 20 Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines. Eur J Med Chem. 2014 Nov 24;87:140-9. doi: 10.1016/j.ejmech.2014.09.056. Epub 2014 Sep 20.
Ref 21 Prenylated Indole Diterpene Alkaloids from a Mine-Soil-Derived Tolypocladium sp. J Nat Prod. 2019 Feb 22;82(2):221-231. doi: 10.1021/acs.jnatprod.8b00589. Epub 2019 Jan 31.
Ref 22 New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A. Eur J Med Chem. 2014 Oct 6;85:179-90. doi: 10.1016/j.ejmech.2014.07.035. Epub 2014 Jul 27.
Ref 23 Novel topoisomerase I inhibitors. Syntheses and biological evaluation of phosphorus substituted quinoline derivates with antiproliferative activity. Eur J Med Chem. 2018 Apr 10;149:225-237. doi: 10.1016/j.ejmech.2018.02.058. Epub 2018 Feb 22.
Ref 24 Bridged tricyclic sesquiterpenes from the tubercle nudibranch Phyllidia coelestis Bergh. J Nat Prod. 2013 Nov 22;76(11):2158-61. doi: 10.1021/np4007074. Epub 2013 Nov 7.
Ref 25 Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships. J Med Chem. 2005 Jun 2;48(11):3796-807. doi: 10.1021/jm049060w.
Ref 26 Bioactive spirobisnaphthalenes from the endophytic fungus Berkleasmium sp. J Nat Prod. 2014 Oct 24;77(10):2151-60. doi: 10.1021/np400988a. Epub 2014 Sep 19.
Ref 27 Synthesis and biological evaluation of indeno[1,5]naphthyridines as topoisomerase I (TopI) inhibitors with antiproliferative activity. Eur J Med Chem. 2016 Jun 10;115:179-90. doi: 10.1016/j.ejmech.2016.03.031. Epub 2016 Mar 14.
Ref 28 Straightforward synthesis and biological evaluation as topoisomerase I inhibitors and antiproliferative agents of hybrid Chromeno[4,3-b][1,5]Naphthyridines and Chromeno[4,3-b][1,5]Naphthyridin-6-ones. Eur J Med Chem. 2019 Sep 15;178:752-766. doi: 10.1016/j.ejmech.2019.06.032. Epub 2019 Jun 14.
Ref 29 Fused chromeno and quinolino[1,8]naphthyridines: Synthesis and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. Bioorg Med Chem. 2021 Jun 15;40:116177. doi: 10.1016/j.bmc.2021.116177. Epub 2021 Apr 27.
Ref 30 Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. Bioorg Med Chem Lett. 2022 Feb 1;57:128517. doi: 10.1016/j.bmcl.2021.128517. Epub 2021 Dec 21.
Ref 31 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. J Med Chem. 2011 Mar 24;54(6):1715-23. doi: 10.1021/jm101354u. Epub 2011 Feb 22.
Ref 32 Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation. Bioorg Med Chem Lett. 2008 Jan 15;18(2):816-20. doi: 10.1016/j.bmcl.2007.11.029. Epub 2007 Nov 17.
Ref 33 Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase II catalytic inhibitors. Eur J Med Chem. 2016 Nov 10;123:211-225. doi: 10.1016/j.ejmech.2016.07.046. Epub 2016 Jul 22.
Ref 34 Kabiramides J and K, trisoxazole macrolides from the sponge Pachastrissa nux. J Nat Prod. 2011 May 27;74(5):1288-92. doi: 10.1021/np100886y. Epub 2011 Mar 16.
Ref 35 Bifunctionalized amphilectane diterpenes from the sponge Stylissa cf. massa. J Nat Prod. 2012 Apr 27;75(4):789-92. doi: 10.1021/np200959j. Epub 2012 Feb 29.
Ref 36 Resin Glycosides from Ipomoea alba Seeds as Potential Chemosensitizers in Breast Carcinoma Cells. J Nat Prod. 2016 Dec 23;79(12):3093-3104. doi: 10.1021/acs.jnatprod.6b00782. Epub 2016 Nov 23.
Ref 37 Extending the record of bis--pyrone polypropionates from marine pulmonate mollusks. J Nat Prod. 2013 Nov 22;76(11):2065-73. doi: 10.1021/np400483c. Epub 2013 Nov 1.
Ref 38 Synthesis, anticancer activities and molecular modeling studies of novel indole retinoid derivatives. Eur J Med Chem. 2012 Dec;58:346-54. doi: 10.1016/j.ejmech.2012.10.013. Epub 2012 Oct 22.
Ref 39 PubChem BioAssay data set.
Ref 40 Synthesis and Biological Evaluation of Calothrixins B and their Deoxygenated Analogues. J Med Chem. 2018 Feb 8;61(3):1285-1315. doi: 10.1021/acs.jmedchem.7b01797. Epub 2018 Jan 22.
Ref 41 Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives. Bioorg Med Chem. 2007 Jun 15;15(12):4237-46. doi: 10.1016/j.bmc.2007.03.067. Epub 2007 Mar 25.
Ref 42 Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. J Med Chem. 2000 Oct 5;43(20):3688-98. doi: 10.1021/jm000029d.
Ref 43 Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings. J Med Chem. 2004 Nov 4;47(23):5651-61. doi: 10.1021/jm040025z.
Ref 44 Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem. 2005 Jul 28;48(15):4803-14. doi: 10.1021/jm050076b.
Ref 45 Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors. J Med Chem. 2006 Aug 24;49(17):5129-40. doi: 10.1021/jm060046o.
Ref 46 Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1846-9. doi: 10.1016/j.bmcl.2006.01.008. Epub 2006 Jan 25.
Ref 47 Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures. J Med Chem. 2007 May 3;50(9):2040-8. doi: 10.1021/jm0613119. Epub 2007 Apr 3.
Ref 48 Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization. J Med Chem. 2007 Sep 6;50(18):4419-30. doi: 10.1021/jm070361q. Epub 2007 Aug 15.
Ref 49 Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships. Bioorg Med Chem. 2009 Oct 15;17(20):7145-55. doi: 10.1016/j.bmc.2009.08.066. Epub 2009 Sep 6.
Ref 50 Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. J Med Chem. 2008 Aug 14;51(15):4609-19. doi: 10.1021/jm800259e. Epub 2008 Jul 17.
Ref 51 Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors. J Med Chem. 2010 Mar 11;53(5):1979-89. doi: 10.1021/jm901649x.
Ref 52 The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode. Bioorg Med Chem. 2010 Aug 1;18(15):5535-52. doi: 10.1016/j.bmc.2010.06.040. Epub 2010 Jun 20.
Ref 53 Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity. J Med Chem. 2011 Jul 28;54(14):4937-53. doi: 10.1021/jm101338z. Epub 2011 Jun 28.
Ref 54 7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents. J Med Chem. 2011 Sep 8;54(17):6106-16. doi: 10.1021/jm200719v. Epub 2011 Aug 8.
Ref 55 Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships. J Med Chem. 2012 Feb 23;55(4):1682-97. doi: 10.1021/jm201512x. Epub 2012 Feb 13.
Ref 56 Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells. J Med Chem. 2014 Feb 27;57(4):1289-98. doi: 10.1021/jm401471v. Epub 2014 Feb 6.
Ref 57 Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors. J Med Chem. 2014 May 22;57(10):4324-36. doi: 10.1021/jm500294a. Epub 2014 May 6.
Ref 58 Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons. J Med Chem. 2016 Apr 28;59(8):3840-53. doi: 10.1021/acs.jmedchem.6b00003. Epub 2016 Apr 12.
Ref 59 Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I. J Med Chem. 2017 Jul 13;60(13):5364-5376. doi: 10.1021/acs.jmedchem.6b01870. Epub 2017 Jun 28.
Ref 60 Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. J Med Chem. 2009 Sep 24;52(18):5649-61. doi: 10.1021/jm900469e.
Ref 61 Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2). J Med Chem. 2017 Apr 27;60(8):3275-3288. doi: 10.1021/acs.jmedchem.6b01565. Epub 2017 Apr 18.
Ref 62 Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylseleno-imidocarbamates. Eur J Med Chem. 2011 Jan;46(1):265-74. doi: 10.1016/j.ejmech.2010.11.013. Epub 2010 Nov 27.
Ref 63 Structural variations on antitumour agents derived from bisacylimidoselenocarbamate. A proposal for structure-activity relationships based on the analysis of conformational behaviour. Eur J Med Chem. 2013 Aug;66:489-98. doi: 10.1016/j.ejmech.2013.06.001. Epub 2013 Jun 18.
Ref 64 CHMIS-C: a comprehensive herbal medicine information system for cancer. J Med Chem. 2005 Mar 10;48(5):1481-8. doi: 10.1021/jm049838d.
Ref 65 Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors. J Med Chem. 2007 Sep 6;50(18):4388-404. doi: 10.1021/jm070307+. Epub 2007 Aug 4.
Ref 66 Novel hexacyclic camptothecin derivatives. Part 1: synthesis and cytotoxicity of camptothecins with an A-ring fused 1,3-oxazine ring. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4095-7. doi: 10.1016/j.bmcl.2008.05.103. Epub 2008 Jun 12.
Ref 67 A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells. Bioorg Med Chem. 2012 Sep 1;20(17):5094-102. doi: 10.1016/j.bmc.2012.07.016. Epub 2012 Jul 20.
Ref 68 Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine. Eur J Med Chem. 2007 Mar;42(3):293-306. doi: 10.1016/j.ejmech.2006.11.013. Epub 2006 Dec 5.
Ref 69 Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12. J Med Chem. 2009 Aug 27;52(16):5176-87. doi: 10.1021/jm900365v.
Ref 70 Synthesis of indole inhibitors of silent information regulator 1 (SIRT1), and their evaluation as cytotoxic agents. Eur J Med Chem. 2020 Sep 15;202:112561. doi: 10.1016/j.ejmech.2020.112561. Epub 2020 Jul 2.
Ref 71 New antiprotozoal agents: Synthesis and biological evaluation of different 4-(7-chloroquinolin-4-yl) piperazin-1-yl)pyrrolidin-2-yl)methanone derivatives. Bioorg Med Chem Lett. 2017 Feb 1;27(3):460-465. doi: 10.1016/j.bmcl.2016.12.043. Epub 2016 Dec 18.
Ref 72 Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety. Bioorg Med Chem Lett. 2012 Aug 1;22(15):5013-7. doi: 10.1016/j.bmcl.2012.06.016. Epub 2012 Jun 15.
Ref 73 Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5585-9. doi: 10.1016/j.bmcl.2004.08.070.
Ref 74 Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(-D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells. J Med Chem. 2012 Apr 12;55(7):3058-65. doi: 10.1021/jm3001532. Epub 2012 Mar 27.
Ref 75 Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins. Bioorg Med Chem. 2016 Feb 15;24(4):858-72. doi: 10.1016/j.bmc.2016.01.013. Epub 2016 Jan 8.
Ref 76 Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents. J Med Chem. 2015 Aug 27;58(16):6678-96. doi: 10.1021/acs.jmedchem.5b00910. Epub 2015 Aug 19.
Ref 77 Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer. J Med Chem. 2021 Dec 9;64(23):17346-17365. doi: 10.1021/acs.jmedchem.1c01411. Epub 2021 Nov 29.
Ref 78 Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines. Bioorg Med Chem. 2010 May 1;18(9):3066-77. doi: 10.1016/j.bmc.2010.03.051. Epub 2010 Mar 27.
Ref 79 Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Eur J Med Chem. 2011 Aug;46(8):3201-9. doi: 10.1016/j.ejmech.2011.04.029. Epub 2011 Apr 29.
Ref 80 Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents. Eur J Med Chem. 2015 Oct 20;103:615-27. doi: 10.1016/j.ejmech.2014.09.050. Epub 2014 Sep 16.
Ref 81 3-Propionyl-thiazolidine-4-carboxylic acid ethyl esters: a family of antiproliferative thiazolidines. Medchemcomm. 2015;6(1):90-93.
Ref 82 Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents. Eur J Med Chem. 2018 Aug 5;156:479-492. doi: 10.1016/j.ejmech.2018.07.028. Epub 2018 Jul 17.
Ref 83 Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors. Bioorg Med Chem. 2017 Jul 1;25(13):3437-3446. doi: 10.1016/j.bmc.2017.04.030. Epub 2017 May 4.
Ref 84 Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents. J Med Chem. 2013 Jul 11;56(13):5562-86. doi: 10.1021/jm400575x. Epub 2013 Jun 25.
Ref 85 Synthesis of novel hybrid quinolino[4,3-b][1,5]naphthyridines and quinolino[4,3-b][1,5]naphthyridin-6(5H)-one derivatives and biological evaluation as topoisomerase I inhibitors and antiproliferatives. Eur J Med Chem. 2020 Jun 1;195:112292. doi: 10.1016/j.ejmech.2020.112292. Epub 2020 Apr 3.
Ref 86 Humulane and germacrane sesquiterpenes from Ferula lycia. J Nat Prod. 2010 Apr 23;73(4):780-3. doi: 10.1021/np900827a.
Ref 87 Oxiranylmethyloxy or thiiranylmethyloxy-azaxanthones and -acridone analogues as potential topoisomerase I inhibitors. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6766-9. doi: 10.1016/j.bmcl.2009.09.091. Epub 2009 Sep 27.
Ref 88 New insight for fluoroquinophenoxazine derivatives as possibly new potent topoisomerase I inhibitor. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1520-4. doi: 10.1016/j.bmcl.2007.12.053. Epub 2007 Dec 25.
Ref 89 6-Substituted imidazo[1,2-a]pyridines: synthesis and biological activity against colon cancer cell lines HT-29 and Caco-2. Eur J Med Chem. 2011 Sep;46(9):4573-83. doi: 10.1016/j.ejmech.2011.07.036. Epub 2011 Jul 27.
Ref 90 Cytotoxic clerodane diterpenes from Zuelania guidonia. J Nat Prod. 2014 Mar 28;77(3):455-63. doi: 10.1021/np400672g. Epub 2014 Jan 31.
Ref 91 Lignans from the roots of Saururus chinensis. J Nat Prod. 2008 Oct;71(10):1771-4. doi: 10.1021/np8002723. Epub 2008 Oct 8.
Ref 92 Integration of a Diselenide Unit Generates Fluorogenic Camptothecin Prodrugs with Improved Cytotoxicity to Cancer Cells. J Med Chem. 2021 Dec 23;64(24):17979-17991. doi: 10.1021/acs.jmedchem.1c01362. Epub 2021 Dec 1.
Ref 93 11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents. Bioorg Med Chem. 2008 Sep 15;16(18):8598-606. doi: 10.1016/j.bmc.2008.08.018. Epub 2008 Aug 7.
Ref 94 12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents. Bioorg Med Chem. 2009 Apr 1;17(7):2877-85. doi: 10.1016/j.bmc.2009.02.023. Epub 2009 Feb 20.
Ref 95 Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31). Bioorg Med Chem. 2008 Aug 15;16(16):7824-31. doi: 10.1016/j.bmc.2008.06.046. Epub 2008 Jun 26.
Ref 96 Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents. Bioorg Med Chem. 2008 Oct 15;16(20):9295-301. doi: 10.1016/j.bmc.2008.09.002. Epub 2008 Sep 5.
Ref 97 Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide. Eur J Med Chem. 2009 Sep;44(9):3433-8. doi: 10.1016/j.ejmech.2009.02.004. Epub 2009 Feb 20.
Ref 98 Novel securinine derivatives as topoisomerase I based antitumor agents. Eur J Med Chem. 2016 Oct 21;122:149-163. doi: 10.1016/j.ejmech.2016.06.021. Epub 2016 Jun 15.
Ref 99 Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors. Eur J Med Chem. 2014 Jul 23;82:181-94. doi: 10.1016/j.ejmech.2014.05.047. Epub 2014 May 21.
Ref 100 Dihydroxylated 2,4,6-triphenyl pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study. Eur J Med Chem. 2012 Mar;49:219-28. doi: 10.1016/j.ejmech.2012.01.015. Epub 2012 Jan 24.
Ref 101 Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety. Eur J Med Chem. 2012 Jun;52:123-36. doi: 10.1016/j.ejmech.2012.03.010. Epub 2012 Mar 24.
Ref 102 Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid--benzyl ester derivatives as potent topoisomerase II inhibitors. Bioorg Med Chem. 2017 Jun 15;25(12):3116-3126. doi: 10.1016/j.bmc.2017.03.065. Epub 2017 Apr 3.
Ref 103 Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2. J Med Chem. 2010 Aug 26;53(16):6164-79. doi: 10.1021/jm1005447.
Ref 104 Derivatives of the new ring system indolo[1,2-c]benzo[1,2,3]triazine with potent antitumor and antimicrobial activity. J Med Chem. 1999 Jul 15;42(14):2561-8. doi: 10.1021/jm9806087.
Ref 105 In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer. J Med Chem. 2022 Nov 24;65(22):15123-15139. doi: 10.1021/acs.jmedchem.2c00968. Epub 2022 Nov 9.
Ref 106 Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors. Eur J Med Chem. 2017 Jan 5;125:14-28. doi: 10.1016/j.ejmech.2016.09.019. Epub 2016 Sep 8.
Ref 107 Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase II catalytic inhibitor. Eur J Med Chem. 2011 Jun;46(6):1964-71. doi: 10.1016/j.ejmech.2011.01.011. Epub 2011 Jan 15.
Ref 108 Design, synthesis, biological evaluation and structure-activity relationship of sophoridine derivatives bearing pyrrole or indole scaffold as potential antitumor agents. Eur J Med Chem. 2018 Sep 5;157:665-682. doi: 10.1016/j.ejmech.2018.08.021. Epub 2018 Aug 9.
Ref 109 Synthesis and biological evaluation of new camptothecin derivatives obtained by modification of position 20. Bioorg Med Chem. 2010 Dec 15;18(24):8660-8. doi: 10.1016/j.bmc.2010.09.069. Epub 2010 Oct 7.
Ref 110 Synthesis and biological evaluation of a D-ring-contracted analogue of lamellarin D. Bioorg Med Chem. 2017 Nov 15;25(22):6137-6148. doi: 10.1016/j.bmc.2017.02.005. Epub 2017 Feb 9.
Ref 111 Cytotoxic steroidal saponins from Trillium kamtschaticum. Bioorg Med Chem Lett. 2017 Jun 1;27(11):2267-2273. doi: 10.1016/j.bmcl.2017.04.057. Epub 2017 Apr 19.
Ref 112 Design and synthesis of novel 2,4-diaryl-5H-indeno[1,2-b]pyridine derivatives, and their evaluation of topoisomerase inhibitory activity and cytotoxicity. Bioorg Med Chem. 2015 Jan 1;23(1):160-73. doi: 10.1016/j.bmc.2014.11.010. Epub 2014 Nov 11.
Ref 113 Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents. Bioorg Med Chem. 2015 Oct 1;23(19):6454-66. doi: 10.1016/j.bmc.2015.08.018. Epub 2015 Aug 22.
Ref 114 Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents. Eur J Med Chem. 2012 Oct;56:1-9. doi: 10.1016/j.ejmech.2012.07.050. Epub 2012 Aug 7.
Ref 115 Stereochemical Structure Activity Relationship Studies (S-SAR) of Tetrahydrolipstatin. ACS Med Chem Lett. 2018 Feb 21;9(3):274-278. doi: 10.1021/acsmedchemlett.8b00050. eCollection 2018 Mar 8.
Ref 116 Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues. Eur J Med Chem. 2010 Sep;45(9):4221-8. doi: 10.1016/j.ejmech.2010.06.017. Epub 2010 Jun 17.
Ref 117 Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers. J Med Chem. 2011 Jul 14;54(13):4446-61. doi: 10.1021/jm200046z. Epub 2011 Jun 3.
Ref 118 Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines. Bioorg Med Chem Lett. 2016 Apr 1;26(7):1726-31. doi: 10.1016/j.bmcl.2016.02.053. Epub 2016 Feb 20.
Ref 119 Design, synthesis and biological evaluation of lapachol derivatives possessing indole scaffolds as topoisomerase I inhibitors. Bioorg Med Chem. 2016 Nov 15;24(22):5781-5786. doi: 10.1016/j.bmc.2016.09.034. Epub 2016 Sep 15.
Ref 120 Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors. Eur J Med Chem. 2015 Mar 6;92:540-53. doi: 10.1016/j.ejmech.2015.01.024. Epub 2015 Jan 12.
Ref 121 Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5377-81. doi: 10.1016/j.bmcl.2004.08.010.
Ref 122 Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. Eur J Med Chem. 2019 Sep 15;178:81-92. doi: 10.1016/j.ejmech.2019.05.074. Epub 2019 May 30.
Ref 123 Discovery of novel bis-evodiamine derivatives with potent antitumor activity. Bioorg Med Chem. 2022 Jul 1;65:116793. doi: 10.1016/j.bmc.2022.116793. Epub 2022 May 6.
Ref 124 Lactone Derivatives Produced by a Phaeoacremonium sp., an Endophytic Fungus from Senna spectabilis. J Nat Prod. 2017 May 26;80(5):1674-1678. doi: 10.1021/acs.jnatprod.5b00828. Epub 2017 Apr 20.
Ref 125 Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors. Bioorg Med Chem Lett. 2017 May 1;27(9):1929-1933. doi: 10.1016/j.bmcl.2017.03.039. Epub 2017 Mar 18.
Ref 126 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4107-9. doi: 10.1016/j.bmcl.2009.06.010. Epub 2009 Jun 6.
Ref 127 Novel bioactive clerodane diterpenoids from the leaves and twigs of Casearia sylvestris. J Nat Prod. 2002 Feb;65(2):95-9. doi: 10.1021/np010459m.
Ref 128 Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity. J Nat Prod. 2013 Sep 27;76(9):1724-30. doi: 10.1021/np400433g. Epub 2013 Sep 17.
Ref 129 3-(2,6-Dichloro-benzyloxy)-11-oxo-olean-12-ene-29-oic acid, a semisynthetic derivative of glycyrrhetic acid: synthesis, antiproliferative, apoptotic and anti-angiogenesis activity. Medchemcomm. 2015;6(4):564-575.
Ref 130 Cytotoxic and apoptosis-inducing activities against human lung cancer cell lines of cassaine diterpenoids from the bark of Erythrophleum fordii. Bioorg Med Chem Lett. 2017 Jul 1;27(13):2946-2952. doi: 10.1016/j.bmcl.2017.05.006. Epub 2017 May 4.
Ref 131 Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7. doi: 10.1021/np0004606.
Ref 132 Design and one-pot synthesis of new 7-acyl camptothecin derivatives as potent cytotoxic agents. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7659-61. doi: 10.1016/j.bmcl.2012.10.002. Epub 2012 Oct 11.
Ref 133 Candenatenins A-F, phenolic compounds from the heartwood of Dalbergia candenatensis. J Nat Prod. 2009 Aug;72(8):1395-8. doi: 10.1021/np900077h.
Ref 134 Preparation of novel ring-A fused azole derivatives of betulin and evaluation of their cytotoxicity. Eur J Med Chem. 2017 Jan 5;125:629-639. doi: 10.1016/j.ejmech.2016.09.065. Epub 2016 Sep 21.
Ref 135 Synthesis of cytotoxically active derivatives based on alkylated 2,3-seco-triterpenoids. Eur J Med Chem. 2017 Nov 10;140:74-83. doi: 10.1016/j.ejmech.2017.09.005. Epub 2017 Sep 6.
Ref 136 Cytotoxic triterpenoid saponins acylated with monoterpenic acid from Pithecellobium lucidum. J Nat Prod. 2008 Jan;71(1):41-6. doi: 10.1021/np0703794. Epub 2007 Dec 21.
Ref 137 Cytotoxic oleanane triterpene saponins from Albizia chinensis. J Nat Prod. 2009 Apr;72(4):632-9. doi: 10.1021/np800576s.
Ref 138 Synthesis and biological evaluation of 6-fluoro-3-phenyl-7-piperazinyl quinolone derivatives as potential topoisomerase I inhibitors. Eur J Med Chem. 2016 Oct 21;122:465-474. doi: 10.1016/j.ejmech.2016.06.054. Epub 2016 Jul 1.
Ref 139 Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I. J Med Chem. 1995 Mar 17;38(6):1044-7. doi: 10.1021/jm00006a025.
Ref 140 Cytotoxicity and topo I targeting activity of substituted 10--nitrogenous heterocyclic aromatic group derivatives of SN-38. Eur J Med Chem. 2010 Jul;45(7):3200-6. doi: 10.1016/j.ejmech.2010.03.013. Epub 2010 Mar 16.
Ref 141 Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives. ACS Med Chem Lett. 2016 Feb 2;7(4):403-7. doi: 10.1021/acsmedchemlett.5b00441. eCollection 2016 Apr 14.
Ref 142 Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives. J Med Chem. 2001 Jun 7;44(12):2004-14. doi: 10.1021/jm010041l.
Ref 143 Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines. J Med Chem. 2003 Mar 13;46(6):1049-54. doi: 10.1021/jm020420u.
Ref 144 Synthesis and anti-cancer activity evaluation of novel prenylated and geranylated chalcone natural products and their analogs. Eur J Med Chem. 2015 Mar 6;92:439-48. doi: 10.1016/j.ejmech.2015.01.007. Epub 2015 Jan 6.
Ref 145 Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines as selective topoisomerase II-targeting anticancer agents. Bioorg Med Chem. 2018 May 1;26(8):1909-1919. doi: 10.1016/j.bmc.2018.02.035. Epub 2018 Feb 22.
Ref 146 Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors. J Nat Prod. 2009 Sep;72(9):1643-50. doi: 10.1021/np900312u.
Ref 147 Tessaric acid derivatives induce G2/M cell cycle arrest in human solid tumor cell lines. Bioorg Med Chem. 2009 Sep 1;17(17):6251-6. doi: 10.1016/j.bmc.2009.07.053. Epub 2009 Jul 25.
Ref 148 Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents. J Med Chem. 2011 Apr 14;54(7):2012-21. doi: 10.1021/jm1009428. Epub 2011 Mar 9.
Ref 149 Antiproliferative activity of withanolides against human breast cancer cell lines. J Nat Prod. 2010 May 28;73(5):966-8. doi: 10.1021/np9006734.
Ref 150 Design, synthesis and evaluation of novel sophoridinic imine derivatives containing conjugated planar structure as potent anticancer agents. Bioorg Med Chem. 2018 Aug 7;26(14):4136-4144. doi: 10.1016/j.bmc.2018.07.001. Epub 2018 Jul 2.
Ref 151 Indole alkaloids and other constituents of Rauwolfia serpentina. J Nat Prod. 2005 Jun;68(6):848-52. doi: 10.1021/np058007n.
Ref 152 Synthesis, modification, and cytotoxic evaluation of 2,3-secotriterpenic -ketoesters. Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3752-3760. doi: 10.1016/j.bmcl.2018.10.014. Epub 2018 Oct 11.
Ref 153 Synthesis and biological evaluation of new substituted thioglycolurils, their analogues and derivatives. Eur J Med Chem. 2017 Nov 10;140:141-154. doi: 10.1016/j.ejmech.2017.09.009. Epub 2017 Sep 7.
Ref 154 A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships. Bioorg Med Chem. 2018 Oct 1;26(18):5212-5223. doi: 10.1016/j.bmc.2018.09.021. Epub 2018 Sep 20.
Ref 155 Design, synthesis, and structure-activity relationships of new benzofuro[3,2-b]pyridin-7-ols as DNA topoisomerase II inhibitors. Bioorg Med Chem Lett. 2018 Feb 15;28(4):566-571. doi: 10.1016/j.bmcl.2018.01.048. Epub 2018 Feb 3.
Ref 156 N-2-(Phenylamino) Benzamide Derivatives as Dual Inhibitors of COX-2 and Topo I Deter Gastrointestinal Cancers via Targeting Inflammation and Tumor Progression. J Med Chem. 2022 Aug 11;65(15):10481-10505. doi: 10.1021/acs.jmedchem.2c00635. Epub 2022 Jul 22.
Ref 157 Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues. J Med Chem. 2001 May 10;44(10):1594-602. doi: 10.1021/jm0004751.
Ref 158 Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]pyrimidine derivatives. Bioorg Med Chem. 2007 Feb 15;15(4):1659-69. doi: 10.1016/j.bmc.2006.12.010. Epub 2006 Dec 12.
Ref 159 Synthesis of 2,6-diaryl-substituted pyridines and their antitumor activities. Eur J Med Chem. 2008 Apr;43(4):675-82. doi: 10.1016/j.ejmech.2007.05.002. Epub 2007 May 27.
Ref 160 Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem. 1989 Mar;32(3):715-20. doi: 10.1021/jm00123a038.
Ref 161 Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins. Eur J Med Chem. 2017 Jan 5;125:1235-1246. doi: 10.1016/j.ejmech.2016.11.013. Epub 2016 Nov 8.
Ref 162 Cytotoxicity and TOP1-targeting activity of 8- and 9-amino derivatives of 5-butyl- and 5-(2-N,N-dimethylamino)ethyl-5H-dibenzo[c,h][1,6]naphthyridin-6-ones. Eur J Med Chem. 2009 Apr;44(4):1471-6. doi: 10.1016/j.ejmech.2008.09.048. Epub 2008 Oct 11.
Ref 163 Optimization of the Natural Product Calothrixin A to Discover Novel Dual Topoisomerase I and II Inhibitors with Improved Anticancer Activity. J Med Chem. 2022 Jun 9;65(11):8040-8061. doi: 10.1021/acs.jmedchem.2c00615. Epub 2022 May 25.
Ref 164 Synthesis of 6-formyl-pyridine-2-carboxylate derivatives and their telomerase inhibitory activities. Bioorg Med Chem Lett. 2003 Feb 24;13(4):609-12. doi: 10.1016/s0960-894x(02)01041-7.
Ref 165 Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors. Eur J Med Chem. 2015 Aug 28;101:525-33. doi: 10.1016/j.ejmech.2015.07.007. Epub 2015 Jul 8.
Ref 166 Synthesis and in vitro cytotoxicity of hexacyclic camptothecin analogues. Bioorg Med Chem Lett. 1999 Nov 15;9(22):3203-6. doi: 10.1016/s0960-894x(99)00555-7.
Ref 167 2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study. Bioorg Med Chem Lett. 2010 Jan 1;20(1):42-7. doi: 10.1016/j.bmcl.2009.11.041. Epub 2009 Nov 14.
Ref 168 Synthesis and bio-evaluation of novel quinolino-stilbene derivatives as potential anticancer agents. Bioorg Med Chem. 2015 Dec 15;23(24):7629-40. doi: 10.1016/j.bmc.2015.11.007. Epub 2015 Nov 7.
Ref 169 Cytotoxic phloroglucinols from the leaves of Myrtus communis. J Nat Prod. 2012 Feb 24;75(2):225-9. doi: 10.1021/np2009219. Epub 2012 Jan 25.
Ref 170 The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem. 2000 Oct 19;43(21):3970-80. doi: 10.1021/jm000144o.
Ref 171 Synthesis and antiproliferative evaluation of 9-methoxy-6-(piperazin-1-yl)-11H-indeno[1,2-c]quinoline-11-one derivatives. Part 4. Medchemcomm. 2014;5(7):937-948.
Ref 172 Synthesis and evaluation of new 6-amino-substituted benzo[c]phenanthridine derivatives. J Med Chem. 1993 Nov 12;36(23):3686-92. doi: 10.1021/jm00075a025.
Ref 173 Synthesis and biological activity of novel inhibitors of topoisomerase I: 2-aryl-substituted 2-bis-1H-benzimidazoles. Eur J Med Chem. 2011 Feb;46(2):659-69. doi: 10.1016/j.ejmech.2010.11.046. Epub 2010 Dec 8.
Ref 174 Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer. Eur J Med Chem. 2022 Jul 5;237:114376. doi: 10.1016/j.ejmech.2022.114376. Epub 2022 Apr 18.
Ref 175 A resveratrol analog, phoyunbene B, induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. Bioorg Med Chem Lett. 2012 Mar 1;22(5):2114-8. doi: 10.1016/j.bmcl.2011.12.095. Epub 2012 Jan 16.
Ref 176 Synthesis and antitumor activity of lapathoside D and its analogs. Eur J Med Chem. 2012 Jul;53:1-12. doi: 10.1016/j.ejmech.2012.02.032. Epub 2012 Mar 28.
Ref 177 Synthesis and antiproliferative activity of helonioside A, 3',4',6'-tri-O-feruloylsucrose, lapathoside C and their analogs. Eur J Med Chem. 2012 Dec;58:418-30. doi: 10.1016/j.ejmech.2012.10.034. Epub 2012 Oct 27.
Ref 178 Concise synthesis and antiproliferative activity evaluation of ellipticine quinone and its analogs. Eur J Med Chem. 2017 Aug 18;136:1-13. doi: 10.1016/j.ejmech.2017.04.071. Epub 2017 Apr 28.
Ref 179 Concise synthesis of carbazole-1,4-quinones and evaluation of their antiproliferative activity against HCT-116 and HL-60 cells. Eur J Med Chem. 2016 Oct 4;121:561-577. doi: 10.1016/j.ejmech.2016.05.065. Epub 2016 Jun 3.
Ref 180 Substituted 2-arylquinazolinones: Design, synthesis, and evaluation of cytotoxicity and inhibition of topoisomerases. Eur J Med Chem. 2015 Oct 20;103:69-79. doi: 10.1016/j.ejmech.2015.08.040. Epub 2015 Aug 28.
Ref 181 Design, synthesis, cytotoxic activity and molecular docking studies of new 20(S)-sulfonylamidine camptothecin derivatives. Eur J Med Chem. 2016 Jun 10;115:109-20. doi: 10.1016/j.ejmech.2016.02.070. Epub 2016 Mar 3.
Ref 182 Eucalypglobulusals A-J, Formyl-Phloroglucinol-Terpene Meroterpenoids from Eucalyptus globulus Fruits. J Nat Prod. 2018 Dec 28;81(12):2638-2646. doi: 10.1021/acs.jnatprod.8b00430. Epub 2018 Dec 13.
Ref 183 Synthesis, structure, and cytotoxicity studies of some fungal isochromanes. J Nat Prod. 2013 Sep 27;76(9):1737-45. doi: 10.1021/np400460m. Epub 2013 Sep 13.
Ref 184 Cytotoxic components from the leaves of Erythrophleum fordii induce human acute leukemia cell apoptosis through caspase 3 activation and PARP cleavage. Bioorg Med Chem Lett. 2021 Jan 1;31:127673. doi: 10.1016/j.bmcl.2020.127673. Epub 2020 Nov 5.
Ref 185 Rubiyunnanins C-H, cytotoxic cyclic hexapeptides from Rubia yunnanensis inhibiting nitric oxide production and NF-B activation. Bioorg Med Chem. 2010 Dec 1;18(23):8226-34. doi: 10.1016/j.bmc.2010.10.019. Epub 2010 Oct 31.
Ref 186 Design, synthesis and biological evaluation of benzimidazole-rhodanine conjugates as potent topoisomerase II inhibitors. Medchemcomm. 2018 Jun 2;9(7):1194-1205. doi: 10.1039/c8md00278a. eCollection 2018 Jul 1.
Ref 187 Synthesis of benzo[3,4]azepino[1,2-b]isoquinolin-9-ones from 3-arylisoquinolines via ring closing metathesis and evaluation of topoisomerase I inhibitory activity, cytotoxicity and docking study. Bioorg Med Chem. 2011 Sep 15;19(18):5311-20. doi: 10.1016/j.bmc.2011.08.006. Epub 2011 Aug 8.
Ref 188 Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation. Eur J Med Chem. 2020 Dec 15;208:112768. doi: 10.1016/j.ejmech.2020.112768. Epub 2020 Aug 23.
Ref 189 Water-soluble derivatives of evodiamine: Discovery of evodiamine-10-phosphate as an orally active antitumor lead compound. Eur J Med Chem. 2021 Aug 5;220:113544. doi: 10.1016/j.ejmech.2021.113544. Epub 2021 May 24.
Ref 190 New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. J Med Chem. 2012 Sep 13;55(17):7593-613. doi: 10.1021/jm300605m. Epub 2012 Aug 22.
Ref 191 Effects of substituent pattern on the intracellular target of antiproliferative benzo[b]thiophenyl chromone derivatives. Eur J Med Chem. 2021 Oct 15;222:113578. doi: 10.1016/j.ejmech.2021.113578. Epub 2021 May 25.
Ref 192 Design, synthesis, and biological evaluations of tumor-targeting dual-warhead conjugates for a taxoid-camptothecin combination chemotherapy. J Med Chem. 2014 Jul 10;57(13):5777-91. doi: 10.1021/jm500631u. Epub 2014 Jun 19.
Ref 193 Synthesis and topoisomerases inhibitory activity of heteroaromatic chalcones. Bioorg Med Chem. 2016 Nov 15;24(22):5921-5928. doi: 10.1016/j.bmc.2016.09.051. Epub 2016 Sep 21.
Ref 194 Design, docking, and synthesis of novel indeno[1,2-c]isoquinolines for the development of antitumor agents as topoisomerase I inhibitors. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3531-4. doi: 10.1016/j.bmcl.2007.04.064. Epub 2007 Apr 25.
Ref 195 3-Arylisoquinolines as novel topoisomerase I inhibitors. Bioorg Med Chem. 2011 Jan 15;19(2):724-34. doi: 10.1016/j.bmc.2010.10.057. Epub 2010 Nov 2.
Ref 196 Design, synthesis and docking study of 5-amino substituted indeno[1,2-c]isoquinolines as novel topoisomerase I inhibitors. Bioorg Med Chem. 2011 Mar 15;19(6):1924-9. doi: 10.1016/j.bmc.2011.01.064. Epub 2011 Feb 3.
Ref 197 A-ring and E-ring modifications of the cytotoxic alkaloid Luotonin A: Synthesis, computational and biological studies. Bioorg Med Chem. 2020 May 1;28(9):115443. doi: 10.1016/j.bmc.2020.115443. Epub 2020 Mar 16.
Ref 198 Synthesis and antitumor characterization of pyrazolic analogues of the marine pyrroloquinoline alkaloids: wakayin and tsitsikammamines. J Med Chem. 2006 May 18;49(10):2979-88. doi: 10.1021/jm051247f.
Ref 199 Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Bioorg Med Chem. 2008 Mar 15;16(6):3153-62. doi: 10.1016/j.bmc.2007.12.028. Epub 2007 Dec 23.
Ref 200 New somatostatin-drug conjugates for effective targeting pancreatic cancer. Bioorg Med Chem. 2018 Jul 30;26(13):3825-3836. doi: 10.1016/j.bmc.2018.06.032. Epub 2018 Jun 30.
Ref 201 Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines. Bioorg Med Chem. 2015 Jul 1;23(13):3638-54. doi: 10.1016/j.bmc.2015.04.002. Epub 2015 Apr 9.
Ref 202 A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study. Eur J Med Chem. 2016 May 4;113:228-45. doi: 10.1016/j.ejmech.2016.02.050. Epub 2016 Feb 22.
Ref 203 CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives. Bioorg Med Chem. 2017 Aug 15;25(16):4444-4451. doi: 10.1016/j.bmc.2017.06.030. Epub 2017 Jun 19.
Ref 204 Derivatives of grindelic acid: from a non-active natural diterpene to synthetic antitumor derivatives. Eur J Med Chem. 2013 Sep;67:28-38. doi: 10.1016/j.ejmech.2013.06.013. Epub 2013 Jun 18.
Ref 205 Symmetric dimers of ent-kaurane diterpenoids with cytotoxic activity from Croton tonkinensis. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1122-4. doi: 10.1016/j.bmcl.2011.11.116. Epub 2011 Dec 6.
Ref 206 Identification of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-dithiocarbamate-nitrostyrene hybrid as potent antiproliferative and apoptotic inducing agent against cervical cancer cell lines. Eur J Med Chem. 2018 Feb 25;146:621-635. doi: 10.1016/j.ejmech.2018.01.020. Epub 2018 Jan 10.
Ref 207 Synthesis, cytotoxicity and structure-activity relationship of indolizinoquinolinedione derivatives as DNA topoisomerase IB catalytic inhibitors. Eur J Med Chem. 2018 May 25;152:195-207. doi: 10.1016/j.ejmech.2018.04.040. Epub 2018 Apr 22.
Ref 208 Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives. Bioorg Med Chem. 2010 Jul 15;18(14):5172-82. doi: 10.1016/j.bmc.2010.05.062. Epub 2010 Jun 10.
Ref 209 The self-assembly of a camptothecin-lysine nanotube. Bioorg Med Chem Lett. 2016 Jun 15;26(12):2834-2838. doi: 10.1016/j.bmcl.2016.04.056. Epub 2016 Apr 21.
Ref 210 Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. J Med Chem. 2022 Jun 23;65(12):8303-8331. doi: 10.1021/acs.jmedchem.2c00204. Epub 2022 Jun 13.
Ref 211 Hybrids of privileged structures benzothiazoles and pyrrolo[2,1-c] [1,4]benzodiazepin-5-one, and diversity-oriented synthesis of benzothiazoles. Eur J Med Chem. 2012 Apr;50:27-38. doi: 10.1016/j.ejmech.2012.01.014. Epub 2012 Jan 14.
Ref 212 Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors. Eur J Med Chem. 2014 Sep 12;84:555-65. doi: 10.1016/j.ejmech.2014.07.058. Epub 2014 Jul 18.
Ref 213 Synthesis and evaluation of antibacterial and antitumor activities of new galactopyranosylated amino alcohols. Eur J Med Chem. 2016 Jan 27;108:203-210. doi: 10.1016/j.ejmech.2015.11.037. Epub 2015 Nov 24.
Ref 214 Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity.
Ref 215 A new scaffold of topoisomerase I inhibitors: Design, synthesis and biological evaluation. Eur J Med Chem. 2016 Nov 29;124:326-339. doi: 10.1016/j.ejmech.2016.08.045. Epub 2016 Aug 23.
Ref 216 Synthesis and evaluation as potential anticancer agents of novel tetracyclic indenoquinoline derivatives. Bioorg Med Chem. 2013 Mar 1;21(5):1143-9. doi: 10.1016/j.bmc.2012.12.026. Epub 2013 Jan 3.
Ref 217 Antifungal and cytotoxic activity of withanolides from Acnistus arborescens. J Nat Prod. 2010 Jul 23;73(7):1313-7. doi: 10.1021/np100201p.
Ref 218 Indole alkaloids from two cultured cyanobacteria, Westiellopsis sp. and Fischerella muscicola. Bioorg Med Chem. 2012 Sep 1;20(17):5290-5. doi: 10.1016/j.bmc.2012.06.030. Epub 2012 Jul 5.
Ref 219 Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds. Eur J Med Chem. 2022 Aug 5;238:114438. doi: 10.1016/j.ejmech.2022.114438. Epub 2022 May 6.
Ref 220 An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803. doi: 10.1016/s0960-894x(03)00016-7.
Ref 221 Nontoxic combretafuranone analogues with high in?vitro antibacterial activity. Eur J Med Chem. 2018 Jan 1;143:843-853. doi: 10.1016/j.ejmech.2017.11.078. Epub 2017 Nov 29.
Ref 222 Synthesis of 4-N-polyaromatic substituted podophyllotoxins: DNA topoisomerase inhibition, anticancer and apoptosis-inducing activities. Bioorg Med Chem. 2010 Dec 15;18(24):8493-500. doi: 10.1016/j.bmc.2010.10.042. Epub 2010 Nov 10.
Ref 223 Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer. J Med Chem. 2020 Jan 23;63(2):696-713. doi: 10.1021/acs.jmedchem.9b01626. Epub 2020 Jan 10.
Ref 224 Abietane and C20-norabietane diterpenes from the stem bark of Fraxinus sieboldiana and their biological activities. J Nat Prod. 2010 Nov 29;73(11):1914-21. doi: 10.1021/np100583u. Epub 2010 Oct 20.
Ref 225 Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Sep 15;202:112509. doi: 10.1016/j.ejmech.2020.112509. Epub 2020 Jun 30.
Ref 226 Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem. 1995 Feb 3;38(3):395-401. doi: 10.1021/jm00003a001.
Ref 227 Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. J Med Chem. 2018 Nov 21;61(22):9908-9930. doi: 10.1021/acs.jmedchem.8b00639. Epub 2018 Oct 31.
Ref 228 Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer. J Med Chem. 2021 Jun 10;64(11):7617-7629. doi: 10.1021/acs.jmedchem.1c00318. Epub 2021 May 19.
Ref 229 Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors. Eur J Med Chem. 2022 Jan 5;227:113916. doi: 10.1016/j.ejmech.2021.113916. Epub 2021 Oct 11.
Ref 230 Chemical constituents of the bark of Machilus wangchiana and their biological activities. J Nat Prod. 2009 Dec;72(12):2145-52. doi: 10.1021/np900504a.
Ref 231 Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor. Eur J Med Chem. 2017 Feb 15;127:318-333. doi: 10.1016/j.ejmech.2017.01.003. Epub 2017 Jan 2.
Ref 232 Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and II dual inhibitors with DNA non-intercalative catalytic activity. Eur J Med Chem. 2017 Jun 16;133:69-84. doi: 10.1016/j.ejmech.2017.03.048. Epub 2017 Mar 27.
Ref 233 Cryptolepine and aromathecin based mimics as potent G-quadruplex-binding, DNA-cleavage and anticancer agents: Design, synthesis and DNA targeting-induced apoptosis. Eur J Med Chem. 2019 May 1;169:144-158. doi: 10.1016/j.ejmech.2019.02.072. Epub 2019 Mar 4.
Ref 234 Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1. ACS Med Chem Lett. 2020 Apr 10;11(5):1035-1040. doi: 10.1021/acsmedchemlett.0c00131. eCollection 2020 May 14.
Ref 235 Spirooxindole-pyrrolidine heterocyclic hybrids promotes apoptosis through activation of caspase-3. Bioorg Med Chem. 2019 Jun 15;27(12):2487-2498. doi: 10.1016/j.bmc.2019.03.011. Epub 2019 Mar 5.
Ref 236 Design, synthesis of DNA-interactive 4-thiazolidinone-based indolo-/pyrroloazepinone conjugates as potential cytotoxic and topoisomerase I inhibitors. Eur J Med Chem. 2022 Aug 5;238:114465. doi: 10.1016/j.ejmech.2022.114465. Epub 2022 May 18.
Ref 237 Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem. 1991 Jan;34(1):98-107. doi: 10.1021/jm00105a017.
Ref 238 Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in?vitro antiplasmodial and antitrypanosomal activities. Eur J Med Chem. 2015 Jul 15;100:10-7. doi: 10.1016/j.ejmech.2015.05.044. Epub 2015 Jun 1.
Ref 239 Synthesis, transformation and biological evaluation of 2,3-secotriterpene acetylhydrazones and their derivatives. Eur J Med Chem. 2013 Oct;68:203-11. doi: 10.1016/j.ejmech.2013.07.016. Epub 2013 Aug 9.
Ref 240 2-Chlorophenyl-substituted benzofuro[3,2-b]pyridines with enhanced topoisomerase inhibitory activity: The role of the chlorine substituent. Bioorg Med Chem Lett. 2017 Aug 1;27(15):3279-3283. doi: 10.1016/j.bmcl.2017.06.025. Epub 2017 Jun 9.
Ref 241 Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase II-Targeted Chemotherapeutic Agents for Breast Cancer. J Med Chem. 2019 Sep 12;62(17):8194-8234. doi: 10.1021/acs.jmedchem.9b00970. Epub 2019 Aug 22.
Ref 242 Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5763-7. doi: 10.1016/j.bmcl.2007.08.062. Epub 2007 Aug 29.
Ref 243 Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem. 1998 Dec 31;41(27):5410-9. doi: 10.1021/jm980400l.
Ref 244 Novel 4-(4-substituted amidobenzyl)furan-2(5H)-one derivatives as topoisomerase I inhibitors. Eur J Med Chem. 2017 Feb 15;127:187-199. doi: 10.1016/j.ejmech.2016.12.035. Epub 2016 Dec 20.
Ref 245 Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives. Bioorg Med Chem Lett. 2011 Jan 1;21(1):211-4. doi: 10.1016/j.bmcl.2010.11.037. Epub 2010 Nov 12.
Ref 246 Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition. Bioorg Med Chem. 2021 Jun 15;40:116168. doi: 10.1016/j.bmc.2021.116168. Epub 2021 Apr 22.
Ref 247 Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity. J Med Chem. 2019 Apr 11;62(7):3428-3446. doi: 10.1021/acs.jmedchem.8b01938. Epub 2019 Apr 2.
Ref 248 Development of a metabolically stable topoisomerase I poison as anticancer agent. Eur J Med Chem. 2020 Sep 15;202:112551. doi: 10.1016/j.ejmech.2020.112551. Epub 2020 Jul 2.
Ref 249 Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells. Eur J Med Chem. 2021 Jan 1;209:112870. doi: 10.1016/j.ejmech.2020.112870. Epub 2020 Oct 17.
Ref 250 Synthesis and antiproliferative activity of indolizinophthalazine-5,12-dione derivatives, DNA topoisomerase IB inhibitors. Eur J Med Chem. 2010 Sep;45(9):3938-42. doi: 10.1016/j.ejmech.2010.05.048. Epub 2010 Jun 1.
Ref 251 Cucurbitane glucosides from the root of Machilus yaoshansis. J Nat Prod. 2011 Nov 28;74(11):2431-7. doi: 10.1021/np200706n. Epub 2011 Nov 1.
Ref 252 Synthesis and cytotoxic activity of nitric oxide-releasing isosteviol derivatives. Bioorg Med Chem Lett. 2014 May 1;24(9):2202-5. doi: 10.1016/j.bmcl.2014.03.004. Epub 2014 Mar 12.
Ref 253 The cytotoxic potential of cationic triangulenes against tumour cells. Medchemcomm. 2019 Aug 21;10(11):1881-1891. doi: 10.1039/c9md00305c. eCollection 2019 Nov 1.
Ref 254 Pseudoirroratin A, a new cytotoxic ent-kaurene diterpene from Isodon pseudo-irrorata. J Nat Prod. 2002 Feb;65(2):215-7. doi: 10.1021/np010420h.
Ref 255 Chemical constituents of Heteroplexis micocephala. J Nat Prod. 2009 Jun;72(6):1184-90. doi: 10.1021/np900213w.
Ref 256 Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3320-4. doi: 10.1016/j.bmcl.2013.03.106. Epub 2013 Apr 5.
Ref 257 Synthesis and antitumor activity of biotinylated camptothecin derivatives as potent cytotoxic agents. Bioorg Med Chem Lett. 2019 Jan 15;29(2):234-237. doi: 10.1016/j.bmcl.2018.11.049. Epub 2018 Nov 27.
Ref 258 Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: Privileged structure-based design, synthesis, and bioactive evaluation in?vitro and in?vivo. Eur J Med Chem. 2019 Mar 1;165:293-308. doi: 10.1016/j.ejmech.2019.01.004. Epub 2019 Jan 11.
Ref 259 Cytotoxic and antibacterial beilschmiedic acids from a Gabonese species of Beilschmiedia. J Nat Prod. 2012 Jul 27;75(7):1319-25. doi: 10.1021/np300241d. Epub 2012 Jul 3.
Ref 260 Biologically active arborinane-type triterpenoids and anthraquinones from Rubia yunnanensis. J Nat Prod. 2011 Oct 28;74(10):2069-80. doi: 10.1021/np2002918. Epub 2011 Oct 5.
Ref 261 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. Eur J Med Chem. 2019 Dec 1;183:111700. doi: 10.1016/j.ejmech.2019.111700. Epub 2019 Sep 16.
Ref 262 Synthesis and cytotoxic activity of pyridazino[1',6':1,2]pyrido[3,4-b]indol-5-inium derivatives as anti-cancer agents. Bioorg Med Chem Lett. 2002 Sep 16;12(18):2611-4. doi: 10.1016/s0960-894x(02)00472-9.
Ref 263 Antimalarial Activities of Alkyl Cyclohexenone Derivatives Isolated from the Leaves of Poupartia borbonica. J Nat Prod. 2017 Jun 23;80(6):1750-1757. doi: 10.1021/acs.jnatprod.6b01019. Epub 2017 May 30.
Ref 264 Chemical Constituents of the Roots of Euphorbia micractina. J Nat Prod. 2009 Sep;72(9):1620-6. doi: 10.1021/np900305j.
Ref 265 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase II catalytic inhibitor with low DNA damage. Eur J Med Chem. 2013 Nov;69:139-45. doi: 10.1016/j.ejmech.2013.07.048. Epub 2013 Aug 11.
Ref 266 Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1750-1753. doi: 10.1016/j.bmcl.2017.02.066. Epub 2017 Feb 28.
Ref 267 Design, semisynthesis and potent cytotoxic activity of novel 10-fluorocamptothecin derivatives. Bioorg Med Chem Lett. 2017 Oct 15;27(20):4694-4697. doi: 10.1016/j.bmcl.2017.09.012. Epub 2017 Sep 8.
Ref 268 Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines. Bioorg Med Chem. 2015 Jul 1;23(13):3499-512. doi: 10.1016/j.bmc.2015.04.031. Epub 2015 Apr 28.
Ref 269 Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents. J Med Chem. 2010 Nov 11;53(21):7521-31. doi: 10.1021/jm100387d.
Ref 270 Rotenoids and flavonoids with anti-invasion of HT1080, anti-proliferation of U937, and differentiation-inducing activity in HL-60 from Erycibe expansa. Bioorg Med Chem. 2007 Feb 1;15(3):1539-46. doi: 10.1016/j.bmc.2006.09.024. Epub 2006 Dec 8.
Ref 271 Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives. J Med Chem. 1999 May 20;42(10):1816-22. doi: 10.1021/jm980702n.
Ref 272 Synthesis of ferulic ester dimers, functionalisation and biological evaluation as potential antiatherogenic and antiplasmodial agents. Bioorg Med Chem. 2007 Sep 15;15(18):6018-26. doi: 10.1016/j.bmc.2007.06.047. Epub 2007 Jun 29.
Ref 273 New benzo[5,6]pyrrolizino[1,2-b]quinolines as cytotoxic agents. Bioorg Med Chem Lett. 2004 May 3;14(9):2363-5. doi: 10.1016/j.bmcl.2004.01.097.
Ref 274 Cytotoxic azaphilone alkaloids from Chaetomium globosum TY1. Bioorg Med Chem Lett. 2013 May 15;23(10):2945-7. doi: 10.1016/j.bmcl.2013.03.044. Epub 2013 Mar 21.
Ref 275 Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. J Med Chem. 1997 Jun 20;40(13):2040-6. doi: 10.1021/jm970044r.
Ref 276 Novel 7-substituted camptothecins with potent antitumor activity. J Med Chem. 2000 Oct 19;43(21):3963-9. doi: 10.1021/jm000944z.
Ref 277 Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem. 2001 Sep 27;44(20):3264-74. doi: 10.1021/jm0108092.
Ref 278 Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2731-5. doi: 10.1016/s0960-894x(03)00534-1.
Ref 279 Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3 inhibitors. Bioorg Med Chem. 2019 May 1;27(9):1804-1817. doi: 10.1016/j.bmc.2019.03.028. Epub 2019 Mar 15.
Ref 280 A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. Eur J Med Chem. 2014 Aug 18;83:366-73. doi: 10.1016/j.ejmech.2014.06.050. Epub 2014 Jun 25.
Ref 281 Fluorescein hydrazones: A series of novel non-intercalative topoisomerase II catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells. Eur J Med Chem. 2017 Jan 5;125:49-67. doi: 10.1016/j.ejmech.2016.09.004. Epub 2016 Sep 12.
Ref 282 New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers. Bioorg Med Chem. 2010 Feb;18(3):1010-7. doi: 10.1016/j.bmc.2009.12.069. Epub 2010 Jan 4.
Ref 283 Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents. J Med Chem. 2014 Jul 24;57(14):6008-18. doi: 10.1021/jm5003588. Epub 2014 Jul 8.
Ref 284 Synthesis and cytotoxic studies of novel 5-phenylisatin derivatives and their anti-migration and anti-angiogenic evaluation. Eur J Med Chem. 2018 Aug 5;156:800-814. doi: 10.1016/j.ejmech.2018.07.032. Epub 2018 Jul 25.
Ref 285 Molecular docking study on anticancer activity of plant-derived natural products[J]. Medicinal chemistry research, 2010, 19: 817-835.
Ref 286 Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer. ACS Med Chem Lett. 2020 Feb 28;11(4):439-444. doi: 10.1021/acsmedchemlett.9b00513. eCollection 2020 Apr 9.
Ref 287 Resorcylic acid lactones with cytotoxic and NF-B inhibitory activities and their structure-activity relationships. J Nat Prod. 2011 May 27;74(5):1126-31. doi: 10.1021/np200062x. Epub 2011 Apr 22.
Ref 288 Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. J Nat Prod. 2007 Dec;70(12):1884-8. doi: 10.1021/np070332i. Epub 2007 Dec 13.
Ref 289 Cells lacking DNA topoisomerase II beta are resistant to genistein. J Nat Prod. 2007 May;70(5):763-7. doi: 10.1021/np060609z. Epub 2007 Apr 6.
Ref 290 Design, synthesis and in vitro cytotoxicity evaluation of 5-(2-carboxyethenyl)isatin derivatives as anticancer agents. Bioorg Med Chem Lett. 2014 Jan 15;24(2):591-4. doi: 10.1016/j.bmcl.2013.12.001. Epub 2013 Dec 8.
Ref 291 Calothrixins, a new class of human DNA topoisomerase I poisons. J Nat Prod. 2009 Mar 27;72(3):438-42. doi: 10.1021/np8007232.
Ref 292 Novel C-ring analogues of 20(S)-camptothecin. Part 3: synthesis and their in vitro cytotoxicity of A-, B- and C-ring analogues. Bioorg Med Chem Lett. 2000 Feb 21;10(4):369-71. doi: 10.1016/s0960-894x(00)00005-6.
Ref 293 Caesalminaxins A-L, cassane diterpenoids from the seeds of Caesalpinia minax. J Nat Prod. 2013 Dec 27;76(12):2210-8. doi: 10.1021/np400545v. Epub 2013 Dec 4.
Ref 294 In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia sahendica. Bioorg Med Chem. 2011 Aug 15;19(16):4876-81. doi: 10.1016/j.bmc.2011.06.067. Epub 2011 Jun 29.
Ref 295 Synthesis of an immunoconjugate of camptothecin. Bioorg Med Chem Lett. 2002 Jan 21;12(2):217-9. doi: 10.1016/s0960-894x(01)00707-7.
Ref 296 Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase II catalytic inhibitor. Bioorg Med Chem. 2016 Apr 15;24(8):1898-908. doi: 10.1016/j.bmc.2016.03.017. Epub 2016 Mar 8.
Ref 297 Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class. Eur J Med Chem. 2012 Mar;49:379-96. doi: 10.1016/j.ejmech.2012.01.040. Epub 2012 Jan 25.
Ref 298 Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. J Med Chem. 2003 May 22;46(11):2254-7. doi: 10.1021/jm020498a.
Ref 299 A series of alpha-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity. J Med Chem. 2010 Feb 11;53(3):1038-47. doi: 10.1021/jm901029n.
Ref 300 Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem. 1999 Sep 9;42(18):3623-8. doi: 10.1021/jm990124q.
Ref 301 Vasorelaxant activity of diterpenes from Croton zambesicus and synthetic trachylobanes and their structure-activity relationships. J Nat Prod. 2007 Jun;70(6):910-7. doi: 10.1021/np0603976. Epub 2007 Jun 5.
Ref 302 Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro. J Med Chem. 1997 Jan 17;40(2):216-25. doi: 10.1021/jm9605804.
Ref 303 Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest. J Med Chem. 2003 Dec 18;46(26):5790-802. doi: 10.1021/jm030253d.
Ref 304 Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents. Bioorg Med Chem. 2011 Nov 1;19(21):6182-95. doi: 10.1016/j.bmc.2011.09.020. Epub 2011 Sep 16.
Ref 305 Molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c]phenanthridinones as topoisomerase 1 inhibitors. Bioorg Med Chem Lett. 2009 May 1;19(9):2444-7. doi: 10.1016/j.bmcl.2009.03.058. Epub 2009 Mar 18.
Ref 306 New diterpenoids from Caesalpinia species and their cytotoxic activity. Bioorg Med Chem Lett. 2010 May 1;20(9):2847-50. doi: 10.1016/j.bmcl.2010.03.048. Epub 2010 Mar 12.
Ref 307 Synthesis of polyozellin, a prolyl oligopeptidase inhibitor, and its structural revision. Bioorg Med Chem Lett. 2018 Mar 1;28(5):930-933. doi: 10.1016/j.bmcl.2018.01.054. Epub 2018 Jan 31.
Ref 308 2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study. Bioorg Med Chem. 2010 Jan 1;18(1):377-86. doi: 10.1016/j.bmc.2009.10.049. Epub 2009 Oct 29.
Ref 309 Inhibitory activities against topoisomerase I and II by polyhydroxybenzoyl amide derivatives and their structure-activity relationship. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1669-72. doi: 10.1016/j.bmcl.2004.01.060.
Ref 310 2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6185-9. doi: 10.1016/j.bmcl.2012.08.019. Epub 2012 Aug 10.
Ref 311 Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Bioorg Med Chem. 2010 Mar 15;18(6):2245-2254. doi: 10.1016/j.bmc.2010.01.065. Epub 2010 Feb 4.
Ref 312 A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors. J Med Chem. 2013 Oct 24;56(20):7902-10. doi: 10.1021/jm400906z. Epub 2013 Oct 9.
Ref 313 Monodisperse oligoethylene glycols modified Camptothecin, 10-Hydroxycamptothecin and SN38 prodrugs. Bioorg Med Chem Lett. 2019 Feb 15;29(4):581-584. doi: 10.1016/j.bmcl.2018.12.059. Epub 2018 Dec 27.
Ref 314 Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J Med Chem. 1993 Sep 3;36(18):2689-700. doi: 10.1021/jm00070a013.
Ref 315 Antiproliferative Dimeric Aporphinoid Alkaloids from the Roots of Thalictrum cultratum. J Nat Prod. 2017 Nov 22;80(11):2893-2904. doi: 10.1021/acs.jnatprod.7b00387. Epub 2017 Nov 13.
Ref 316 Regioselective synthesis and cytotoxicities of camptothecin derivatives modified at the 7-, 10- and 20-positions. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3739-41. doi: 10.1016/j.bmcl.2003.08.012.
Ref 317 Selective phenolic acylation of 10-hydroxycamptothecin using poly (ethylene glycol) carboxylic acid. Bioorg Med Chem Lett. 2003 Feb 10;13(3):577-80. doi: 10.1016/s0960-894x(02)00926-5.
Ref 318 Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions. Eur J Med Chem. 2021 Jan 1;209:112844. doi: 10.1016/j.ejmech.2020.112844. Epub 2020 Sep 17.
Ref 319 Synthesis of benzo-annulated tryptanthrins and their biological properties. Bioorg Med Chem. 2012 Aug 15;20(16):4962-7. doi: 10.1016/j.bmc.2012.06.034. Epub 2012 Jul 2.
Ref 320 Antitumor agents 294. Novel E-ring-modified camptothecin-4-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents. Bioorg Med Chem. 2012 Jul 15;20(14):4489-94. doi: 10.1016/j.bmc.2012.05.030. Epub 2012 May 19.
Ref 321 Cytotoxic triterpenoids from the rhizomes of Astilbe chinensis. J Nat Prod. 2009 Jul;72(7):1241-4. doi: 10.1021/np900028v.
Ref 322 Synthesis and anti-cancer activity evaluation of 5-(2-carboxyethenyl)-isatin derivatives. Eur J Med Chem. 2016 Apr 13;112:145-156. doi: 10.1016/j.ejmech.2015.12.050. Epub 2016 Feb 6.
Ref 323 Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J Med Chem. 2000 Jun 1;43(11):2285-9. doi: 10.1021/jm000129j.
Ref 324 Synthesis of polyfunctionalized piperidone oxime ethers and their cytotoxicity on HeLa cells. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6678-86. doi: 10.1016/j.bmcl.2011.09.063. Epub 2011 Sep 21.
Ref 325 DrugMatrix in vitro pharmacology data.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.